Abstract

Vertical Tabs

General Information

Abstract submission will open in August 1st, 2021!

The poster exhibition and the oral poster communication session are the mainstay of the annual European Association of Hospital Pharmacists (EAHP) Congress and only the best are selected!

The EAHP Scientific Committee (SC) encourages all hospital pharmacists, other health care professionals and scientists to submit their work for consideration leading to possible acceptance and display at the annual EAHP congress. The SC strives to receive submissions of hospital pharmacy related initiatives from applicants in Europe and all over the world. All potential contributors are requested to carefully read and comply with the guidelines presented in this webpage. Abstracts/posters which have already been published at the international level may only be submitted if new data is included, the work is presented from the hospital pharmacy perspective or in a new context giving new inspirations for colleagues. Data, which have been published in international, peer-reviewed journals, should not be submitted.

IMPORTANT: When submitting your abstract, please be sure that your hospital server will accept emails from abstract[at]eahp[dot]eu. Otherwise, you will not receive the emails from our system. Alternatively, you may use a personal email address such as gmail, hotmail, etc.

DEADLINE	ACTION
Thursday, 15 October 2021	Deadline for abstract submissions. Abstracts submitted after the deadline will not be accepted
Tuesday, 10 November 2021	Authors will be advised of their abstract status after the first review. Please check your spam if you did not receive the email.
Thursday, 19 November 2021	Modifications due from abstract authors who were requested to make changes
Thursday, 03 December 2021	Authors will be advised of their abstract status after review of modifications

The SC accepts two types of abstracts: scientific abstracts and "Good Practice Initiatives" (GPIs). GPIs comprise hospital pharmacy practice or education initiatives, which may inspire colleagues internationally, but do not necessarily comply with the traditional abstract demands. For further information regarding definition of a GPI, please go here. For authors interested in submitting a GPI, please go here.

Abstract submission for 2022 opens 1st August, 2021.

If you have any questions concerning the abstract submission process, please send an email to abstract[at]eahp[dot]eu.

Abstract Submissions and guidelines

The SC accepts two types of abstracts: scientific abstracts and "Good Practice Initiatives" (GPIs). GPIs comprise hospital pharmacy practice or education initiatives, which may inspire colleagues internationally, but do not necessarily comply with the traditional abstract demands. For further information regarding definition of a GPI, please go here.

To check if your abstract meets the eligibility criteria for being a GPI or an abstract, answer all the following questions:

Table 1: The eligibility criteria for being a GPI or an abstract.

QUESTION	DEFINITION
1. Is your abstract relevant for hospital pharmacists?	Yes: Your abstract may be a scientific abstract or a GPI
1. Is your abstract relevant for hospital pharmacists?	No: Please do not submit your work to EAHP
2. Does your abstract describe a protocol or plan for a project not yet conducted?	Yes: Please do not submit your work to EAHP
	No: Your abstract may be a scientific abstract or a GPI
3. Is your abstract about the development and implementation of a pharmacy practice or a program in pharmacy education?	Yes: Your abstract may be a GPI
	No: Your abstract may be a scientific abstract
4. Can other colleagues use your experience as the basis to introduce the same type of improvement in their settings by e.g. observing what you did in your setting?	Yes: Your abstract may be a GPI
	No: Your abstract may be a scientific abstract
5. Does your abstract describe a project conducted as a scientific study using e.g. robust methodology?	Yes: Your abstract may be a scientific abstract
	No: Your abstract may be a GPI

For authors interested in submitting a GPI, please go here.

If you want to submit a scientific abstract, please check the instructions below.

ABSTRACT SUBMISSIONS AND GUIDELINES

The EAHP Scientific Committee (SC) is looking for contributions with:

A high grade of relevance and/or innovation to the European community of Hospital Pharmacists,
A high impact on the future of hospital pharmacy practice, or
A high relevance regarding practice changes due to the investigated intervention.

SCOPE OF ABSTRACTS AND TOPIC GROUPS

We encourage the submission of abstracts from all disciplines of hospital pharmacy or related areas. The major categories and examples of topics are illustrated in the table below. The topics are not meant to represent a complete and exclusive list, but examples only that guide authors to select the most appropriate topic groups during the submission process.

Table 2: Categories for abstract submission with examples.

CATEGORY	EXAMPLES OF TOPICS
Section 1: Introductory Statements and Governance	Management theories, human resources, training requirements, financing, resource optimization, staffing, organisation, working environment, medicines management policies, drug & therapeutics committees, communication technology (telepharmacy, eHealth), national standards of hospital pharmacy services, pharmacoeconomics, health technology assessment
Section 2: Selection, Procurement and Distribution	Procurement processes, logistics, storage conditions, ordering systems, drug distribution technology (e.g., bar code scanning, electronic cabinets, dose dispensing), home delivery, supply chain management, medicines shortages, policy for medicines brought into the hospital by patients, preparation conditions, dispensing conditions, distribution conditions, disposal of medicines, medicines formulary systems, drug use evaluations
Section 3: Production and Compounding	Production technology, use of suitable commercially available pharmaceutical equivalents, risk assessment prior to production, formulation, quality control, best practice quality requirements, procedures for reconstitution or mixing of medicines, stability studies
Section 4: Clinical Pharmacy Services	Multidisciplinary therapeutic decision-making, quality improvement interventions, adherence, seamless care between and within healthcare settings, monitoring medication changes, service evaluation, service implementation, outcome evaluation, medicines reconciliation, medication history, prescription review, medication management review, medication appropriateness, drug-related problems, patient education, career education, health care professional education, patient knowledge, therapeutic drug monitoring, interactions, clinical pharmacokinetics, drug information and pharmacotherapy, nutrition support
Section 5: Patient Safety and Quality Assurance	Medication errors, adverse drug events, pharmacovigilance, medication error reporting, root cause analysis, high-risk medicines, patient safety programmes, risk minimization procedures, computerised decision support, safe transcription steps, accurate recording of allergy etc., quality and safety procedures, safe medicines use (preparation and administration), labelling, quality assurance, traceability, drug efficacy/safety evaluations
Section 6: Education and Research	Development of curricula, participation in European-wide competency frameworks (e.g., for initial post graduate education and training in hospital pharmacy), research methods, publication skills, pharmacy practice research, pharmacoepidemiology, protocols

IMPORTANT ITEMS TO CONSIDER BEFORE WRITING YOUR ABSTRACT

We kindly invite all applicants to carefully consider the following before submitting your abstract:

The prerequisite for a good abstract is a well-conducted study with clear study aims and methodology.
The purpose of the study should be understandable and should allow the reader to follow what has been done at a glance.
The interventions and relevant outcomes should be clearly defined.
The authors are strongly requested, prior to submission, to see what is published in their relevant field and reflect on the added value of their work (e.g. if they present data of national or even local peculiarities).
Before writing the abstract, clarify for yourself what is the new evidence you want to present and consider why colleagues should be interested in your study.

ABSTRACT STRUCTURE

Abstracts must be structured and written in five paragraphs: (1) Background and importance, (2) Aim and objectives, (3) Materials and methods, (4) Results, (5) Conclusion and relevance.

This structure of an EAHP congress abstract has to be strictly adhered to. The online abstract submission will guide you through this process. Abstracts are limited to no more than 350 words (or less if you use graphs or tables) and must be typed in English. The online submission system does not allow you to enter abstracts above this limit.

A blinded approach is used during the abstract review process, so it is recommended that the institution name and/or country name are NOT indicated in the abstract title and text. Contact data will not be displayed during the review process. This process is meant to ensure that the reviews are conducted in the most ethical and professional way possible.

Title: The title of the abstract must be strictly coherent with the data included in the abstract. Do not use abbreviations. If you are submitting a case report, the area of focus and "case report" should appear in the title.
Contact data: The name of every author, preceded by initials, and the name of the presenting author underlined and entered as instructed via the online submission process. Omit degrees, titles or institutional appointments. Then, insert the institution, city, country where the study took place or the case occurred, as well as the email address of the presenting author.
(1) Background and importance: The background sets the frame of your study. To set the scene you must answer the following questions: What is already known about this topic? what are the unmet needs which brought you to conduct this study? To answer those questions, you have to do a literature search to identify whether other observations in this field are already published. You should present the problem you want to focus on and highlight why the answer to the problem is important. For case reports briefly summarize why this case is unique with medical literature references.
(2) Aim and objectives: State the aim of the study. This very clear and concise text should state: What did you investigate and among whom? If you present a case report give patient information regarding the main concerns and symptoms of the patient in this section. Add medical, family, and psychosocial history including genetic information if applicable and needed. Relevant past interventions and their outcomes should also be reported here.
(3) Materials and methods: Describe the method, facilities (e.g. equipment/statistics, models), design, setting and participants and interventions being used. Please describe the intervention and which outcome measures were used, when applicable. If you do a literature review or a meta-analysis you have to give information regarding the data sources and the study selection criteria. For case reports relevant physical examination (PE) and other clinical findings should be reported in this section. Also the timeline of the case with relevant data from this episode of care organized as a timeline could be important. In some cases diagnostics and prognostic characteristics should be given when applicable. Please present therapeutic Interventions in this section.
(4) Results: Present the necessary data in a way that it is easy to understand. There is no discussion of the results in this part. For case reports clinician- and patient-assessed outcomes when appropriate should be given here. Please refer also to important follow-up diagnostic and other test results. Intervention adherence and tolerability (how was this assessed?) besides adverse and unanticipated events should be reported.
(5) Conclusion and relevance: Discuss your results and compare to literature data if available. Are other observations in this field already published and relevant to be mentioned? Based on your results, what are the answers to the problem you focused on? What are the new findings? What are the implications for practice and research? For case reports, please present strengths and limitations in your approach to this case. Please discuss the relevant medical literature and the rationale for your conclusions. You must present the primary "take-away" lessons from this case report.
References and/or acknowledgements: These may be given at the end of the abstract.

Please click here to download the abstract structure template which can give you an idea of an abstract structure before the online submission. Please note that only submitted online abstracts will be reviewed.

We advise authors to use scientifically common principles in abstract writing.

Abbreviations may be used only if they are defined (spelled out in full text at first mention, followed by abbreviation in parentheses). Only general standard abbreviations for e.g. millilitres, seconds, and moles may be used without explanation.
Don't use excessive decimals e.g. a person might weigh 70,237 kg at a given moment, but only 70 kg should be mentioned.
References should be limited to a minimum, unless they are important for understanding methods, background or conclusions drawn. References should be added in a special field during the abstract submission, which is optional for use and not mandatory. Comprehensive bibliography can be displayed on the poster.
The authors are encouraged to submit well-edited abstracts and avoid submission of negligent work.

THE SUBMISSION PROCESS

Please consider the selection of the appropriate topic group before submission and compare with the examples prior to submission (Table 2). The topics are directly related to the EAHP statements.
For every abstract there must be 3-5 keywords selected by the authors. These are used for indexing purposes and have to be strictly in line with the content of the abstract.
You can only add 1 presenting author and up to 10 co-authors.

THE REVIEW PROCESS

Each abstract is read, assessed and scored independently by two members of the SC and considered from two perspectives: the scientific content and the practical value of the submission.
In case of divergence between the two reviewers, the full SC discusses the submission in plenum and comes to a view whether to accept the abstract or not.
You will be notified in a timely manner as to the outcomes of the review process. You may be asked to revise your abstract and re-submit it.
All accepted abstracts will be allocated a spot for display at the congress.
The SC selects outstanding abstracts for poster walks and poster prize competition. Only those abstracts that are considered to have a high grade of relevance, innovation and added value in a well-written form are eligible for winning the poster prize.

SPECIFICS REGARDING STUDY TYPES AND METHODOLOGY

Particular attention is given to those abstracts that report scientifically valid results with appropriate study methodology giving the type of study design, interventions and outcomes. Outcomes could comprise either direct patient benefit, economical or clinical outcomes, or a combination of these.
Quantitative studies should include at least 30 patients.
Case Reports of a single or of a few patients will be accepted only if they include original and new data, that is not as yet published in literature. Please find below more information.
Case reports of ADRs will only be accepted if they present some kind of causality or probability assessment (e.g. Naranjo algorithm)
Everyday clinical practice studies are of interest if effectiveness is reported in an adequately chosen size of study population, which is in line with the prevalence of the disease studied.
New drug interactions not already described in the literature are encouraged to be reported but should come with a possible mechanism or explanation.If interventions of improvements processes are reported, please always report baseline values or data regarding the situation prior to the intervention as well. Otherwise comparison is not scientifically valid and therefore of limited value and validity.
Abstracts reporting purely lab sciences or associated sciences to pharmacy (e.g. microbiology, biology, chemistry etc.) are only accepted if the implications of these basic study findings to hospital pharmacy practice are made clear by the authors.
Drug Usage Evaluation (DUE) will only be considered if data of at least 30 patients are reported.
Authors planning to perform and report the results of a DUE are referred to relevant guidelines (e.g. those from American Society of Health-system Pharmacists).

EAHP welcomes well-described reports of cases that include the following:

Unreported or unusual side effects or adverse interactions involving medications.
Unexpected or unusual presentations of a disease.
New associations or variations in disease processes.
Presentations, diagnoses and/or management of new and emerging diseases.
An unexpected association between diseases or symptoms.
An unexpected event in the course of observing or treating a patient.
Findings that shed new light on the possible pathogenesis of a disease or an adverse effect.

Abstracts of case reports submited to the SC of EAHP with the aim to present a poster at the EAHP Congress should make a contribution to medical knowledge and must have educational value or highlight the need for a change in clinical practice or diagnostic/prognostic approaches. EAHP will not consider case reports describing preventive or therapeutic interventions, as these generally require stronger evidence.

Case reports should be writen in the same way like the other abstracts, meaning you have to use the same template.

REASONS FOR REJECTION

Abstracts/posters which have already been published at the international level may only be submitted if new data is included, the work is presented from the hospital pharmacy perspective or in a new context giving new inspirations for colleagues. Data, which have been published in international, peer-reviewed journals, should not be submitted.

This practice is well established in many countries.
This abstract is not relevant to Hospital Pharmacy.
The committee did not understand the abstract either due to English use or other reasons.
Quantitative studies should usually include at least 30 participants.
The abstract does not follow the given structure.
The conclusion does not cover the aim of the study.
Insufficient data was included to support your conclusions.
An inappropriate or weak study methodology was used.
The abstract is not presenting a study with a defined aim, a described method to obtain results, presentation of the obtained results and/or a conclusion based on these findings.
The abstract may be better suited as a GPI. Please resubmit using the appropriate format.
This topic has already been studied and published several times.
If a same author or a same group of authors has submitted the same abstract several times by mistake, they should send an email to the EAHP office to inform them and delete the duplicated abstracts. Otherwise, the judges will reject all abstracts.
If a same abstract has been submitted by its author(s) both as a Good Practice Initiative and as an abstract, the judges will reject both abstracts.
Other

RECOMMENDATIONS

Prior to conducting your study, reflect on the appropriate methodology and the number of patients (e.g. power analysis) that is necessary for this study design. Your study must include at least 30 patients to be accepted.
Ask other colleagues who are not involved in the study if the abstract is understandable and your proposed message is conveyed.
Consider the coherence of the abstract. If not coherent, please strongly consider rewriting your abstract.
The conclusion should be limited to statements that directly arise from the results presented. General statements without reflection of results or not in line with the aim of the study have to be avoided, as this is a common reason for abstract rejection.
The word count has to be adhered to. Be aware, that this is an abstract. The purpose of an abstract is to report clear, concise and relevant scientific results. Additional data, which are not ultimately needed for understanding, can be shown in the final poster.
Please avoid formatting of abstracts, don't use bold type, and ensure that at the final checking stage that any special characters or symbols used are displayed correctly.
Abstracts reporting vague or unclear interventions and/or irrelevant outcomes will be rejected.

DISCLAIMER

While every effort is made by publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned.

Accordingly, the publishers and the European Association of Hospital Pharmacists (EAHP), the editorial committee and their respective employees, officers and agents, accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. While every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, described within this Journal, should only be followed in conjunction with the drug manufacturer's own published literature.

The author is responsible for obtaining the permission and licenses used to complete his/her study. Please note that EAHP cannot be held responsible in case an author disrespects his/her obligation to obtain the permission and licenses.

Please click here to read the author licence from BMJ.

IMPORTANT: The abstracts that were rejected last year CANNOT BE RESUBMITTED again unless major modifications have been made. Should the authors not follow this rule, they will be banned from the submission process for the following EAHP congresses.

Good luck to all!

The EAHP Scientific Committee

Poster guidelines

POSTER GUIDELINES

SIZE

841 mm wide x 1189 mm high (A0) - portrait format (posters may not be smaller or larger than this size).

1. ASSISTANCE PROVIDED AT CONGRESS CENTRE

1.1. A poster panel on which to hang posters
1.2. A number for each poster board: this number indicates your assigned display station and also corresponds to the abstract number
1.3. Mounting materials, including double sided adhesive tape. Note that the use of drawing pins will NOT be allowed
1.4. Staff to advise during poster mounting

2. THE FOLLOWING COMPONENTS SHOULD BE INCLUDED AND USED AS HEADING WHERE APPROPRIATE

2.1. Title
2.2. Contact data
2.3. Background and Importance
2.4. Aim and Objectives
2.5. Materials and Methods
2.6. Results
2.7. Conclusion and Relevance
2.8. References and/or Acknowledgements

3. IT IS OFTEN USEFUL TO HAVE A SUMMARISED VERSION OF THE POSTER TO HAND TO INTERESTED READERS

You should also provide a notepad so that interested readers can leave their contact addresses, and a drop-box in which they can leave business cards or envelopes.

4. DESIGNING THE POSTER

4.1. Remember that viewers should be able to grasp the meaning of the poster without listening to an explanation or reading a report. To assist in this:
4.1.1. Communicate the message simply
4.1.2. Do not clutter the poster with too much detail
4.1.3. Only use materials that can be mounted on the poster board (plus handouts)
4.1.4. Use title lettering at least 2.5 cm high with text lettering at least 8 mm high and 0.7 mm thick. Test readability from 1 m or more away.
4.1.5. Use pie charts, histograms, graphs, tables, clip art, drawings, symbols and photos to illustrate key points. Use colour effectively in these and make them simple, rather than complex.
4.1.6. Design the poster to be read from left to right and top to bottom
4.1.7. Where possible, use one-line statements or bullet phrases to highlight key points, rather than full sentences (this list is set off by bullet points)
4.1.8. Use bold face type for headings and sub-headings
4.1.9. Proof-read the poster carefully. Ask a person independent of the project to review the text for clarity, organisation and brevity
4.1.10. Bring white correction tape or fluid and black felt tip pen to the meeting to correct errors or scratches

5. POSTER CERTIFICATES

Poster certificates for the presented posters will be sent to the authors by email within 15 days after the Congress. The duplicates can be provided by the author's request within 60 days after the last Congress. Please note that in case of loss of your poster certificates, the certificate duplicates of the last EAHP congress as well as any other previous EAHP congresses certificates will not be provided after the deadline of 60 days.

6. POSTER PDFs FOR WEB SITE

Authors should send a pdf of their poster to abstract[at]eahp[dot]eu for inclusion on the EAHP web site following the congress. Deadline for receipt of your poster pdf is 15 March 2021.

7. DISCIPLINARY ACTION

If an author is unable to present his poster during the congress, he absolutely needs to notify the EAHP by sending an email to abstract[at]eahp[dot]eu. If same situation happens 3 years in a row, the EAHP reserves the right to reject any other abstracts submitted by the same author for future congresses. In addition, should the author not insure that their poster is hunger during the congress either by the author or a colleague, the abstract will be removed from the online version of the abstract book.

Poster prize winners

ENCOURAGEMENT PRIZE FOR INVESTIGATORS

The best abstracts/posters (up to 12 award nominees) – with regards to aspects like originality, scientific quality and practical applicability – will be awarded with 3 prizes amounting EURO 750, EURO 500 and EURO 250.

Please be aware that the judges reserve the right not to award prizes if there are no clear winners.

Award nominees will be requested to give an oral presentation, taking place in different dates and times throughout the congress.

2022 Award nominee oral presentations

TBC

Oral presentations are to consist of 5 minutes for presentation and 2 minutes for questions and answers. Poster prize nominees should disclose whether their work or comparable/similar work was submitted at an earlier International conference or somewhere else. More details will be sent to the authors by email. The winners will be announced at the closing ceremony on 25 March 2022.

Check the posters of last year's winners here!

The Scientific Committee also choose up to 18 abstracts for the Poster walk. These abstracts will be highlighted in the online poster area in the congress platform and will include a recorded video of their presentation so you can watch their presentation at any time!

Online abstract poster walks

Please find below the online abstract Poster Walks of the last EAHP Congresses.

Please select the desired annual Congress to view the posters presented in the different topic categories.

25th Anniversary EAHP Congress - Hospital Pharmacy 5.0 - the future of patient care (2021)

National Poster Prize Winners
PDF document	Poster number	Poster Title
	NP-001	IMPACT OF AN ORAL NUTRITION PROTOCOL IN PATIENTS TREATED WITH ELECTIVE RADICAL CYSTECTOMY: A LONG TERM FOLLOW-UP (submitted in 2019)
	NP-002	MEDICATION SAFETY IN PATIENTS TREATED WITH ORAL ANTITUMOR AGENTS: A PROSPECTIVE, RANDOMIZED INVESTIGATION TO IMPROVE PATIENT SAFETY AND WELL-BEING BY INTENSIFIED CLINICAL PHARMACEUTICAL/ PHARMACOLOGICAL CARE (submitted in 2019)
	NP-003	STEADY-STATE PHARMACOKINETICS AND EARLY SAFETY DATA IN HIV-INFECTED AFRICAN CHILDREN WEIGHING ≥25KG AFTER SWITCHING TO 50MG FILM-COATED DOLUTEGRAVIR TABLETS IN THE ODYSSEY TRIAL (submitted in 2019)
	NP-004	INITIATION OF A CLINICAL PHARMACIST LED, PROSPECTIVE AUDIT ON ANTIBIOTIC PRESCRIBING (submitted in 2019)
	NP-005	IMPLEMENTING MEDICATION RECONCILIATION ON HOSPITAL ADMISSION: A MULTICENTER PILOT STUDY IN ESTONIA AND FINLAND (submitted in 2019)
	NP-006	A PAIR OF PHARMACY TECHNICIAN / NURSE TO TRAIN ON THE ANTI-RETURN VALVES (submitted in 2019)
	NP-007	A MIXED METHODS EVALUATION OF THE CROSS-SECTOR PHARMACIST VOCATIONAL TRAINING FOUNDATION PROGRAMME: IS THE TRAINING PROGRAMME FIT FOR PURPOSE? (submitted in 2019)
	NP-008	MONITORING OF PRESCRIPTIONS ON PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) IN MEDICAL PATIENTS IN BEATRIZ ÂNGELO HOSPITAL (submitted in 2019)
	NP-009	THE IMPACT OF TNFa INHIBITORS ON GLUCOCORTICOIDS USE AMONG PATIENTS WITH ARTHRITIDES (submitted in 2019)
	NP-010	CLINICAL AND PHARMACOKINETIC RESULTS AFTER THE SWITCH TO INFLIXIMAB BIOSIMILAR IN INFLAMMATORY BOWEL DISEASE: 2 YEARS OF REAL-LIFE EXPERIENCE (submitted in 2019)
	NP-011	MEDICATION RECONCILIATION IN AN EMERGENCY DEPARTMENT – PROCESS ASSESSMENT FOR A MORE EFFICIENT SERVICE (submitted in 2019)
	NP-012	COST EFFECTIVENESS ANALYSIS AND INDIRECT COMPARISON CAN SUPPORT THE PRICE’ DEFINITION OF A DRUG? THE CASE OF ENCORAFENIB AND BINIMETINIB IN METASTATIC MELANOMA, THE PHARMACIST’POINT OF VIEW (submitted in 2019)
	NP-013	THE NEOCHECK PROJECT: DEVELOPMENT OF A PRESCRIPTION-SCREENING TOOL SPECIFIC TO NEONATOLOGY (submitted in 2019)
	NP-014	MEDICINE BOXES FOR DISTRIBUTION OF PAID PHARMACEUTICALS TO OUTPATIENTS IN THE FUTURE (submitted in 2019)
	NP-015	QUALITY ASSESSMENT OF 3D PRINTED SILDENAFIL AND FUROSEMIDE TABLETS FOR THE PAEDIATRIC POPULATION USING AN INNOVATIVE EXTRUSIONBASED TECHNIQUE
	NP-016	EPIDEMIOLOGY AND RESISTANCE MAP TO AID ANTIBIOTIC GUIDELINE DEVELOPMENT SINGLE CENTRE RETROSPECTIVE STUDY FROM AN EMERGENCY DEPARTMENT
	NP-017	RISK ASSESSMENT OF OCCUPATIONAL EXPOSURE TO CYTOTOXIC DRUGS IN AN OUTPATIENT HOSPITAL PHARMACY
	NP-018	BUILDING CAPACITY WITHIN A HEPATITIS C TREATMENT MODEL. THE VALIDATION PROCESS FOR A HEPATITIS C PRE-TREATMENT PHARMACIST ASSESSMENT COMPLEX INTERVENTION TOOLKIT
	NP-019	DEVELOPMENT OF A CONVERSION FACTOR BETWEEN DEFINED DAILY DOSES OF ADULTS AND NEONATES
	NP-020	ANTINEOPLASTIC AND OTHER HAZARDOUS DRUGS: RISK POTENTIAL AND EXPOSURE – LESS IS MORE!

Section 1: Introductory Statements and Governance
PDF document	Poster number	Poster Title
	1ISG-001	CAN RIVAROXABAN BECOME COST SAVING COMPARED WITH VITAMIN K ANTAGONISTS IN THE TREATMENT OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN FRANCE? (submitted in 2019)
	1ISG-002	BIOLOGICAL DRUGS FOR THE TREATMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS: A COST ANALYSIS AND AN APPLICATION OF A CORRELATION ANALYSIS TO INVESTIGATE COST EFFECTIVENESS (submitted in 2019)
	1ISG-003	STUDY OF THE USE OF INTRAVENOUS IMMUNOGLOBULINS DURING THE FOURTH QUARTER OF 2018 AND ANALYSIS OF ITS OFF-LABEL USE (submitted in 2019)
	1ISG-004	ECONOMIC COMPARISON OF THERAPEUTIC ALTERNATIVES FOR FIRSTLINE OF TREATMENT MULTIPLE MYELOMA (submitted in 2019)
	1ISG-005	ABC-VEN CROSSTAB ANALYSIS: A DECISION MAKING SYSTEM APPLIED FOR ANTICANCER MEDICINES (submitted in 2019)
	1ISG-006	EFFECTIVENESS EVALUATION OF HIGHCOST DRUGS FOR ADVANCED NON-SMALL-CELL LUNG CANCER: REAL WORLD EVIDENCE, COMPLIANCE WITH CLINICAL PRACTICE GUIDELINES AND ECONOMIC EVALUATION (submitted in 2019)
	1ISG-007	NEW CANCER DRUGS APPROVALS IN PORTUGAL (submitted in 2019)
	1ISG-008	COST EFFICACY ANALYSIS OF ABIRATERONE IN NEWLY DIAGNOSED HIGH RISK METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (submitted in 2019)
	1ISG-009	BUDGET IMPACT ANALYSIS OF A NATALIZUMAB EXTENDED INTERVAL DOSING REGIMEN (submitted in 2019)
	1ISG-010	INTRODUCTION OF RITUXIMAB BIOSIMILAR: AN OPPORTUNITY TO IMPROVE HEALTH SYSTEM EFFICIENCY? (submitted in 2019)
	1ISG-011	ASSESSMENT OF ASTHMA DIAGNOSED POPULATION ELIGIBLE FOR NEW MONOCLONAL ANTIBODY THERAPY AND RELATED COST IN THE VENETO REGION (submitted in 2019)
	1ISG-012	NATIONAL REPORTING SYSTEM FOR DRUG SHORTAGES : CLASSIFICATION AND TRENDS IN REPORTED CAUSES FROM 2015 TO 2018 (submitted in 2019)
	1ISG-013	SMARTPHONE APPLICATIONS FOR PATIENTS DIAGNOSED WITH GENITOURINARY TUMOURS: ANALYSIS OF THE QUALITY USING THE MOBILE APPLICATION RATING SCALE (submitted in 2019)
	1ISG-014	COST EFFECTIVENESS ANALYSIS OF PATIENTS' SELF-ADMINISTRATION OF MEDICATION (SAM) DURING HOSPITALISATION IN A CARDIOLOGY UNIT (submitted in 2019)
	1ISG-015	EVALUATION OF BISPECTRAL INDEX MONITORING IN GENERAL ANAESTHESIA THROUGH A HEALTH TECHNOLOGY ASSESSMENT METHOD: A POSSIBLE INTRODUCTION IN CLINICAL PRACTICE IN AN ITALIAN HOSPITAL? (submitted in 2019)
	1ISG-016	ENVISIONING SUSTAINABILITY IN PERSONALISED MEDICINE: FONDO AIFA 5% AND THE ITALIAN EXAMPLE (submitted in 2019)
	1ISG-017	IMPACT OF SUPPLY PROBLEMS IN A HOSPITAL PHARMACY SERVICE (submitted in 2019)
	1ISG-018	APPLICATION OF A TIME SLOT MODEL IN ONCOLOGY: DELIVERY PLANNING AND PROCESS OPTIMISATION (submitted in 2019)
	1ISG-019	HOSPITAL PHARMACISTS AGED <45 YEARS: AN EMPLOYMENT STATUS AND JOB SATISFACTION SURVEY IN ITALY (submitted in 2019)
	1ISG-020	COST SAVINGS IMPACT OF BIOSIMILARS: A LOCAL EXPERIENCE ON TRASTUZUMAB
	1ISG-021	INDIRECT COMPARISON OF BRIGATINIB VERSUS ALECTINIB IN THE ALK-POSITIVE NON-SMALL CELL LUNG CANCER
	1ISG-022	ECONOMIC ANALYSIS AFTER THE INCORPORATION OF BEVACIZUMAB BIOSIMILAR IN A THIRD LEVEL HOSPITAL
	1ISG-023	PHARMACOECONOMIC ANALYSIS OF REFERENCE BEVACIZUMAB: OPPORTUNITY FOR IMPROVED EFFICIENCY
	1ISG-024	BIOLOGICAL DRUGS IN THE TREATMENT OF IMMUNE MEDIATED INFLAMMATORY DISEASES: MONITORING OF PRESCRIPTION APPROPRIATENESS
	1ISG-025	BUDGET IMPACT ANALYSIS OF BIOSIMILAR ADALIMUMAB VERSUS REFERENCE ADALIMUMAB
	1ISG-026	MULTIDISCIPLINARY DOCTOR-PHARMACIST COLLABORATION IN THE MANAGEMENT OF REFUNDS POLICIES OF OPHTHALMIC DRUGS AT SANT'ANDREA HOSPITAL , VERCELLI
	1ISG-027	CARBON FOOTPRINT OF A STERILISATION UNIT
	1ISG-028	BECOMING OF GRADUATE HOSPITAL PHARMACISTS: A FRENCH NATIONAL SURVEY
	1ISG-029	CRANIOPLASTY: A REVIEW OF CUSTOMISED CRANIOPLASTY IMPLANTS
	1ISG-030	ECONOMIC IMPACT OF BIOLOGICAL MEDICINES ON A THIRD LEVEL HOSPITAL

Section 2: Selection, Procurement and Distribution
PDF document	Poster number	Poster Title
	2SPD-001	IMPLEMENTATION OF HOME DELIVERY AND TELEPHARMACY SYSTEMS IN A THIRD LEVEL HOSPITAL (submitted in 2019)
	2SPD-002	IMPROVEMENT IN AN ANTIMICROBIAL STEWARDSHIP PROGRAMME AFTER IMPLEMENTING A SCREENING ALERT SYSTEM (submitted in 2019)
	2SPD-003	ECONOMIC IMPACT OF THE INTRODUCTION OF LAMIVUDINE PLUS DOLUTEGRAVIR BITHERAPY IN HIV NAIVE PATIENTS (submitted in 2019)
	2SPD-004	EFFICIENCY OF PRECISION DOSING WITH INTRAVENOUS IMMUNOGLOBULINS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES (submitted in 2019)
	2SPD-005	ECONOMIC ANALYSIS OF OSIMERTINIB IN PREVIOUSLY UNTREATED EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (submitted in 2019)
	2SPD-006	ASSESSMENT OF REGORAFENIB, RAMUCIRUMAB AND CABOZANTINIB AS SECONDLINE THERAPY IN HEPATOCARCINOMA AND ALFA-FETOPROTEIN VALUE ≥400 NG/ML (submitted in 2019)
	2SPD-007	OUT OF SUPPLY OF CHEMOTHERAPY INJECTABLE MEDICINES OVER 9 MONTHS: PATIENT IMPACT (submitted in 2019)
	2SPD-008	IMPACT OF FRENCH EXPERIMENT FOR INCENTIVISING ETANERCEPT BIOSIMILAR USE AFTER 10 MONTHS (submitted in 2019)
	2SPD-009	COST MINIMISATION STUDY OF THE BIOLOGICAL TREATMENT OF INFLAMMATORY BOWEL DISEASE: USTEKINUMAB VERSUS VEDOLIZUMAB (submitted in 2019)
	2SPD-010	ECONOMIC IMPACT OF SWITCHING THE ADMINISTRATION ROUTE OF TOCILIZUMAB IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (submitted in 2019)
	2SPD-011	TRANS-INTERFACE GAIN SHARE PROGRAMME FOR BIOSSIMILAR INFLIXIMAB (submitted in 2019)
	2SPD-012	COST MINIMISATION STUDY IN SEVERE ASTHMA TREATMENT (submitted in 2019)
	2SPD-013	APPLICATION OF THE ABC ANALYSIS METHOD FOR OPTIMIZING THE STOCK MANAGEMENT OF MEDICAL DEVICES IN COMMON USE (submitted in 2019)
	2SPD-014	EVALUATING THE METHODOLOGICAL QUALITY OF PIVOTAL CLINICAL TRIALS´S PUBLICATIONS FOR ORPHAN DRUGS AUTHORISED IN 2018. ARE THEY RELIABLE? (submitted in 2019)
	2SPD-015	COST OF STOCKOUT. A GROWING PROBLEM (submitted in 2019)
	2SPD-016	FUTURE DISTRIBUTION MODELTS FOR PAID PHARMACEUTICALS: THE PATIENT'S PERSPECTIVE (submitted in 2019)
	2SPD-017	IMPACT OF THE IMPLEMENTATION OF THE FALSIFIED MEDICINES DIRECTIVE AT THE LISBON PORTUGUESE INSTITUTE OF ONCOLOGY (FG, EPE) (submitted in 2019)
	2SPD-018	FOUR YEAR STUDY OF DRUGS SHORTAGES IN TWO PUBLIC HOSPITALS (submitted in 2019)
	2SPD-019	FOUR YEARS OF SHORTAGES REGARDING THE ANATOMIC, THERAPEUTIC AND CHEMICAL CLASSIFICATION (submitted in 2019)
	2SPD-020	IMPACT OF MEDICINE SHORTAGES ON AN OUTPATIENT CLINIC OF A GENERAL HOSPITAL (submitted in 2019)
	2SPD-021	SURVEY OF DRUG SHORTAGES IN HUNGARIAN HOSPITALS (submitted in 2019)
	2SPD-022	DRUG SHORTAGES AND DRUG UNAVAILABILITY: ANALYSIS FROM AN ITALIAN HOSPITAL (submitted in 2019)
	2SPD-023	HOW MUCH DOES FALSIFIED MEDICINES DIRECTIVE ACTUALLY COSTS? DETAILED COST EVALUATION OF SERIALISATION IN A REPRESENTATIVE SAMPLE OF HUNGARIAN HOSPITAL PHARMACIES (submitted in 2019)
	2SPD-024	SHORTAGES OF MEDICINES IN HOSPITAL: RESULTS OF A SURVEY ON THE PERCEPTION OF HEALTH WORKERS IN THE WARDS VSV REAL WORLD (submitted in 2019)
	2SPD-025	APPLICATION OF HAZARD VULNERABILITY ANALYSIS TO EVALUATE THE RISK LEVEL OF MEDICINE SHORTAGES (submitted in 2019)
	2SPD-026	MANAGEMENT OF DRUG SHORTAGES (submitted in 2019)
	2SPD-027	ECONOMIC IMPACT OF DRUG SHORTAGES (submitted in 2019)
	2SPD-028	REFERENCING A MIDLINE: HOW TO MAKE A CHOICE? (submitted in 2019)
	2SPD-029	OFF-LABEL DRUGS: USE ANALYSIS AND PHARMACOEPIDEMIOLOGY IN A COVID CENTRE IN ROME
	2SPD-030	POSITIONING OF DORAVIRINE IN THE PHARMACOTHERAPEUTIC GUIDE OF A THIRD LEVEL HOSPITAL.
	2SPD-031	SUBGROUP ANALYSIS ABOUT EFFICACY OF EARLY USE OF REMDESIVIR IN COVID-19
	2SPD-032	NETWORK META-ANALYSIS OF THERAPEUTIC ALTERNATIVES IN UNTREATED METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER
	2SPD-033	EVALUATION OF DOCETAXEL IN LOW AND HIGH BURDEN METASTATIC HORMONE SENSITIVE PROSTATE CANCER
	2SPD-034	USE OF DARATUMUMAB BASED TREATMENTS IN PATIENTS WITH MULTIPLE MYELOMA AND HEPATIC IMPAIRMENT
	2SPD-035	BIOLOGICAL THERAPIES EFFECTIVENESS COMPARISON FOR PATIENTS WITH SEVERE-MODERATE PSORIASIS
	2SPD-036	CENTRALISED PROPOFOL RECONDITIONING PROCEDURE DURING COVID-19
	2SPD-037	ANALYSIS OF DRUG DISPENSES OUTSIDE THE HOSPITAL GUIDE IN A PSYCHIATRIC HOSPITAL
	2SPD-038	BEVACIZUMAB VERSUS RANIBIZUMAB IN OPHTHALMOLOGY OUTPATIENT SURGERY
	2SPD-039	MAKE OR BUY: PHARMACOECONOMIC EVALUATION OF GARGLE SOLUTIONS USED FOR SARS-CoV-2 SAMPLE COLLECTION
	2SPD-040	IMPACT OF AUTOMATED DISPENSING CABINETS ON DISPENSING ERRORS, INTERRUPTIONS AND PILLBOX PREPARATION TIME
	2SPD-041	QUANTITATIVE EVALUATION AND ECONOMIC IMPACT OF MEDICINE SHORTAGES IN A TEACHING HOSPITAL
	2SPD-042	MEDICAL DEVICE’S ACTIVE VIGILANCE OF THE PHARMACIST IN THE DIGITALISATION OF INTRAOCULAR LENSES (IOLs) LOGISTIC PATH
	2SPD-043	PROCEDURE FOR DELIVERY OF RETROCESSION DRUGS BY THE HOSPITAL PHARMACIST TO THE COMMUNITY PHARMACY DURING THE COVID-19 CRISIS: SATISFACTION SURVEY OF PHARMACIES
	2SPD-044	DruGhost: web based platform of drugs’ unavailability
	2SPD-045	OPTIMISATION OF THE BUYING PROCESS: BUILDING A TIME EARNING COMPARATOR TO EASE THE CHOICE BETWEEN EQUIVALENT SPECIALTIES
	2SPD-046	ORGANISATIONAL CHALLENGES OF THE PHARMACY SERVICE AS A CONSEQUENCE OF THE COVID-19 PANDEMIC
	2SPD-047	NEW REQUIREMENTS OF OUTPATIENTS IN THE COVID-19 ERA: ADAPTING PHARMACEUTICAL CARE
	2SPD-048	POLITICAL REPORT–OPTIONS TO BREAK THROUGH MEDICINE SHORTAGES

Section 3: Production and Compounding
PDF document	Poster number	Poster Title
	3PC-001	COMPATIBILITY AND STABILITY ASSESSMENT OF A SODIUM GLYCEROPHOSPHATE FORMULATION MIXED IN BAGS FOR NEONATAL TOTAL PARENTERAL NUTRITION (submitted in 2019)
	3PC-002	MICROBIOLOGICAL STABILITY TEST OF 15% TOPICAL RESORCINOL FOR QUALITY CONTROL (submitted in 2019)
	3PC-003	TERLIPRESSIN PH STABILITY FOR CONTINUOUS INFUSION (submitted in 2019)
	3PC-004	PHYSICOCHEMICAL STABILITY OF CEFEPIME IN POLYPROPYLENE SYRINGES AND IN ELASTOMERIC DEVICES. (submitted in 2019)
	3PC-005	PHYSICOCHEMICAL STABILITY OF CEFAZOLIN IN POLYPROPYLENE SYRINGES AND IN ELASTOMERIC DEVICES. (submitted in 2019)
	3PC-006	PHYSICOCHEMICAL STABILITY OF AZTREONAM IN POLYPROPYLENE SYRINGES AT HIGH CONCENTRATION FOR INTENSIVE CARE UNITS. (submitted in 2019)
	3PC-007	LEVOFLOXACIN 0.05 % EYEDROPS ELABORATION: A CASE OF STUDY (submitted in 2019)
	3PC-008	INTRAVENOUS PERFUSION OF CEFTOLOZANE-TAZOBACTAM USING ELASTOMERIC INFUSION PUMPS (submitted in 2019)
	3PC-009	TREATMENT OF RECURRENT OTOMYCOSIS WITH LOCAL APPLICATION OF A COMPOUNDED FORMULATION OF VORICONAZOLE EAR DROPS: CASE SERIES (submitted in 2019)
	3PC-010	EVALUATION OF THE PRODUCTION ACCURACY AND ERROR RATE IN THE AUTOMATED COMPOUNDING OF CYTOTOXIC PREPARATIONS BY A ROBOT (submitted in 2019)
	3PC-011	CLOSED SYSTEM TRANSFER DEVICE BASED ON AIR FILTRATION: THE DRUG VAPOUR CHALLENGE (submitted in 2019)
	3PC-012	MANAGEMENT OF NON-ADMINISTERED CHEMOTHERAPY PREPARATION: AN OPPORTUNITY TO MINIMISE DRUG WASTE IN ONCOLOGY PHARMACY (submitted in 2019)
	3PC-013	COMPARATIVE BIOPHYSICAL STABILITY STUDY OF ZIV-AFLIBERCEPT (ZALTRAP, OPENED VIALS) STORED AT 4ºC AND ROOM TEMPERATURE FOR 2 WEEKS (submitted in 2019)
	3PC-014	USE OF CABAZITAXEL AND REDUCTION OF WASTE: THE POTENTIAL OF DRUG-DAY. (submitted in 2019)
	3PC-015	SHORT TERM STABILITY OF DILUTED SOLUTIONS OF THE MONOCLONAL ANTIBODY DARATUMUMAB (submitted in 2019)
	3PC-016	STABILITY OF COMPOUNDED NIVOLUMAB SOLUTION AFTER PNEUMATIC SYSTEM TRANSPORTATION (submitted in 2019)
	3PC-017	INCREASING PHARMACY PRODUCTIVITY BY EXPANDING THE ROLE OF THE INTRAVENOUS COMPOUNDING ROBOT IN A COMPREHENSIVE CANCER CENTRE (submitted in 2019)
	3PC-018	MITOMYCIN C STABILITY ACCORDING TO PH AND TEMPERATURE CONDITIONS (submitted in 2019)
	3PC-019	IN USE PHYSICOCHEMICAL AND MICROBIOLOGICAL STABILITY OF DILUTED SOLUTIONS OF THE MONOCLONAL ANTIBODY NIVOLUMAB (submitted in 2019)
	3PC-020	PHYSICOCHEMICAL STABILITY OF 25 MG/ML PEMETREXED DIARGININE IN PARTIALLY-USED VIALS AND 3 AND 12 MG/ML DILUTED IN DEXTROSE 5% IN POLYOLEFIN BAG. (submitted in 2019)
	3PC-021	STORAGE OF NIVOLUMAB, PEMBROLIZUMAB AND DARATUMUMAB FOR 14 DAYS AFTER COMPOUNDING IN THE HOSPITAL PHARMACY: A MICROBIOLOGICAL STABILITY STUDY (submitted in 2019)
	3PC-022	PARTICULATE QUALITY OF A CONTROLLED ATMOSPHERE AREA. COMPLIANCE WITH GOOD MANUFACTURING PRACTICES AT REST AND DURING ACTIVITY, HIGHLIGHTING OF FACTORS IMPACTING ON CONTAMINATION (submitted in 2019)
	3PC-023	DEVELOPMENT AND VALIDATION OF A DISCRIMINATIVE METHOD FOR ANTHRACYCLINES DRUGS USED IN ONCOLOGY BY VISIBLE SPECTROMETER (submitted in 2019)
	3PC-024	THE EFFECTS OF FREEZE-THAW CYCLING ON THE STABILITY OF THE ADALIMUMAB BIOSIMILAR SB5 (submitted in 2019)
	3PC-025	MAGISTRAL FORMULATION FOR A PATIENT WITH MULTIPLE FOOD ALLERGY (submitted in 2019)
	3PC-026	FORMULATION AND GALENIC CHARACTERISATION OF A TACROLIMUS ADHESIVE GEL FOR TREATMENT OF ULCERATIVE PROCTITIS (submitted in 2019)
	3PC-027	LONG TERM STABILITY OF A READY TO USE TOPICAL ANAESTHETIC GEL KIT (submitted in 2019)
	3PC-028	COMPOUNDING AN ORAL LIQUID FORMULATION OF DIAZEPAM ALCOHOL FREE (submitted in 2019)
	3PC-029	PAEDIATRIC DRUG RESISTANT EPILEPSY: NITRAZEPAM 1MG/ML SOLUTIONS TO AVOID CLINICAL THERAPEUTIC ERROR (submitted in 2019)
	3PC-030	ANALYTICAL METHOD VALIDATION TO CARRY OUT PHYSICOCHEMICAL STABILITY STUDIES OF METHADONE ORAL SOLUTIONS. (submitted in 2019)
	3PC-031	CURRENT STATE OF THE ANTI-INFECTIVE OPHTHALMIC COMPOUNDING FORMULATION IN PHARMACY SERVICES: A NATIONAL SURVEY (submitted in 2019)
	3PC-032	AUTOLOGOUS TISSUE ADHESIVE IN OPHTHALMOLOGICAL SURGERY (submitted in 2019)
	3PC-033	INTRACAMERAL AND INTRASTROMAL VORICONAZOLE ADMINISTRATION IN FUSARIUM KERATITIS (submitted in 2019)
	3PC-034	CONTENT UNIFORMITY OF EXTEMPORANEOUS COMPOUNDED SUSPENSIONS (submitted in 2019)
	3PC-035	93% OXYGEN SELF-PRODUCTION: EXPERIENCE IN NA ITALIAN HOSPITAL (submitted in 2019)
	3PC-036	CASE STUDY: DEVELOPMENT OF AN OINTMENT ACCORDING TO THE PHARMACEUTICAL INSPECTION CONVENTION GUIDELINE (submitted in 2019)
	3PC-037	STERILITY OF SINGLE USE VIALS WHEN ACCESSED USING A CLOSED SYSTEM TRANSFER DEVICE (submitted in 2019)
	3PC-038	PHYSICOCHEMICAL STABILITY OF THE BEVACIZUMAB BIOSIMILAR, ABP 215, IN INTRAVENOUS BAGS AFTER PREPARATION AND STORAGE (submitted in 2019)
	3PC-039	OPTIMISATION OF MIXING AN ORAL POWDER MIXTURE OF CODEINE PREPARED IN THE HOSPITAL PHARMACY FOR FILLING INTO HARD CAPSULES (submitted in 2019)
	3PC-040	GALENIC VALIDATION OF A DEXAMETHASONE 0.01% MOUTHWASH SOLUTION TO PREVENT EVEROLIMUS RELATED STOMATITIS (submitted in 2019)
	3PC-041	SURFACE CONTAMINATION WITH CYTOTOXIC DRUGS IN EUROPEAN HOSPITAL WARDS (submitted in 2019)
	3PC-042	THE SIGNIFICANCE OF PHARMACY PREPARATION IN PAEDIATRICS: MAKING INDIVIDUAL THERAPIES FOR CRITICALLY ILL CHILDREN POSSIBLE (submitted in 2019)
	3PC-043	HAZARDOUS DRUGS: IMPACT OF MEASURES FOR SAFE HANDLING (submitted in 2019)
	3PC-044	IN USE PHYSICOCHEMICAL STABILITY OF PEMBROLIZUMAB UNDER THE DILUTION CONDITION REQUIRED FOR USE IN A DAY HOSPITAL (submitted in 2019)
	3PC-045	IMPACT OF THE PREPARATION OF A CLINICAL SOLUTION OF RITUXIMAB 1.0 MG/ML ON THE PARTICULATES (AGGREGATION) MEASURED BY DYNAMIC LIGHT SCATTERING: SODIUM CHLORIDE AND GLUCOSE CONCENTRATION, AND AGITATION EFFECT (submitted in 2019)
	3PC-046	PARENTERAL NUTRITION ADMIXTURES: REVIEW OF THE MICROBIOLOGICAL SAMPLING PLAN (submitted in 2019)
	3PC-047	STUDY OF THE TRIGON DEPOT ALLERGY TEST (TRIAMCINOLONE AND EXCIPIENTS: CARBOXYMETHYLCELLULOSE, POLYSORBATE 80) DEVELOPED IN THE PHARMACY DEPARTMENT (submitted in 2019)
	3PC-048	IMPORTANCE OF NON-STERILE FORMULATION IN A PAEDIATRIC HOSPITAL (submitted in 2019)
	3PC-049	IMIPENEM-CILASTATIN FORTIFIED EYE DROPS FOR THE TREATMENT OF CORNEAL ULCERS CAUSED BY: CONTACT LENSES. DEVELOPMENT AND CHARACTERISATION (submitted in 2019)
	3PC-050	IMPORTANCE OF COMPOUNDING IN THE PAEDIATRIC HOSPITAL PHARMACY (submitted in 2019)
	3PC-051	CIRCUIT TO PREPARE AND CONDITION ORAL HAZARDOUS MEDICINES (submitted in 2019)
	3PC-052	HAZARDOUS MEDICINES IN A PAEDIATRIC HOSPITAL (submitted in 2019)
	3PC-053	IMPACT OF SERIALISATION ON RECEPTION OF MEDICINES AND ACTIVITY SMOOTHING (submitted in 2019)
	3PC-054	SODIUM BENZOATE SUSPENSION IN NON-KETOTIC HYPERGLYCINAEMIA: A CASE REPORT (submitted in 2019)
	3PC-055	STABILITY OF UROKINASE IN CITRATE BASED SOLUTIONS
	3PC-056	A STABLE READY-TO-USE FORMULATION OF PHENYLEPHRINE HCL IN SYRINGES
	3PC-057	USING DIFFERENT TECHNIQUES TO PREPARE ORODISPERSIBLE FILMS IN A HOSPITAL PHARMACY
	3PC-058	PHYSICOCHEMICAL STABILITY OF MEROPENEM IN POLYPROPYLENE SYRINGES AT 41.7 mg/mL FOR INTENSIVE CARE UNITS
	3PC-059	PHYSICOCHEMICAL STABILITY OF CEFTOLOZANE/TAZOBACTAM IN POLYPROPYLENE SYRINGES AT 61.5/31.25 mg/mL AND IN ELASTOMERIC DEVICES AT 25.0/12.5 mg/mL
	3PC-060	PHYSICOCHEMICAL STABILITY OF VANCOMYCIN SOLUTION IN ELASTOMERIC DEVICES AT 37.5 MG/ML IN 0.9% SODIUM CHLORIDE AND DEXTROSE 5% IN WATER
	3PC-061	PHYSICOCHEMICAL STABILITY OF CLOXACILLIN SOLUTION IN POLYPROPYLENE SYRINGES AT 125 MG/ML IN 0.9% SODIUM CHLORIDE AND DEXTROSE 5% IN WATER
	3PC-062	IMPACT OF THE PREPARATION OF THE 1.0 MG/ML NIVOLUMAB CLINICAL SOLUTION ON THE PARTICULATES (AGGREGATION) MEASURED BY DYNAMIC LIGHT SCATTERING: NaCl AND GLUCOSE CONCENTRATION AND AGITATION EFFECT
	3PC-063	PERFORMANCE QUALIFICATION OF ROBOTIC SYSTEM FOR CYTOTOXIC DRUG PREPARATION IN A FULLY GMP COMPLIANT HOSPITAL PHARMACY
	3PC-064	A MULTICENTRE STUDY COMPARING CHEMOTHERAPY PREPARATIONS USING A DIGITAL VIDEO MONITORING
	3PC-065	IMPACT OF LIGHT STRESS ON THE ISOFORM PROFILE OF NIVOLUMAB (OPDIVO) IN OPENED VIALS ESTIMATED BY (RP)UHPLC-UV-(HESI/ORBITRAP)-MS
	3PC-066	COMPOUNDING AN EYE DROP FORMULATION OF TOPICAL INSULIN FOR CORNEAL DEFECTS REFRACTORY TO PREVIOUS TREATMENT: EXPERIENCE IN REAL CLINICAL PRACTICE
	3PC-067	KEY ROLE OF HOSPITAL PHARMACY IN A NON-PROFIT STUDY INVOLVING RUXOLITINIB 5mg CPS: IMPLEMENTATION AND QUALITY ASSURANCE OF AN INVESTIGATIONAL MANUFACTURING PRODUCT
	3PC-068	LONG TERM STABILITY OF CO-ADMINISTRATION OF BUMETANIDE AND SCOPOLAMINE FOR THE PALLIATIVE CARE UNIT
	3PC-069	IMPROVING SAFETY AND QUALITY FOR ASEPTIC TRANSFER PROCEDURES IN HOSPITAL PHARMACIES
	3PC-070	EVALUATION OF COMPATIBILITY OF ACETYLSALICYLIC ACID AND ATENOLOL WITH MEDICATIONS COMMONLY USED IN INTENSIVE CARE UNITS
	3PC-071	FULLY AUTOMATED CENTRAL INTRAVENOUS ADDITIVE SERVICE (CIVAS): A 12 MONTH ANALYSIS OF PERFORMANCES AND IMPACT OF COVID-19 ON STERILE ANTIBIOTICS PRODUCTION
	3PC-072	WHICH MODEL TO ESTIMATE AT BEST THE THEORETICAL OSMOLARITY OF NOMINATIVE PARENTERAL NUTRITION?
	3PC-073	EVALUATION OF ANTIOBIOTICS' PHYSICOCHEMICAL INCOMPATIBILITY WITH THE PRESENCE OF DIVALENT CATIONS

Section 4: Clinical Pharmacy Services
PDF document	Poster number	Poster Title
	4CPS-001	EXPERIENCE WITH THE NEW DIRECT ACTING ANTIVIRAL AGENTS IN A THIRD LEVEL HOSPITAL IN 2018 (submitted in 2019)
	4CPS-002	ANTICHOLINERGIC BURDEN IN CONSTIPATED PATIENT ADMITTED TO AN EMERGENCY DEPARTMENT (submitted in 2019)
	4CPS-003	LIRAGLUTIDE IN CHRONIC INTESTINAL FAILURE: OVERVIEW AND CASE REPORT (submitted in 2019)
	4CPS-004	EVALUATION OF THE USE OF HYDROCORTISONE, VITAMIN C AND THIAMINE FOR THE TREATMENT OF SEPTIC SHOCK (submitted in 2019)
	4CPS-005	RISK FACTORS FOR PERSISTENCE AND TOLERANCE OF COW'S MILK ALLERGY (submitter in 2019)
	4CPS-006	USE OF AMMONIUM TETRATHIOMOLYBDATE IN WILSON DISEASE (submitted in 2019)
	4CPS-007	PHARMACEUTICAL CARE AS A MEANS OF PREVENTION AGAINST DRUG IATROGENESIS: CASE OF ORAL ANTICOAGULANTS (submitted in 2019)
	4CPS-008	RISK FACTORS ASSOCIATED WITH RE-ADMISSION TO THE EMERGENCY DEPARTMENT, IN PATIENTS WITH PREVIOUS GASTROINTESTINAL HAEMORRHAGE SECONDARY TO ORAL ANTICOAGULANT THERAPY (submitted in 2019)
	4CPS-009	DURATION OF DUAL ANTIPLATELET THERAPY IN CORONARY ARTERY DISEASE: IS PHARMACIST INTERVENTION NECESSARY TO IMPROVE PATIENT SAFETY? (submitted in 2019)
	4CPS-010	SAFETY AND EFFICACY OF LOW MOLECULAR WEIGHT HEPARINS IN PATIENTS WITH PORTAL VEIN THROMBOSIS (submitted in 2019)
	4CPS-011	PRESCRIPTION ANALYSIS OF DIRECT ACTING ORAL ANTICOAGULANTS (submitted in 2019)
	4CPS-012	AUDIT OF ORAL ANTICOAGULANT PRESCRIBING; WHAT HAS CHANGED IN 4 YEARS? (submitted in 2019)
	4CPS-013	EFFECT OF 2MG INTRAVENOUS PHYTONADIONE TREATMENT ON INTERNATIONAL NORMALISED RATIO IN THE HOSPITALISED ADULT (submitted in 2019)
	4CPS-014	CLINICAL AND ASSISTED IMPACT OF ISCHAEMICAL ICTUS IN PATIENTS TREATED WITH ORAL ANTICOAGULANTS (submitted in 2019)
	4CPS-015	SITUATIONAL ANALYSIS OF POSTOPERATIVE IRON SUPPLEMENTATION PRESCRIPTIONS IN A PLASTIC SURGERY DEPARTMENT (submitted in 2019)
	4CPS-016	INAPPROPRIATE USE OF HUMAN ALBUMIN IN A TEACHING HOSPITAL (submitted in 2019)
	4CPS-017	EFFICACY AND SAFETY OF TOLVAPTAN IN THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE (submitted in 2019)
	4CPS-018	EFFICACY OF UREA IN THE TREATMENT OF HYPONATRAEMIA IN SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION (submitted in 2019)
	4CPS-019	ALIROCUMAB AND EVOLOCUMAB: EFFECTIVENESS AFTER 3 YEARS OF FOLLOW-UP IN A REAL WORLD SETTING (submitted in 2019)
	4CPS-020	USE, EFFICACY AND ADHERENCE TO TREATMENT WITH PCKS9 INHIBITORS IN REAL CLINICAL PRACTICE (submitted in 2019)
	4CPS-021	ALIROCUMAB AND EVOLOCUMAB: RESULTS IN CLINICAL PRACTICE. (submitted in 2019)
	4CPS-022	PCSK9 INHIBITORS: EVALUATION OF EFFECTIVENESS IN OUR CENTRE IN RELATION TO THE OFFICIAL CLINICAL ENDPOINTS (submitted in 2019)
	4CPS-023	LONG-TERM EFFICACY, SAFETY AND ADHERENCE TO ALIROCUMAB IN PATIENTS WITH DYSLIPIDAEMIA FROM A TERTIARY HOSPITAL COHORT (submitted in 2019)
	4CPS-024	EFFECTIVENESS OF ANTI-INTERLEUKIN-17 DRUGS IN PSORIASIS IN CLINICAL PRACTICE (submitted in 2019)
	4CPS-025	DUPILUMAB IN THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS: CASE REPORTS (submitted in 2019)
	4CPS-026	DALBAVANCIN OFF-LABEL USE: EFFECTIVENESS AND SAFETY (submitted in 2019)
	4CPS-027	ANTIBIOTIC THERAPY REASSESSMENT AND ITS DOCUMENTATION: CAN VIRTUAL TOOLS IMPROVE PRACTICES? (submitted in 2019)
	4CPS-028	EXPERIENCE OF CEFTAROLINE USE IN A THIRD LEVEL HOSPITAL (submitted in 2019)
	4CPS-029	PRELIMINARY RESULTS OF AN ANTIMICROBIAL STEWARDSHIP PROGRAMME IN AN ONCOLOGY DEPARTMENT (submitted in 2019)
	4CPS-030	INCIDENCE AND RISK FACTORS FOR PROSTHETIC JOINT INFECTION WITHIN 90 DAYS AFTER HEMIARTHROPLASTY FOR FEMORAL NECK FRACTURES IN THE ELDERLY (submitted in 2019)
	4CPS-031	AUDIT OF ANTIBIOTIC PROPHYLAXIS PRACTICE IN VISCERAL SURGERY IN AN AFRICAN COUNTRY (submitted in 2019)
	4CPS-032	ANTIBIOTIC PRESCRIPTION THROUGH MOTIVATED REQUEST: CLINICAL PHARMACY TOOL TO IMPROVE APPROPRIATENESS AND LIMIT RESISTANT BACTERIAl STRAINS. A FOLLOW-UP AFTER A YEAR OF MONITORING IN A LOCAL HOSPITAL (submitted in 2019)
	4CPS-033	OFF-LABEL USE OF NEBULISED AZTREONAM LYSINE IN PATIENTS WITH CHRONIC GRAM-NEGATIVE BACTERIAL LUNG COLONISATION (submitted in 2019)
	4CPS-034	IS IT POSSIBLE TO RATIONALISE THE ANTIBIOTIC USE AMONG HOSPITALISED PATIENTS BY CLINICAL PHARMACISTS’ ACTIVITY? (submitted in 2019)
	4CPS-035	CLINICAL PHARMACOKINETICS OF VANCOMYCIN IN NEUTROPENIC PATIENTS (submitted in 2019)
	4CPS-036	PHARMACEUTICAL INTERVENTIONS IN A SMALL HOSPITAL (submitted in 2019)
	4CPS-037	CLINICAL OUTCOME IN PAEDIATRIC INTENSIVE CARE UNIT PATIENTS TREATED WITH VANCOMYCIN (submitted in 2019)
	4CPS-038	STABILITY TO HIGH TEMPERATURES OF THE ANTIMICROBIALS USED IN OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY PROGRAMMES (submitted in 2019)
	4CPS-039	NOSOCOMIAL INFECTION BY MULTIRESISTANT PATHOGENS IN KIDNEY TRANSPLANTED PATIENTS (submitted in 2019)
	4CPS-040	ADEQUACY OF ANTIBIOTIC PRESCRIPTIONS IN A NURSING HOME (submitted in 2019)
	4CPS-041	PHARMACIST LED ANTIMICROBIAL STEWARDSHIP PROGRAMME (submitted in 2019)
	4CPS-042	PHARMACIST'S MISSION IN INFECTION MANAGEMENT : EVALUATION OF IMPROVEMENT ACTIONS (submitted in 2019)
	4CPS-043	EFFECTIVENESS OF A NEW INTERNAL PROTOCOL FOR DOSAGE OF VANCOMYCIN IN NEONATES (submitted in 2019)
	4CPS-044	THE ROUTINE USE OF ANTIBIOTICS AFTER INSERTION OF A CARDIAC IMPLANTABLE ELECTRONIC DEVICE (CIED): EVIDENCE AND CURRENT PRACTICE (submitted in 2019)
	4CPS-045	COST EFFECTIVENESS ANALYSIS OF MEROPENEM DOSE OPTIMISATION IN CRITICAL PATIENTS (submitted in 2019)
	4CPS-046	MONITORING THE PRESCRIPTION OF NEW ANTIBIOTICS: THE WORK OF THE ANTIMICROBIAL STEWARDSHIP TEAM IN A THIRD LEVEL HOSPITAL (submitted in 2019)
	4CPS-047	ASSESSING THE IMPACT OF ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN HOSPITALS: ROLE OF HOSPITAL PHARMACISTS. (submitted in 2019)
	4CPS-048	BETA-LACTAM ANTIBIOTICS IN CRITICAL ILL PATIENTS: ARE WE DOSING CORRECTLY OUR PATIENTS CORRECTLY? (submitted in 2019)
	4CPS-049	UNDERDOSING WITH HIGH DOSE PIPERACILLIN/TAZOBACTAM ADMINISTERED VIA CONTINUOUS INFUSION IN OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY: A STABILITY OR VISCOSITY PROBLEM? (submitted in 2019)
	4CPS-050	CONFORMITY OF ANTIBIOTIC THERAPY DURATION IN PATIENTS WITH FEBRILE NEUTROPENIA, HOSPITALISED IN THE HAEMATOLOGY DEPARTMENT OF A UNIVERSITY HOSPITAL (submitted in 2019)
	4CPS-051	ANTIBIOTICS IN THE EMERGENCY DEPARTMENT: IS IT POSSIBLE TO IMPROVE THE PRESCRIPTIONS FOR INFECTIOUS RESPIRATORY DISEASES IN AMBULATORY PATIENTS? (submitted in 2019)
	4CPS-052	EVALUATION OF PIPERACILIN/TAZOBACTAM DOSAGE IN SEPTIC PATIENTS ATTENDING THE EMERGENCY DEPARTMENT (submitted in 2019)
	4CPS-053	ANTIMICROBIAL STEWARDSHIP PROGRAMME IN AN INTENSIVE CARE UNIT (submitted in 2019)
	4CPS-054	A MULTIDISCIPLINARY AND EDUCATIONAL APPROACH TO ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN THE EMERGENCY DEPARTMENT (submitted in 2019)
	4CPS-055	EVALUATION OF USE, EFFECTIVENESS AND SAFETY OF ISAVUCONAZOL (submitted in 2019)
	4CPS-056	PROPER USE OF ANTIFUNGALS: IMPLEMENTATION OF OPERATIONAL MULTIDISCIPLINARY TEAMS DEDICATED TO ANTIFUNGALS (submitted in 2019)
	4CPS-057	THERAPEUTIC DRUG MONITORING OF VORICONAZOLE (submitted in 2019)
	4CPS-058	MANAGEMENT OF THE HOSPITALISED PATIENT WITH FLU (submitted in 2019)
	4CPS-059	STRATEGY FOR CHANGE IN ANTIRETROVIRAL THERAPY: LOOKING FOR BETTER RESULTS (submitted in 2019)
	4CPS-060	PRESCRIPTION ANALYSIS OF TENOFOVIR DISPROXIL FUMARATE AND TENOFOVIR ALAFENAMIDE FUMARATE IN A THIRD LEVEL HOSPITAL (submitted in 2019)
	4CPS-061	ADHERENCE TO ANTIRETROVIRAL TREATMENT AS A FUNCTION OF THE COMPLEXITY OF THE TREATMENT (submitted in 2019)
	4CPS-062	PATIENTS WITH DARUNAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE TREATMENT IN A THIRD LEVEL HOSPITAL (submitted in 2019)
	4CPS-063	USE OF OSELTAMIVIR IN THE TREATMENT OF INFLUENZA A (submitted in 2019)
	4CPS-064	ADHERENCE TO ANTIRETROVIRAL TREATMENT IN PATIENTS WITH HIV (submitted in 2019)
	4CPS-065	SWITCHING TO EQUIVALENT ALTERNATIVES: ANTIRETROVIRAL OPTIMISATION STRATEGY (submitted in 2019)
	4CPS-066	CHANGING FROM COBICISTAT TO A RITONAVIR BOOSTED REGIMEN IN HIV POSITIVE PATIENTS (submitted in 2019)
	4CPS-067	ANALYSIS OF USAGE OF DIRECT ACTIN ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C. (submitted in 2019)
	4CPS-068	EFFECTIVENESS OF DOLUTEGRAVIR AND LAMIVUDINE THERAPY IN A TWO DRUG REGIMEN IN A THIRD LEVEL HOSPITAL. (submitted in 2019)
	4CPS-069	EVALUATION OF PALIVIZUMAB AS PROPHYLAXIS AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION (submitted in 2019)
	4CPS-070	ANALYSIS OF THE USE OF NON-SPECIFIC INTRAVENOUS IMMUNOGLOBULINS IN A TERTIARY HOSPITAL. (submitted in 2019)
	4CPS-071	ANALYSIS OF EFFECTIVENESS: USE OF PERTUZUMAB AND TRASTUZUMAB IN NEOADJUVANT TREATMENT IN PATIENTS WITH HER2 POSITIVE BREAST CANCER AND ITS CORRELATION WITH PLASMA LEVELS OF TRASTUZUMAB (submitted in 2019)
	4CPS-072	COMPARISON OF IMMUNE CHECKPOINT INHIBITORS (NIVOLUMAB, PEMBROLIZUMAB, ATÉZOLIZUMAB AND DURVALUMAB) IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER: TOLERANCE AND FINANCIAL IMPACT (submitted in 2019)
	4CPS-073	EFFECTIVENESS AND SAFETY OF PLATIN/PERMETREXED COMBINATION IN NON-SMALL CELL LUNG CANCER. (submitted in 2019)
	4CPS-074	CYCLIN DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER: POTENTIAL DRUG INTERACTIONS (submitted in 2019)
	4CPS-075	IBRUTINIB ASSOCIATED ATRIAL FIBRILLATION: INCIDENCE AND MANAGEMENT IN THE REAL LIFE CLINICAL SETTING (submitted in 2019)
	4CPS-076	INDIRECT COMPARISON BETWEEN PEMBROLIZUMAB MONOTHERAPY AND PEMBROLIZUMAB CHEMOTHERAPY REGIMENE IN SQUAMOUS LUNG CANCER (submitted in 2019)
	4CPS-077	DETECTION AND COMMUNICATION OF CONCOMITANT USE OF CAPECITABINE AND PROTON PUMP INHIBITORS (submitted in 2019)
	4CPS-078	EFFECTIVENESS AND SAFETY OF ERIBULIN FOR ADVANCED BREAST CANCER TREATMENT (submitted in 2019)
	4CPS-079	SEQUENCING OF IBRUTINIB, IDELALISIB AND VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKAEMIA: EXPERIENCE IN A TERTIARY HOSPITAL (submitted in 2019)
	4CPS-080	REAL LIFE TYROSINE KINASE INHIBITOR DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (submitted in 2019)
	4CPS-081	GEFITINIB IN NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY. (submitted in 2019)
	4CPS-082	RISK OF MYELOTOXICITY IN NON-CANCER PATIENTS TREATED WITH CHEMOTHERAPY (submitted in 2019)
	4CPS-083	SAFETY AND TOLERABILITY OF PALBOCICLIB IN CLINICAL PRACTICE IN A TERTIARY HOSPITAL (submitted in 2019)
	4CPS-084	ANTHRACYCLINES DOSAGE IN PAEDIATRIC OBESE PATIENTS (submitted in 2019)
	4CPS-085	IMPROVED ACCESS TO CHEMOTHERAPEUTIC TREATMENT IN PATIENTS WITH MULTIPLE MYELOMA (submitted in 2019)
	4CPS-086	IMATINIB DOSE OPTIMISATION THROUGH THERAPEUTIC MONITORING IN CHRONIC MYELOID LEUKAEMIA AS PART OF PHARMACEUTICAL CARE (submitted in 2019)
	4CPS-087	OPTIMISATION OF RESOURCES IN THE USE OF IMUNOTHERAPY: NIVOLUMAB AND PEMBROLIZUMAB IN WEIGHT-BASED DOSING INSTEAD OF FLAT DOSE. (submitted in 2019)
	4CPS-088	CHECKPOINT INHIBITORS IN NON-MICROCYTIC LUNG CANCER: RESULTS IN COMMON CLINICAL PRACTICE (submitted in 2019)
	4CPS-089	COMPARATIVE EFFECTIVENESS OF NINTEDANIB PLUS DOCETAXEL VERSUS DOCETAXEL MONOTHERAPY IN ADENOCARCINOMA NON-SMALL CELL LUNG CANCER (submitted in 2019)
	4CPS-090	EFFICACY AND SAFETY OF ERLOTINIB IN NON-SMALL CELL LUNG CANCER (submitted in 2019)
	4CPS-091	EVALUATION OF AGGRESSIVENESS OF CANCER CARE NEAR THE END OF LIFE IN PATIENTS WITH PANCREATIC CANCER (submitted in 2019)
	4CPS-092	EVALUATION OF AGGRESSIVENESS OF CANCER CARE NEAR THE END OF LIFE IN PATIENTS WITH METASTATIC NON-MICROCYTIC LUNG CANCER (submitted in 2019)
	4CPS-093	EFFECTIVENESS OF DEXAMETHASONE MOUTHWASH 0.1MG/ML FOR PREVENTION OF EVEROLIMUS RELATED STOMATITIS (submitted in 2019)
	4CPS-094	CHARACTERISATION OF POTENTIAL DRUG-DRUG INTERACTIONS IN ONCOLOGICAL PATIENTS TREATED WITH ORAL ANTICANCER DRUGS (submitted in 2019)
	4CPS-095	REVIEWING THE LATEST CLINICAL RESEARCH FOR TREATING ADVANCED NON-SMALL CELL LUNG CANCER: SELECTION OF RANDOMISED CONTROLLED TRIALS PUBLISHED IN 2018 (submitted in 2019)
	4CPS-096	EVALUATION OF CLINICAL PHARMACY SERVICES IN A HAEMATOLOGY OUTPATIENT SETTING. (submitted in 2019)
	4CPS-097	SECOND LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WITH IMMUNE CHECKPOINT INHIBITORS (submitted in 2019)
	4CPS-098	INDIRECT TREATMENT COMPARISONS OF IBRUTINIB-OBINOTUZUMAB VERSUS VENETOCLAX-OBINOTUZUMAB IN NAIVE CHRONIC LYMPHOCYTIC LEUKAEMIA (submitted in 2019)
	4CPS-099	REAL WORLD EVIDENCE OF PEMBROLIZUMAB AS MONOTHERAPY IN NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY STUDY (submitted in 2019)
	4CPS-100	ANTHRACYCLINE DOSING IN OBESE ADULT PATIENTS: A SYSTEMATIC REVIEW (submitted in 2019)
	4CPS-101	TRIFLURIDINE-TIPIRACIL FOR METASTATIC COLORECTAL CANCER: REAL WORLD DATA EXPERIENCE (submitted in 2019)
	4CPS-102	INFLUENCE OF PALBOCICLIB TOXICITY IN THE REAL WORLD CLINICAL PRACTICE (submitted in 2019)
	4CPS-103	IS THERE A ROLE FOR THE PHARMACIST IN SCREENING FOR METABOLIC SYNDROME? (submitted in 2019)
	4CPS-104	SWITCHING ORAL ANTIANDROGENIC TREATMENT IN PATIENTS WITH CASTRATE METASTATIC PROSTATE CANCER: AN ANALYSIS. (submitted in 2019)
	4CPS-105	TOLERANCE PROFILE TO ANTI-THYMOCYTE IMMUNOGLOBULIN TREATMENT AND ITS RELATION TO INFECTIOUS PARAMETERS IN PAEDIATRIC PATIENTS (submitted in 2019)
	4CPS-106	ANALYSIS OF THE PRESCRIPTION AND SAFE DRUG ADMINISTRATION OF OCRELIZUMAB (submitted in 2019)
	4CPS-107	IMPACT OF A TOOL IN THE ELECTRONIC CLINICAL HISTORY FOR THE OPTIMISATION OF BIOLOGIC DRUGS IN RHEUMATOLOGY (submitted in 2019)
	4CPS-108	A REVIEW OF INFLIXIMAB BIOSIMILAR TO BIOSIMILAR SWITCH: REMSIMA TO FLIXABI (submitted in 2019)
	4CPS-109	ANALYSIS OF CHANGES IN DISEASE MODIFYING TREATMENT IN THE MANAGEMENT OF PATIENTS WITH MULTIPLE SCLEROSIS (submitted in 2019)
	4CPS-110	VEDOLIZUMAB: OUTCOMES AND THERAPEUTIC DRUG MONITORING IN INFLAMMATORY BOWEL DISEASE (submitted in 2019)
	4CPS-111	CLINICAL AND ECONOMIC IMPACT OF INFLIXIMAB BIOSIMILAR INFLECTRA IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHROPATHY AND ANKYLOSING SPONDYLITIS NAÏVE AND SWITCHED PATIENTS: AFTER 5 YEARS OF FOLLOW-UP (submitted in 2019)
	4CPS-112	ADHERENCE TO ADALIMUMAB, GOLIMUMAB AND USTEKINUMAB THERAPY IN INFLAMMATORY BOWEL DISEASE (submitted in 2019)
	4CPS-113	INOTUZUMAB OZOGAMIZIN FOR THE TREATMENT OF THE RELAPSE B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA IN AN ADULT PATIENT: A CASE REPORT. (submitted in 2019)
	4CPS-114	BELIEFS ABOUT MEDICATION AND QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS TREATED WITH NATALIZUMAB (submitted in 2019)
	4CPS-115	THERAPEUTIC DRUG MONITORING OF ETANERCEPT BIOSIMILAR IN PSORIATIC PATIENTS (submitted in 2019)
	4CPS-116	TEN YEARS OF EXPERTISE IN USTEKINUMAB USE FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS (submitted in 2019)
	4CPS-117	CASE REPORT: USEFULNESS OF THERAPEUTIC DRUG MONITORING OF VEDOLIZUMAB IN MANAGING ACUTE GRAFT VERSUS HOST DISEASE (submitted in 2019)
	4CPS-118	REAL CLINICAL IMPACT OF DRUG-DRUG INTERACTIONS OF IMMUNOSUPPRESSANTS IN TRANSPLANT PATIENTS. (submitted in 2019)
	4CPS-119	“REAL WORLD” EXPERIENCE OF TOFACITINIB AND BARICITINIB IN THE TREATMENT OF RHEUMATOID ARTHRITIS: EFFECTIVENESS AND SAFETY EVALUATION (submitted in 2019)
	4CPS-120	TEN YEAR ANALYSIS OF THE USE OF INFLIXIMAB IN ULCERATIVE COLITIS (submitted in 2019)
	4CPS-121	EVALUATION OF COST AND EFFICACY OF ECULIZUMAB IN COMPLEMENT MEDIATED THROMBOTIC MICROANGIOPATHY IN THE CLINICAL SETTING (submitted in 2019)
	4CPS-122	POTENTIAL OPTIMISATION OF TREATMENT WITH USTEKINUMAB IN CROHN'S DISEASE (submitted in 2019)
	4CPS-123	EVALUATION OF ADHERENCE TO ORAL DISEASE MODIFYING THERAPIES (ORAL-DMT) IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (submitted in 2019)
	4CPS-124	ADHERENCE TO SELECTIVE IMUNOSUPPRESSIVE DRUGS TREATMENTS IN PATIENTS WITH INFLAMMATORY IMMUNE-MEDIATED DISEASES (submitted in 2019)
	4CPS-125	ACCEPTANCE OF PHARMACOKINETIC RECOMMENDATIONS FOR EVEROLIMUS IN RENAL TRANSPLANT PATIENTS (submitted in 2019)
	4CPS-126	A POPULATION PHARMACOKINETIC MODEL OF ADALIMUMAB IN A COHORT OF PAEDIATRIC PATIENTS WITH INFLAMMATORY BOWOL DISEASE: A PRELIMINARY ANALYSIS (submitted in 2019)
	4CPS-127	ECONOMIC IMPACT OF INTENSIFICATION REGIMENS IN INFLAMMATORY BOWEL DISEASE (submitted in 2019)
	4CPS-128	LIVER TRANSPLANT AND DIABETES MELLITUS (submitted in 2019)
	4CPS-129	PILOT STUDY TO SURVEY THE ATTITUDE, SUPPLEMENT USE AND STORAGE CONDITIONS OF DRUG PRODUCTS AMONG PATIENTS RECEIVING BIOLOGICAL THERAPY (submitted in 2019)
	4CPS-130	ONE IN A MILLION: A TNF RECEPTOR-1 ASSOCIATED SYNDROME RESISTANT TO ANTI-TNF-ALPHA THERAPY. (submitted in 2019)
	4CPS-131	EFFECTIVENESS OF NUSINERSEN IN PAEDIATRIC PATIENTS SMA1 AND SMA2 (submitted in 2019)
	4CPS-132	INDIRECT TREATMENT COMPARISON OF ANTICALCITONIN GENE RELATED PEPTIDE PATHWAY ANTIBODIES IN CHRONIC MIGRAINE (submitted in 2019)
	4CPS-133	IS PARACETAMOL A REAL ALTERNATIVE IN THE MANAGEMENT OF PATENT DUCTUS ARTERIOSUS IN PRETERM INFANTS? (submitted in 2019)
	4CPS-134	PREVALENCE ANALYSIS OF PATIENTS TREATED WITH TRIPTANS AT RISK OF DEVELOPING MEDICATION OVERUSE HEADACHE AND DEVELOPMENT OF A PRESCRIPTION OPTIMISATION STRATEGY. (submitted in 2019)
	4CPS-135	PERPHENAZINE AND PROPRANOLOL POISONING: A CASE REPORT. (submitted in 2019)
	4CPS-136	DEXMEDETOMIDINE TREATMENT FOR THE SEDATION OF PRETERM NEONATES (submitted in 2019)
	4CPS-137	REVIEW OF 3 MONTH PRESCRIPTIONS CONTAINING DRUGS INDUCING QT PROLONGATION AND TORSADE DE POINTE (submitted in 2019)
	4CPS-138	AN OBSERVATIONAL RETROSPECTIVE STUDY ON TREATMENT ADHERENCE OF LONG ACTING INJECTABLE ANTIPSYCHOTICS (submitted in 2019)
	4CPS-139	PSYCHOTROPIC DRUG USAGE IN OCTOGENARIAN AND NONAGENARIAN COMPLEX CHRONIC PATIENTS (submitted in 2019)
	4CPS-140	CURRENT STATUS OF CLINICAL TRIALS FOR ALZHEIMER’S DISEASE (submitted in 2019)
	4CPS-141	EFFECTIVENESS OF IMMUNOTHERAPY IN SEVERE UNCONTROLLED ASTHMA (submitted in 2019)
	4CPS-142	EFFECTIVENESS AND SAFETY OF ANTI-IL-5 BIOLOGIC AGENTS IN SEVERE EOSINOPHILIC ASTHMA (submitted in 2019)
	4CPS-143	TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTION PULMONARY DISEASE: ARE OUR HOSPITAL NURSES AND PHYSICIANS READY TO TREAT AND EDUCATE IN-PATIENTS? (submitted in 2019)
	4CPS-144	SAFETY AND EFFECTIVENESS OF REDUCED DOSE OF OMALIZUMAB FOR CHRONIC IDIOPATHIC URTICARIA (submitted in 2019)
	4CPS-145	EVALUATION OF A PHARMACEUTICAL CARE PROGRAMME FOR PATIENTS BEING TREATED WITH OMALIZUMAB (submitted in 2019)
	4CPS-146	EFFECTIVENESS AND SAFETY OF OMALIZUMAB IN THE TREATMENT OF SEVERE UNCONTROLLED ASTHMA (submitted in 2019)
	4CPS-147	THERAPEUTIC POSITIONING AND USE OF INTRAVITREAL RANIBIZUMAB AND AFLIBERCEPT (submitted in 2019)
	4CPS-148	CLINICAL EVALUATION AND SATISFACTION OF PATIENTS TREATED WITH PRGF-ENDORET (PLASMA RICH IN GROWTH FACTORS) (submitted in 2019)
	4CPS-149	INITIAL THERAPY FOR NEOVASCULAR AGE RELATED MACULAR DEGENERATION: ARE THE GUIDELINES MET IN CLINICAL PRACTICE? (submitted in 2019)
	4CPS-150	ASSESSMENT OF BURDEN OF DISEASE IN TERMS OF HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH MULTIPLE MYELOMA NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (submitted in 2019)
	4CPS-151	THE IMPACT OF AN INTEGRATED ELECTRONIC MEDICAL RECORD ON THERAPEUTIC DRUG MONITORING (submitted in 2019)
	4CPS-152	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS IN THE EXCHANGE OF THERAPEUTIC EQUIVALENTS (submitted in 2019)
	4CPS-153	INTENSIFICATION IN BIOLOGICAL TREATMENT IN ULCERATIVE COLITIS (submitted in 2019)
	4CPS-154	POTENTIALLY INAPPROPRIATE MEDICATION FOR ELDERLY HOSPITALISED PATIENTS IN A TRAUMA AND ORTHOPAEDIC SURGERY DEPARTMENT (submitted in 2019)
	4CPS-155	REAL LIFE EXPERIENCE OF HOME CARE ADMINISTRATION OF 5-AZACITIDINE AND DOMICILIARY MANAGEMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (submitted in 2019)
	4CPS-156	ANALYSIS OF THE EFFECTIVENESS AND SAFETY OF DARATUMUMAB IN MONOTHERAPY IN ADULT PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (submitted in 2019)
	4CPS-157	INTRAVENOUS BIOSIMILAR PRESCRIBING TRENDS IN A THIRD LEVEL SPANISH HOSPITAL (submitted in 2019)
	4CPS-158	PRESCRIBING TRENDS OF ADALIMUMAB AND ETANERCEPT BIOSIMILAR DRUGS IN A THIRD LEVEL HOSPITAL (submitted in 2019)
	4CPS-159	MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA AT A TERTIARY CARE TEACHING HOSPITAL (submitted in 2019)
	4CPS-160	MANAGEMENT OF DRUGS IN PATIENTS WITH SWALLOWING DIFFICULTIES IN A PUBLIC RESIDENTIAL CARE HOME: ROLE OF THE HOSPITAL PHARMACIST (submitted n 2019)
	4CPS-161	PHARMACIST INTERVENTIONS IN A HOSPITAL AT HOME UNIT (submitted in 2019)
	4CPS-162	PHARMACEUTICAL INTERVENTIONS IN DRUGS PROVIDED TO THE OUTPATIENT HOSPITAL PHARMACY (submitted in 2019)
	4CPS-163	CLINICAL PHARMACIST RESIDENCE IN AN INTENSIVE CARE UNIT: SCOPE AND RELEVANCE (submitted in 2019)
	4CPS-164	A SAFE HANDLING HAZARDOUS DRUGS STRATEGY TO IMPROVE THE SAFETY OF HEALTH PROFESSIONALS: REDUCING EXPOSURE BY MEDICAL PRESCRIPTION REVIEW IN NURSING HOMES (submitted in 2019)
	4CPS-165	ANALYSIS OF ANTIBIOTIC CONSUMPTION IN A NURSING HOME (submitted in 2019)
	4CPS-166	ANALYSIS OF THE MAINTENANCE RATE OF LONG ACTING INJECTABLE ANTIPSYCHOTIC TREATMENT IN OUTPATIENTS (submitted in 2019)
	4CPS-167	EVALUATION OF PHARMACEUTICAL INTERVENTIONS: IMPROVEMENT PLANS (submitted in 2019)
	4CPS-168	DEVELOPMENT OF A BELGIAN CLASSIFICATION SYSTEM FOR CLINICAL PHARMACY ACTIVITIES (submitted in 2019)
	4CPS-169	EFFECT OF ABIRATERONE VERSUS ENZALUTAMIDE ON PROSTATE SPECIFIC ANTIGEN LEVELS IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (submitted in 2019)
	4CPS-170	ANALYSIS AND EVALUATION OF PHARMACEUTICAL INTERVENTIONS PERFORMED IN THE EMERGENCY DEPARTMENT OF A TERTIARY HOSPITAL (submitted in 2019)
	4CPS-171	PHARMACISTS AT THE HEALTH CENTRE (submitted in 2019)
	4CPS-172	OFF-LABEL USE OF INTRALESIONAL CIDOFOVIR IN RECURRENT RESPIRATORY PAPILLOMATOSIS: A CASE REPORT. (submitted in 2019)
	4CPS-173	ROLE OF THE PHARMACIST IN THE MULTIDISCIPLINARY MANAGEMENT OF OSTEOMYELITIS: FROM MEDICATION RECONCILIATION TO SUPPORT IN CLINICAL DECISION MAKING. (submitted in 2019)
	4CPS-174	FACILITATORS AND BARRIERS TO PERFORMING COMPREHENSIVE MEDICATION REVIEWS AND FOLLOW-UP IN OLDER HOSPITALISED PATIENTS BY MULTIPROFESSIONAL WARD TEAMS INCLUDING A CLINICAL PHARMACIST (submitted in 2019)
	4CPS-175	EVOLUTION OF ANTIMICROBIAL CONSUMPTION IN A TRAUMA INTENSIVE CARE UNIT USING DEFINED DAILY DOSES PER 100 OCCUPIED BED DAYS (submitted in 2019)
	4CPS-176	ELECTROLYTE DISTURBANCES IN PREMATURE INFANTS WITH INTRAUTERINE GROWTH RESTRICTION RECEIVING PARENTERAL NUTRITION (submitted in 2019)
	4CPS-177	COMPARATIVE STUDY OF PATIENT PROFILES AND INITIAL ANTIRETROVIRAL TREATMENT IN 2014 VERSUS 2018 (submitted in 2019)
	4CPS-178	TRANSCRIPTION OF SUPPORTIVE MEDICATION FOR INPATIENT CHEMOTHERAPY BY DESIGNATED ONCOLOGY WARD PHARMACISTS (submitted in 2019)
	4CPS-179	THE WIDE REVIEW OF POLYPHARMACY IN THE FRAIL OLDER PERSON (submitted in 2019)
	4CPS-180	FROM EVIDENCE BASED MEDICINE TO PRACTICE: GUM CHEWING FOR POSTOPERATIVE RECOVERY OF GASTROINTESTINAL FUNCTION AFTER COLORECTAL SURGERY WITH INTERPROFESSIONAL TEAMWORK (submitted in 2019)
	4CPS-181	BUDGETARY IMPACT OF BIOSIMILAR PRESCRIPTION IN THE TREATMENT OF RHEUMATIC DISEASES (submitted in 2019)
	4CPS-182	PRELIMINARY DESIGN OF HOSPITAL TELEPHARMACY (submitted in 2019)
	4CPS-183	SELECTION OF A POPULATION PHARMACOKINETIC MODEL OF ADALIMUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE SUITABLE FOR THERAPEUTIC DRUG MONITORING (submitted in 2019)
	4CPS-184	EVALUATION OF A CLINICAL PHARMACY SERVUCE ON AN INPATIENT WARD IN AN ACUTE HOSPITAL (submitted in 2019)
	4CPS-185	ADMINISTRATION OF ORAL ANTICANCER DRUGS FOR PATIENTS WITH SWALLOWING DIFFICULTIES (submitted in 2019)
	4CPS-186	DESCRIPTION OF PHARMACEUTICAL INTERVENTIONS IN AN INTENSIVE CARE UNIT (submitted in 2019)
	4CPS-187	PROGNOSTIC VALUE OF HAEMATOLOGICAL INFLAMMATORY MARKERS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER TREATED WITH PEMBROLIZUMAB (submitted in 2019)
	4CPS-188	PHARMACEUTICAL INTERVENTION TO REDUCE THE ANTICHOLINERGIC BURDEN IN OLDER HOSPITALISED PATIENTS (submitted in 2019)
	4CPS-189	FALL INCIDENTS IN NURSING HOME PATIENTS: DEVELOPMENT OF A PREDICTIVE CLINICAL RULE (FINDER) (submitted in 2019)
	4CPS-190	EVALUATION OF A NEW CLINICAL PHARMACY SERVICE WITHIN A NEWLY LAUNCHED SURGICAL ADMISSION PROCESS (submitted in 2019)
	4CPS-191	PHARMACEUTICAL INTERVENTIONS IN A MEDICATION RECONCILIATION PROGRAMME UPON ADMISSION IN SURGICAL PATIENTS (submitted in 2019)
	4CPS-192	ESTIMATING THE SURVIVAL PROGNOSIS OF PATIENTS WITH ADVANCED GASTROINTESTINAL MALIGNANCY ON HOME PARENTERAL NUTRITION: A RETROSPECTIVE, MONOCENTRE STUDY (submitted in 2019)
	4CPS-193	MEASURING THE IMPACT OF HOSPITAL PHARMACIST PRESCRITION REVIEWING IN AN ONCOLOGY SETTING ON THE PHARMACOVIGILANCE REPORTING IN A COMPREHENSIVE CANCER CENTRE (submitted in 2019)
	4CPS-194	THE UNDERREPORTING RATE AS A PHARMACOVIGILANCE PROCESS INDICATOR IN A COMPREHENSIVE CANCER CENTRE (submitted in 2019)
	4CPS-195	PHARMACEUTICAL INTERVENTIONS IN PARENTERAL NUTRITION FOR CRITICALLY ILL PATIENTS (submitted in 2019)
	4CPS-196	STABILITY OF LIPID EMULSION IN PAEDIATRIC PARENTERAL NUTRITION WITH HIGH ELECTROLYTIC LOAD (submitted in 2019)
	4CPS-197	MONITORING OF OFF-LABEL USE: ANALYSIS OF PRESCRIPTIONS IN THE PHARMACY'S ANTIBLASTIC DRUGS UNIT (submitted in 2019)
	4CPS-198	RESULTS OF A MEDICATION RECONCILIATION PROGRAMME IN COMPLEX CHRONIC PATIENTS AT HOSPITAL DISCHARGE (submitted in 2019)
	4CPS-199	PHARMACEUTICAL INTERVENTIONS IN HAEMODIALYSIS PATIENTS: A 2 YEAR OVERVIEW (submitted in 2019)
	4CPS-200	DIFFERENCES IN ALLELIC FREQUENCIES OF RELEVANT PHARMACOGENETIC POLYMORPHISMS MAY LEAD TO LOCAL GENE PANEL DEVELOPMENT (submitted in 2019)
	4CPS-201	IDENTIFICATION OF HAZARDOUS DRUGS AND PROCESS IN A UNIVERSITY HOSPITAL (submitted in 2019)
	4CPS-202	NUTRITIONAL RISK EVALUATION IN INSTITUTIONALISED ELDERLY PATIENTS IN A PUBLIC NURSING HOME (submitted in 2019)
	4CPS-203	NURSES: WHAT DO YOU THINK ABOUT A PHARMACEUTICAL PRESENCE IN THE EMERGENCY WARD? (submitted in 2019)
	4CPS-204	MEDICINE RECONCILIATION AT HOSPITAL DISCHARGE (submitted in 2019)
	4CPS-205	ASSESSMENT OF THE PALATABILITY OF ANTIBIOTIC ORAL SUSPENSIONS: A LITERATURE REVIEW. (submitted in 2019)
	4CPS-206	IMPACT OF MEDICATION RECONCILIATION IN COMPLEX CHRONIC PATIENTS (submitted in 2019)
	4CPS-207	TREATMENT ADEQUACY IN DOMICILIARY CARE PROGRAMME PATIENTS (submitted in 2019)
	4CPS-208	NUTRITIONAL SUPPORT IN ONCOLOGY: A CROSS SECTIONAL STUDY AMONG CANCER PATIENTS (submitted in 2019)
	4CPS-209	AN EXPLORATION INTO A PHARMACIST-LED MEDICINES RECONCILIATION SERVICE IN AN ACUTE HOSPITAL SETTING. (submitted in 2019)
	4CPS-210	PHARMACISTS’ COMMUNICATION WITH FOREIGN LANGUAGE SPEAKING PATIENTS IN A FOREIGNER SETTLEMENT AREA, JAPAN (submitted in 2019)
	4CPS-211	ADHERENCE AND INTERACTIONS IN PATIENTS TREATED WITH ABIRATERONE AND ENZALUTAMIDE (submitted in 2019)
	4CPS-212	HEALTHCARE PROVIDERS' VIEWS OF PHARMACY TEAM INVOLVEMENT IN THE PREPARATION AND ADMINISTRATION OF MEDICINES ON INPATIENTS WARDS: AN EXPLORATORY STUDY (submitted in 2019)
	4CPS-213	PATIENT PERCEPTIONS OF GENERIC MEDICINES 20 YEARS AFTER THE RIGHT OF SUBSTITUTION BY PHARMACISTS (submitted in 2019)
	4CPS-214	IMPROVING INTRAVENOUS TO ORAL SWITCH BY IDENTIFYING AND TACKLING BARRIERS PERCEIVED BY PHYSICIANS AND NURSES (submitted in 2019)
	4CPS-215	THE IMPACT OF CLINICAL PHARMACIST DRIVEN INTERVENTIONS ON PATIENT SAFETY IN HOSPITALISED PATIENTS: PRELIMINARY RESULTS OF A POINT PREVALENCE STUDY (submitted in 2019)
	4CPS-216	PROMOTION OF THE QUALITY OF DRUG EDUCATION FOR THE PATIENTS USING NASOGASTRIC TUBE FEEDING BEFORE DISCHARGE (submitted in 2019)
	4CPS-217	NETUPITANT-PALONOSETRON IN BREAST CANCER: POTENTIAL DRUGS INTERACTIONS
	4CPS-218	ANTIDIABETIC TREATMENT IN FRAIL PATIENTS WITH TYPE II DIABETES ADMITTED TO THE EMERGENCY DEPARTMENT FOR ALTERED GLYCAEMIA
	4CPS-219	COMPARISON OF THE NUMBER OF PARENTAL NUTRITION PRESCRIPTIONS IN 2020 DURING THE COVID-19 PANDEMIC WITH THE SAME TIME PERIOD IN 2019
	4CPS-220	PATIENT SATISFACTION WITH PHARMACIST EDUCATION ON ORAL ANTICOAGULANT MEDICATION
	4CPS-221	EFFECT OF SARS-CoV-2 PANDEMIC ON DIRECT ORAL ANTICOAGULANTS USE IN THE PRIMARY CARE SETTING
	4CPS-222	CONCORDANCE BETWEEN GUIDELINES ON PERIOPERATIVE MANAGEMENT OF NOVEL ORAL ANTICOAGULANTS AND ITS IMPLEMENTATION AND PREVENTABLE CAUSES OF THE OCCURRENCE OF ISCHAEMIC STROKE
	4CPS-223	REAL WORLD EXPERIENCE OF SELEXIPAG FOR PULMONARY ARTERIAL HYPERTENSION
	4CPS-224	THROMBOPROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS: ASSESSMENT OF THE CURRENT PRACTICES IN A 950 BED HOSPITAL GROUP
	4CPS-225	IMPLEMENTATION OF A COMPUTER ALGORITHM IN THE ELECTRONIC HEALTH RECORD TO IDENTIFY INPATIENTS WITH UNTREATED ATRIAL FIBRILLATION TO OPTIMISE STROKE PREVENTION
	4CPS-226	EFFECTIVENESS OF CARBOXYMALTOSE IRON IN PREOPERATIVE ANAEMIA TREATMENT
	4CPS-227	HUMAN SERUM ALBUMIN: ANALYSIS OF USE
	4CPS-228	VERNAKALANT VERSUS FLECAINIDE FOR CONVERSION OF RECENT ONSET ATRIAL FIBRILLATION IN PATIENTS ATTENDING THE EMERGENCY DEPARTMENT
	4CPS-229	ANALYSIS OF CLINICAL PHARMACIST INTERVENTIONS IN THE HEART FAILURE DAY HOSPITAL.
	4CPS-230	ANTIARRHYTHMIC THERAPY EVALUATION IN A HOSPITAL SETTING
	4CPS-231	REAL WORLD DATA OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF HYPERLIPIDAEMIA: ANALYSIS 3 YEARS AFTER INTRODUCTION IN CLINICAL PRACTICE
	4CPS-232	USE OF DUPILUMAB IN THE TREATMENT OF ATOPIC DERMATITIS IN REAL CLINICAL PRACTICE
	4CPS-233	HOME MANAGEMENT OF ACUTE MULTIPLE SCLEROSIS OUTBREAK: ADAPTATION TO CORONAVIRUS PANDEMIC
	4CPS-234	GLUCOCORTICOID INDUCED HYPERGLYCAEMIA IN NON-DIABETIC PATIENTS IN AN EMERGENCY DEPARTMENT
	4CPS-235	SYSTEMIC CORTICOSTEROIDS IN THE TREATMENT OF SARS-CoV-2 INFECTION
	4CPS-236	USE OF ETELCALCETIDE IN PATIENTS UNDERGOING HAEMODIALYSIS
	4CPS-237	FEASIBILITY OF CONTINUOUS ADMINISTRATION OF ANTIMICROBIALS IN HOSPITAL: NOTHING IS EVER AS IT SEEMS?
	4CPS-238	EVALUATION OF EFFECTIVENESS OF COMPOUNDED ORAL VANCOMYCIN CAPSULES FOR TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION
	4CPS-239	THERAPEUTIC DRUG MONITORING OF GENTAMICIN IN NEONATES
	4CPS-240	THERAPEUTIC MONITORING OF VANCOMYCIN IN A COHORT OF PAEDIATRIC PATIENTS
	4CPS-241	IMPACT OF ANTIBIOTIC PRESCRIBING IN AN EMERGENCY DEPARTMENT ON HOSPITAL STAYS, READMISSION AND MORTALITY
	4CPS-242	ACUTE RESPIRATORY INFECTIONS: AN ANALYSIS OF HOSPITAL ANTIBIOTHERAPY PRESCRIPTION QUALITY FOR THE PAEDIATRIC POPULATION
	4CPS-243	HEALHCARE ASSOCIATED CLOSTRIDIOIDES DIFFICILE INFECTION IN SURGICAL AND MEDICAL PATIENTS
	4CPS-244	THERAPEUTIC DRUG MONITORING GUIDED PHARMACY INTERVENTIONS TO OPTIMISE THE DOSAGE OF BETA-LACTAMS ADMINISTERED IN CONTINUOUS INFUSION IN NON-CRITICALLY ILL PATIENTS.
	4CPS-245	DURATION OF ANTIBIOTIC TREATMENT IN PATIENTS DISCHARGED FROM A SHORT STAY HOSPITALISATION UNIT
	4CPS-246	CORONAVIRUS FIRST WAVE EFFECT ON ANTIBIOTIC CONSUMPTION AND ANTIMICROBIAL RESISTANCE
	4CPS-247	VARIATIONS IN CONSUMPTION OF ANTIMICROBIALS IN INTERNAL MEDICINE WARDS OF HOSPITALS
	4CPS-248	APPROPRIATENESS OF THE CLOSTRIDIUM DIFFICILE INFECTION PRESCRIPTION PRIOR TO THE IMPLEMENTATION OF A PROTOCOL FOR ITS MANAGEMENT
	4CPS-249	SECOND GENERATION β-LACTAM/ β-LACTAMASE INHIBITOR COMBINATIONS: CEFTAZIDIME-AVIBACTAM AND CEFTOLOZANE-TAZOBACTAM EXPERIENCE OF USE
	4CPS-250	EVALUATION OF PRESCRIPTION ADEQUACY TO THE ANTIBIOTHERAPY PROTOCOL IN INTRA-ABDOMINAL INFECTION IN A REGIONAL HOSPITAL
	4CPS-251	EVALUATION OF CLOSTRIDIUM DIFFICILE INFECTION MANAGEMENT PRIOR TO IMPLEMENTATION OF A PROTOCOL FOR IMPROVEMENT
	4CPS-252	STUDY OF THE IMPLEMENTATION OF A VANCOMYCIN PHARMACOKINETIC MONITORING PROGRAMME IN PAEDIATRICS
	4CPS-253	THE IMPORTANCE OF THE PHARMACOKINETIC PROFILE IN PATIENTS WITH ULTRA-RARE DISEASES:A CASE REPORT
	4CPS-254	A RETROSPECTIVE STUDY OF ANTIMICROBIAL STEWARDSHIP IN A UNIVERSITY HOSPITAL
	4CPS-255	CLINICAL EXPERIENCE OF CEFTAROLINE USE IN A THIRD LEVEL HOSPITAL
	4CPS-256	HEPATITIS C RETREATMENT OF A PATIENT WHO FAILED MULTIPLE TREATMENTS INCLUDING PROTEASE INHIBITOR AND NON-STRUCTURAL PROTEIN 5A INHIBITORS: A CASE REPORT
	4CPS-257	RELEVANCE OF RITONAVIR INTERACTIONS IN HIV TREATMENTS THAT INVOLVE TREATMENT MODIFICATION
	4CPS-258	EVALUATION OF MEDICINES ADHERENCE AND ASSOCIATED FACTORS IN PATIENTS WITH CHRONIC HEPATITIS B
	4CPS-259	ONE YEAR WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE
	4CPS-260	ANALYSIS OF DRUGS INTERACTIONS BETWEEN CORONAVIRUS (COVID-19) ANTIVIRAL TREATMENT AND CONCOMITANT MEDICATION
	4CPS-261	USE OF INTRAVENOUS IMMUNOGLOBULIN: BY THE BOOK?
	4CPS-262	CLINICAL EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN NEUROLOGY: A RETROSPECTIVE COHORT STUDY AT THE MATER MISERICORDIAE UNIVERSITY HOSPITAL
	4CPS-263	CASE REPORT OF KAWASAKI DISEASE AND SARS-COV-2 INFECTION IN A PAEDIATRIC HOSPITAL
	4CPS-264	AUTOIMMUNE MYOPATHY RESULTING FROM A THERAPY WITH NIVOLUMAB FOR METASTATIC NON-SMALL CELL LUNG CANCER: A CASE REPORT
	4CPS-265	CEMIPLIMAB FOR THE TREATMENT OF RELAPSE OF A CUTANEOUS SQUAMOUS CELL CARCINOMA IN AN ADULT PATIENT: A CASE REPORT
	4CPS-266	AFATINIB AS FIRSTLINE TREATMENT FOR ADVANCED LUNG ADENOCARCINOMA IN A PATIENT HARBOURING EXON 19 DELETION IN EGFR: A CASE REPORT
	4CPS-267	RETROSPECTIVE ANALYSIS OF CARBOPLATIN DOSING PRESCRIBED IN A CHEMOTHERAPY REGIMEN AND ITS RELATIONSHIP WITH TOXICITY
	4CPS-268	NIVOLUMAB VERSUS PEMBROLIZUMAB IN SECONDLINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER IN CLINICAL PRACTICE
	4CPS-269	HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY ASSOCIATED WITH CYTOREDUCTIVE SURGERY IN PERITONEAL CANCER TREATMENTS: A MULTIDISCIPLINARY EXPERIENCE TO EVALUATE ITS EFFICACY
	4CPS-270	RESULTS OF EFFECTIVENESS AND SAFETY IN REAL CLINICAL PRACTICE OF NIVOLUMAB, PEMBROLIZUMAB AND ATEZOLIZUMAB IN NON-SMALL CELL LUNG CANCER
	4CPS-271	EVALUATION OF THE EFFICACY OF ANTI-PD-L1 IMMUNOTHERAPY IN NON-MICROCRITICAL LUNG CANCER IN CLINICAL PRACTICE
	4CPS-272	PHARMACIST ROLE IN HEALTH OUTCOME OF VD-PACE SAVAGE REGIMEN IN AN ADULT FEMALE PATIENT WITH RARE RELAPSED AND REFRACTORY IgD LAMBDA MULTIPLE MYELOMA
	4CPS-273	DOES AGE REALLY MATTERS ON THE PREVALENCE OF DRUG-DRUG INTERACTIONS WITH ENDOVENOUS CHEMOTHERAPY?
	4CPS-274	REAL WORLD EFFECTIVENESS OF PALBOCICLIB AND RIBOCICLIB IN WOMEN WITH METASTATIC BREAST CANCER.
	4CPS-275	EFFICACY AND SAFETY OF TRIFLURIDINE/TIPIRACIL IN PATIENTS WITH METASTATIC COLORECTAL CANCER: REAL WORLD DATA
	4CPS-276	ATEZOLIZUMAB IN NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY REAL WORLD DATA STUDY.
	4CPS-277	CETUXIMAB VERSUS BEVACIZUMAB IN METASTATIC COLORECTAL CANCER: A COMPARATIVE EFFECTIVENESS AND PATIENT REPORTED OUTCOMES MULTI-COHORT STUDY
	4CPS-278	EFFECTIVENESS AND SAFETY OF CISPLATIN PLUS GEMCITABINE IN METASTATIC BREAST CANCER
	4CPS-279	CANCER PAIN MANAGEMENT APPROACH CONSIDERING POTENTIAL DRUG INTERACTIONS IN PATIENTS RECEIVING ORAL ANTITUMOUR TREATMENT
	4CPS-280	BENEFITS OF PHARMACOKINETIC ESTIMATION OF METHOTREXATE LEVELS IN PAEDIATRIC OSTEOSARCOMA PATIENTS
	4CPS-281	HIGH DOSE METHOTREXATE IN PEDIATRIC OSTEOSARCOMA PATIENTS: EFFECTIVENESS AND SAFETY.
	4CPS-282	EPIDEMIOLOGY AND CLINICAL COURSE OF PATIENTS WITH CANCER DIAGNOSED WITH SARS-COV-2 INFECTION
	4CPS-283	ONCOHAEMATOLOGICAL PHARMACEUTICAL CARE CONSULTATION. IS THE INFORMATION ON THE EUROPEAN PUBLIC ASSESSMENT REPORT OF DRUGS ENOUGH?
	4CPS-284	TREATMENT OF CYCLIN INHIBITOR INDUCED NEUTROPENIA: IMPACT ON PROGRESSION FREE SURVIVAL
	4CPS-285	MULTIDISCIPLINARY ORAL THERAPY OUTPATIENT CLINIC: AN ITALIAN SINGLE CENTRE EXPERIENCE
	4CPS-286	EARLY IMPACT OF COVID ON THE ACTIVITY OF A CLINICAL RESEARCH ONCOLOGY PHARMACY UNIT AT A TERTIARY CARE HOSPITAL
	4CPS-287	IMPACT OF SARS-COV-2 INFECTION IN ACUTE MYELOID LEUKAEMIA PATIENTS: EXPERIENCE OF THE PETHEMA REGISTRY
	4CPS-288	CLINICAL PHARMACIST'S IMPACT IN IMPROVING THE SAFETY OF THERAPIES FOR PATIENTS USING ORAL ANTICANCER AGENTS: A PROSPECTIVE SINGLE CENTRE STUDY
	4CPS-289	ANALYSIS OF ANTINEOPLASTIC DRUG CONTAMINATION LEVEL IN THE HOSPITAL PHARMACY: PROBLEM MONITORING AND SOLVING
	4CPS-290	BORTEZOMIB INDUCED ACUTE NECROHAEMORRHAGIC PANCREATITIS: A CASE REPORT
	4CPS-291	PALBOCICLIB: EARLY NEUTROPENIA AS A PHARMACODYNAMIC MARKER IN A REAL WORLD SETTING?
	4CPS-292	EFFECTIVENESS AND SAFETY OF IBRUTINIB IN CHRONIC LYMPHATIC LEUKAEMIA: MULTICENTRE STUDY
	4CPS-293	EFFICACY AND SAFETY OF CYCLIN DEPENDENT KINASE INHIBITORS IN METASTATIC BREAST CANCER
	4CPS-294	EFFICACY AND SAFETY PROFILE OF TRIFLURIDINE TIPIRACIL AND REGORAFENIB IN THE TREATMENT OF METASTATIC COLORECTAL CANCER
	4CPS-295	IMMUNOTHERAPY FOR CANCER THERAPEUTIC POSITIONING REPORTS: KNOWLEDGE, EXPECTATIONS AND EXPERIENCES THROUGH A NATIONAL SURVEY.
	4CPS-296	IMPACT OF THE COVID-19 PANDEMIC ON CLINICAL LUNG CANCER MANAGEMENT
	4CPS-297	SPINAL CORD APLASIA CAUSED BY 6-MERCAPTOPURINE IN A CAUCASIAN GIRL WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AND HOMOZYGOUS MUTATION IN NUDIX HYDROLASE 15: CASE REPORT
	4CPS-298	EFFICACY AND SAFETY PROFILE OF ANTI-EGFR TYROSINE KINASE INHIBITOR THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER
	4CPS-299	PATIENTS’ MISCONCEPTIONS FOLLOWING INITIATION OF ANTINEOPLASTIC TREATMENT FOR COLORECTAL CANCER
	4CPS-300	EFFECTIVENESS AND SAFETY OF CEMIPLIMAB IN SQUAMOUS CELL CARCINOMA OF THE SKIN IN A THIRD LEVEL HOSPITAL
	4CPS-301	ASSOCIATION OF ANTIBIOTICS AND PROTON PUMP INHIBITORS ON CLINICAL ACTIVITY OF FIRSTLINE PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER: 2 YEARS OF REAL WORLD DATA
	4CPS-302	SORAFENIB IN HEPATOCARCINOMA: RESULTS IN A REAL WORLD SETTING
	4CPS-303	EFFICACY AND SAFETY OF MONOTHERAPY WITH PEMBROLIZUMAB IN NON-MICROCYTIC METASTATIC LUNG CANCER IN CLINICAL PRACTICE.
	4CPS-304	RITUXIMAB AS AN ALTERNATIVE IN NEUROLOGIC DISORDERS: LONG TERM STUDY
	4CPS-305	EFFECTIVENESS AND SAFETY OF BRAF/MEK INHIBITORS IN ADVANCED OR METASTATIC MELANOMA IN TWO TERTIARY HOSPITALS
	4CPS-306	DAROLUTAMIDE, ENZALUTAMIDE AND APALUTAMIDE: PLACE IN THERAPEUTICS OF CASTRATION RESISTANT NON METASTATIC PROSTATE CANCER
	4CPS-307	SAFETY EVALUATION OF NEW ANTIANDROGENIC DRUGS IN CASTRATION RESISTANT NON-METASTATIC PROSTATE CANCER
	4CPS-308	EXPERIENCE WITH TERIFLUNOMIDE TREATMENT FOR MULTIPLE SCLEROSIS IN A UNIVERSITY HOSPITAL
	4CPS-309	BARRIERS TO ADHERENCE WITH PRESCRIBED TREATMENTS IN MULTIPLE SCLEROSIS PATIENTS
	4CPS-310	TOFACITINIB EFFECTIVENESS AND SAFETY RESULTS: REAL WORLD DATA
	4CPS-311	REAL WORLD TOXICITY AND MANAGEMENT OF CHIMERIC ANTIGEN RECEPTOR T CELL THERAPIES TARGETING CD19 IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES
	4CPS-312	PHARMACEUTICAL INTERVENTIONS IN A NON-ONCOHAEMATOLOGICAL DAILY HOSPITAL
	4CPS-313	EXPERIENCE OF THE USE OF BARICITINIB IN COVID-19 PNEUMONIA
	4CPS-314	3 DAY COURSE OF LOW DOSE SUBCUTANEOUS ANAKINRA IN PATIENTS WITH REFRACTORY MODERATE-SEVERE COVID-19: A PROOF-OF-CONCEPT STUDY
	4CPS-315	EVALUATION OF THE EFFECTIVENESS OF EARLY ADMINISTRATION OF TOCILIZUMAB IN PATIENTS WITH COVID-19
	4CPS-316	MULTIPLE SCLEROSIS OUTPATIENT PHARMACEUTICAL CARE BY AN IMPLANTED TELEPHARMACY TOOL DURING SARS-COV-2 PANDEMIC
	4CPS-317	IMMUNOSUPPRESSIVE TREATMENT MANAGEMENT IN A COHORT OF HOSPITALIZED SOLID ORGAN RECIPIENTS AFFECTED BY COVID-19
	4CPS-318	COMPOUNDING TACROLIMUS OPHTHALMIC OINTMENT 0,02% IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE OPHTHALMIC SYNDROMES: EFFECTIVENESS AND SAFETY ASSESSMENT
	4CPS-319	PIRFENIDONE AND NINTEDANIB FOR THE TREATMENT OF THE IDIOPATHIC PULMONARY FIBROSIS: AN ITALIAN HOSPITAL EXPERIENCE
	4CPS-320	IMPROVING MEDICATION ADHERENCE AND PATIENTS’ EXPERIENCE AFTER HEART TRANSPLANT USING A MULTILEVEL eHEALTH INTERVENTION: THE mHEART CLINICAL TRIAL
	4CPS-321	ANAKINRA IN SEVERE COVID-19 PNEUMONIA: RETROSPECTIVE STUDY
	4CPS-322	ADALIMUMAB CONCENTRATIONS PRIOR TO THE IMPLEMENTATION OF THERAPEUTIC DRUG MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
	4CPS-323	EVALUATION OF THE USE, ADHERENCE AND TOLERANCE OF 0.03% TACROLIMUS EYE DROPS
	4CPS-324	EFFECTIVENESS AND SAFETY OF IXEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS
	4CPS-325	EFFECTS ON ADHERENCE IN PATIENTS WITH ARTHROPATHIES CHANGING TREATMENT
	4CPS-326	ADALIMUMAB’S PERSISTENCE IN RHEUMATHOLOGICAL DISEASES
	4CPS-327	EFFECTIVENESS, SAFETY AND ADHERENCE OF BARICITINIB AND TOFACITINIB IN RHEUMATOID ARTHRITIS
	4CPS-328	BIOLOGICAL DRUGS FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS: ANALYSIS ACCORDING TO THE MECHANISM OF ACTION
	4CPS-329	DO PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES THINK THEY KNOW THEIR MEDICATION?
	4CPS-330	INDIVIDUALISING THERAPIES THROUGH PHARMACOKINETICS: ADALIMUMAB FOR INFLAMMATORY BOWEL DISEASE
	4CPS-331	MMATORY PARAMETERS ANALYSIS IN SEVERE COVID-19 PATIENTS TREATED WITH TOCILIZUMAB
	4CPS-332	TOCILIZUMAB FOR TREATING COVID PNEUMONIA: ANALYSIS OF EFFECTIVENESS AND SECURITY
	4CPS-333	TREATING MULTIPLE SCLEROSIS PATIENTS WITH INFUSION OF DISEASE MODIFYING TREATMENTS DRUGS DURING THE COVID-19 PANDEMIC
	4CPS-334	INFLUENCE OF ANTHROPOMETRIC, DEMOGRAPHIC AND THERAPEUTIC FACTORS ON SERUM CONCENTRATIONS OF ANTI-TNF DRUGS
	4CPS-335	EXPERIENCE IN THE USE OF TOCILIZUMAB IN PATIENTS WITH COVID-19. HAS IT REALLY BEEN EFFECTIVE?
	4CPS-336	IMPACT OF CHECK OF MEDICATION APPROPRIATENESS (CMA) IN OPTIMISING ANALGESIC PRESCRIBING
	4CPS-337	PERSISTENCE OF BIOSIMILAR TREATMENT FOR IMMUNE MEDIATED INFLAMMATORY DISEASES IN CLINICAL PRACTICE
	4CPS-338	USE AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA
	4CPS-339	INTRATHECAL ADMINISTRATION OF BACLOFEN FOR THE REDUCTION OF SPASTICITY
	4CPS-340	PROFILE OF PATIENTS WITH ABUSIVE CONSUMPTION OF QUICK RELEASE FENTANYL IN A HEALTHCARE AREA
	4CPS-341	THE ROLE OF PHARMACISTS IN PROVIDING PHARMACEUTICAL CARE FOR PATIENTS WITH HEADACHES
	4CPS-342	TRANSIENT VALPROIC ACID TOXICITY: HYPERAMMONAEMIA IN A PAEDIATRIC PATIENT
	4CPS-343	PREGABALIN AND GABAPENTIN DRUG UTILISATION REVIEW
	4CPS-344	PRESCRIPTION AUDITING OF THE 3 MONTHLY FORMULATION OF PALIPERIDONE PALMITATE IN ADULT PATIENTS WITH SCHIZOPHRENIA
	4CPS-345	MANAGEMENT OF BRONCHIOLITIS IN HOSPITALISED CHILDREN
	4CPS-346	EVALUATION OF THE IMPLEMENTATION OF "INHALER INTERVIEWS" DURING MEDICATION RECONCILIATION IN THE PNEUMOLOGY SERVICE
	4CPS-347	CLINICAL TRIAL DRUGS: DISPENSING OPTIMISATION FOR OUTPATIENTS OF A CANCER CENTRE
	4CPS-348	THE HOSPITAL PHARMACY IN THE CREATION OF CLEAN CIRCUITS IN THE FACE OF COVID-19
	4CPS-349	ROLE OF HOSPITAL PHARMACISTS IN ONCOGERIATRIC CONSULTATIONS: A RETROSPECTIVE STUDY
	4CPS-350	ROLE OF THE PHARMACIST IN INTERNAL MEDICINE: ANALYSIS OF PHARMACEUTICAL INTERVENTIONS DURING A ROTATION IN AN INTERNAL MEDICINE DEPARTMENT
	4CPS-351	MEDICATION DELIVERY CONFIRMATION TO AMBULATORY PATIENTS BY INSTANT MESSAGING APP
	4CPS-352	PATIENTS IN CHARGE: WHY WE SHOULD IMPLEMENT AN ONLINE PERSONAL HEALTH RECORD AS A TOOL FOR MEDICATION RECONCILIATION
	4CPS-353	COLLABORATION BETWEEN HOSPITAL AND COMMUNITY PHARMACISTS ABOUT DISCHARGED PATIENTS: A PILOT STUDY
	4CPS-354	EFFICACY AND SAFETY WITH ERENUMAB AND GALCANEZUMAB: OUR EXPERIENCE
	4CPS-355	EVALUATION OF PATIENTS CONSULTING THE EMERGENCY DEPARTMENT FOR BRADYCARDIA RELATED TO MEDICATION
	4CPS-356	COST-MINIMISATION ANALYSIS OF THE USE OF NIVOLUMAB AND PEMBROLIZUMAB
	4CPS-357	CLINICAL CHARACTERISTICS AND MORTALITY OF COVID-19 IN A LONG TERM CARE FACILITY
	4CPS-358	POINT PREVALENCE REVIEW OF MEDICINES RECONCILIATION FOLLOW-UP BY MEDICAL TEAMS
	4CPS-359	DEVELOPMENT AND VALIDATION OF A 30 DAY REVISIT RISK PREDICTION MODEL IN PATIENTS ADMITTED TO THE EMERGENCY DEPARTMENT DUE TO DRUG RELATED PROBLEMS
	4CPS-360	RISK OF MALNUTRITION IN PATIENTS WITH COVID-19 DISEASE WHO RECEIVE ORAL NUTRITIONAL SUPPLEMENTS
	4CPS-361	INTERVENTIONS OF A CLINICAL PHARMACIST IN AN INTENSIVE CARE UNIT
	4CPS-362	NONAGENARIANS VERSUS NON-NONAGENARIANS IN THE HIP FRACTURE PATIENT: FROM A PHARMACOTHERAPEUTIC POINT OF VIEW
	4CPS-363	DOES PATIENT CENTRED CARE PRACTICE IMPROVE MEDICATION ADHERENCE OF PATIENTS WITH TYPE 2 DIABETES MELLITUS?
	4CPS-364	PERSONALISED QT RISK ASSESSMENT - TO INFORM MEDICATION PRESCRIBING?
	4CPS-365	INTEGRATION OF THE HOSPITAL PHARMACIST INTO A MULTIDISCIPLINARY COMPLEX CHRONIC PATIENT CARE TEAM
	4CPS-366	COMPARING THE MEDICATION PROCESS ACROSS COUNTRIES USING THE FUNCTIONAL RESONANCE ANALYSIS METHOD
	4CPS-367	IMPACT OF PHARMACEUTICAL CONSULTATION IMPLEMENTATION ON THE PHARMACEUTICAL INTERVENTIONS AND THE ROLE OF PHARMACISTS IN MULTIDISCIPLINARY TEAMS
	4CPS-368	SYSTEMATIC REVIEW OF THE ASSOCIATION BETWEEN ANTICHOLINERGIC BURDEN AND XEROSTOMIA AND XEROPHTHALMIA
	4CPS-369	PHARMACHECK AS A SCREENING TOOL TO INTERCEPT HIGH RISK SITUATIONS IN INTERNAL MEDICINE THAT COULD LEAD TO ADVERSE DRUG EVENTS
	4CPS-370	PHARMACISTS´ INTERVENTIONS BEFORE AND AFTER THE USE OF A CLINICAL DECISION SUPPORT TOOL TO DETECT DRUG RELATED PROBLEMS
	4CPS-371	USABILITY EVALUATION OF A PERSONALISED HEALTH RECORD FOR DETECTING MEDICATION DISCREPANCIES
	4CPS-372	PHARMACEUTICAL INTERVENTIONS IN HOSPITALIZED PATIENTS DURING THE FIRST WAVE OF SARS-COV-2 PANDEMIC
	4CPS-373	PHARMACEUTICAL CARE IN HOSPITALISATION UNITS: ANALYSIS OF INTERVENTIONS
	4CPS-374	A SCREENING MODEL TO IDENTIFY ELDERLY POLYPHARMACY PATIENTS THAT MAY BENEFIT FROM PHARMACIST LED MEDICATION REVIEW DURING HOSPITAL ADMISSION
	4CPS-375	EXCESSIVE POLYPHARMACY AND OTHER DETERMINANTS FOR UNPLANNED HOSPITAL ADMISSIONS
	4CPS-376	ANTIRETROVIRAL THERAPY OPTIMISATION STRATEGIES IN PATIENTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS: A DECISIVE TASK FOR HOSPITAL PHARMACISTS
	4CPS-377	APPROPRIATENESS OF NUTRITIONAL SUPPORT FOR PATIENTS WITH INVASIVE MECHANICAL VENTILATION WITH COVID-19 DISEASE REQUIRING INTENSIVE CARE
	4CPS-378	ORAL THERAPY ADHERENCE AND SATISFACTION IN PATIENTS WITH MULTIPLE MYELOMA
	4CPS-379	PARENTERAL NUTRITION MANAGEMENT IN CORONAVIRUS CRITICAL PATIENTS: CASE REPORT
	4CPS-380	AN INTEGRATED PHARMACIST LED MEDICATION REVIEW SERVICE FOR ELECTIVE SURGERY PATIENTS AT THE PRE-ANAESTHESIA OUTPATIENT CLINIC
	4CPS-381	PROACTIVE MEDICATION RECONCILIATION AND PATIENT FLOW IN THE EMERGENCY DEPARTMENT ADMISSIONS
	4CPS-382	IMPACT OF A CLINICAL PHARMACIST AT TRANSITION OF CARE: A PROSPECTIVE STUDY IN AN ORTHOPAEDIC WARD OF A REGIONAL HOSPITAL
	4CPS-383	DRUG PRESCRIPTION IN THE ELDERLY. ARE WE DOING WELL?
	4CPS-384	POTENTIAL DRUG-RELATED PROBLEMS IN THE TIME OF COVID-19
	4CPS-385	IMPACT OF FULLY AUTOMATISED CENTRAL INTRAVENOUS ADDITIVE SERVICE (CIVAS) ON DAILY NURSING PRACTICE
	4CPS-386	ONE YEAR EXPERIENCE OF A NEW PROGRAMME OF TELEMATIC PHARMACEUTICAL CONSULTATION AND DELIVERY OF HOSPITAL DISPENSING MEDICATION
	4CPS-387	COVID-19 TREATMENT: A FOLLOW-UP OF INPATIENTS DURING THE SECOND WAVE OF THE PANDEMIC
	4CPS-388	TELEPHARMACY DURING SARS-COV-2
	4CPS-389	GOVERNANCE OF CLINICAL TRIALS BETWEEN HEALTH NEEDS, ACCESS TO CARE, INNOVATION AND SUSTAINABILITY IN THE COVID-19 PANDEMIC ERA
	4CPS-390	DISPENSING OF ANTICANCER INVESTIGATIONAL DRUGS DURING THE LOCKDOWN FOR THE SARS-COV-2 PANDEMIC: EXPERIENCE IN AN ONCOLOGICAL CENTRE
	4CPS-391	NON-ADHERENCE IN RHEUMATOLOGICAL IMMUNE MEDIATED DISEASES
	4CPS-392	EFFECT OF COVID 19 PANDEMIC ON ANTIRETROVIRAL THERAPY ADHERENCE
	4CPS-393	IMPACT OF MULTIDISCIPLINARY TEAM INTERVENTION IN MEDICATION RECONCILIATION FOR GERIATRIC PATIENTS
	4CPS-394	EVALUATION OF THE DEGREE OF THERAPEUTIC KNOWLEDGE IN LUNG TRANSPLANT RECIPIENTS
	4CPS-395	PHARMACY SERVICE’S ADAPTATION TO THE COVID-19 PANDEMIC: TELEPHARMACY AND HOME DRUG DELIVERY
	4CPS-396	EFFECT OF PATIENT'S OWN MEDICATION USE ON PATIENT SELF-REPORTED MEDICATION KNOWLEDGE DURING HOSPITALISATION: A PRE-POST INTERVENTION STUDY
	4CPS-397	ASSESSMENT OF PHARMACEUTICAL INTERVENTIONS IN AN INTENSIVE CARE UNIT AFTER COMPUTERISED PHYSICIAN ORDER ENTRY SYSTEM IMPLEMENTATION
	4CPS-398	USE OF INTRAVENOUS IRON IN HEART FAILURE OCTOGENARIANS AND NONAGENARIANS WITH IRON DEFICIENCY
	4CPS-399	EVALUATING CLINICAL PHARMACY SERVICES ON AN INTENSIVE CARE UNIT: A SATISFACTION SURVEY
	4CPS-400	THE ROLE AND VALUE OF A WARD BASED PHARMACIST IN THE INTENSIVE CARE UNIT: THE CRITICAL CARE PHYSICIANS’ AND NURSES’ PERCEPTIONS
	4CPS-401	TELEPHARMACY PROGRAMME IMPLEMENTATION DURING THE COVID-19 PANDEMIC
	4CPS-402	COVID-19 AND DIGESTIVE SURGERY: MEDICAL DEVICES FOR SURGICAL SMOKE FILTRATION
	4CPS-403	CHRONIC KIDNEY DISEASE (CKD) PATIENTS AND POLYPHARMACY: HOW TO OPTIMISE AND SIMPLIFY PRESCRIPTIONS?
	4CPS-404	MULTIDISCIPLINARY TEAM AIMED TO OPTIMISE INDIVIDUALISED SPECIAL DRUGS PRESCRIPTIONS AND AUTHORISATION BY HOSPITAL MEDICAL DIRECTOR THROUGH AN INFORMATIC APPLICATION
	4CPS-405	STRONGYLOIDES STERCORALIS PROPHYLAXIS WITH IVERMECTIN IN COVID-19 PATIENTS

Section 5: Patient Safety and Quality Assurance
PDF document	Poster number	Poster Title
	5PSQ-001	PHARMACIST INTERVENTION TO IMPROVE THE SAFETY OF PATIENTS TREATED WITH PROTON PUMP INHIBITORS (submitted in 2019)
	5PSQ-002	HYPOMAGNESAEMIA ALERT! MONITOR CLOSELY THE PROTON PUMP INHIBITORS FOR CHRONIC TREATMENT IN ELDERLY PATIENTS (submitted in 2019)
	5PSQ-003	EFFECTIVENESS OF ANTIEMETIC THERAPY DURING CHEMOTHERAPY IN A REGIONAL HOSPITAL (submitted in 2019)
	5PSQ-004	ADEQUACY OF ANTIEMETIC TREATMENT DURING CHEMOTHERAPY IN A REGIONAL HOSPITAL (submitted in 2019)
	5PSQ-005	ANALYSIS OF THE ADEQUACY OF VITAMIN D PRESCRIPTIONS (submitted in 2019)
	5PSQ-006	PARENTERAL NUTRITION IN A NEONATOLOGY INTENSIVE CARE UNIT: DURATION AND COMPLICATIONS (submitted in 2019)
	5PSQ-007	THE PHARMACEUTICAL GOVERNANCE OF LOW MOLECULAR WEIGHT HEPARINS: APPROPRIATENESS ANALYSIS (submitted in 2019)
	5PSQ-008	RESISTANCE TO SODIUM HEPARIN TREATMENT OR TREATMENT FAILURE TO THE EQUIVALENT ANALOGUE? (submitted in 2019)
	5PSQ-009	EVALUATION OF DIRECT ORAL ANTICOAGULANT USE IN PATIENTS ADMITTED FOR UPPER GASTROINTESTINAL AND INTRACRANIAL HAEMORRHAGES IN THE EMERGENCY SERVICE (submitted in 2019)
	5PSQ-010	BENEFITS PROVIDED BY RECOMBINANT LONG HALF-LIFE COAGULATION FACTORS IN PATIENTS WITH SEVERE HAEMOPHILIA “A” IN PROPHYLAXIS (submitted in 2019)
	5PSQ-011	COMPLICATIONS OF DRUG CONTAINING PARENTERAL NUTRITION: A COHORT STUDY. (submitted in 2019)
	5PSQ-012	DRUG INTERACTIONS AND POLYPHARMACY IN A COHORT OF HIV POSITIVE HAEMOPHILIAC PATIENTS (submitted in 2019)
	5PSQ-013	ANALYSIS OF THE RISK OF QT INTERVAL PROLONGATION IN INSTITUTIONALISED ELDERLY PATIENTS IN A NURSING HOME (submitted in 2019)
	5PSQ-014	RETROSPECTIVE EVALUATION OF RESUSCITATION MEDICATION UTILISATION IN HOSPITALISED ADULT PATIENTS WITH CARDIAC ARREST (submitted in 2019)
	5PSQ-015	COMPARING THREE CRITERIA FOR ASSESSMENT OF WHAT MEDICINES INCLUDED IN NATIONAL HOSPITAL FORMULARY ARE CLASSIFIED AS POTENTIALLY INAPPROPRIATE MEDICATIONS FOR OLDER PATIENTS (submitted in 2019)
	5PSQ-016	TOLVAPTAN ASSOCIATED CREATINE KINASE ELEVATION IN TWO PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (submitted in 2019)
	5PSQ-017	PCSK-9 INHIBITORS: REAL WORLD EFFECTIVENESS (submitted in 2019)
	5PSQ-018	ADALIMUMAB IN PALMOPLANTAR PUSTULOSIS (submitted in 2019)
	5PSQ-019	EFFICACY OF SECUKINUMAB IN MODERATE-SEVERE PSORIASIS WITH A REDUCED TREATMENT REGIMEN (submitted in 2019)
	5PSQ-020	ANALYSIS OF THE EFFECTIVENESS OF SECUKINUMAB AND IXEKIZUMAB IN THE TREATMENT OF MODERATE-SEVERE PSORIASIS (submitted in 2019)
	5PSQ-021	TRANSVAGINAL MESH IN PELVIC ORGAN PROLAPSES: 2017-2019 RETROSPECTIVE ANALYSIS (submitted in 2019)
	5PSQ-022	ANALYSIS OF INFECTIONS ASSOCIATED WITH CENTRAL VENOUS CATHETERS USED FOR ADMINISTRATION OF PARENTERAL NUTRITION IN A THIRD LEVEL HOSPITAL (submitted in 2019)
	5PSQ-023	EFFECTIVENESS OF CEFTAZIDIME-AVIBACTAM IN INFECTIONS BY MULTIRESISTANT MICROORGANISMS. (submitted in 2019)
	5PSQ-024	PHARMACOLOGIC INTERVENTION BY HOSPITAL PHARMCIST FOR LEUCOPENIA DUE TO TAZOBACTAM/PIPERACILLIN IN THE POSTPARTUM PERIOD: A CASE REPORT (submitted in 2019)
	5PSQ-025	PHARMACEUTICAL INTERVENTION FOR THE OPTIMISATION THE USE OF ANTIBIOTICS IN A TERTIARY HOSPITAL (submitted in 2019)
	5PSQ-026	IMPACT OF THE EARLY SWITCHING FROM INTRAVENOUS TO ORAL ANTIBIOTICS IN A TERTIARY HOSPITAL (submitted in 2019)
	5PSQ-027	OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY WORKING GROUP IN A HOSPITAL AT HOME UNIT: THE ESSENTIAL ROLE OF PHARMACISTS (submitted in 2019)
	5PSQ-028	PRESCRIPTION PROFILE OF ISAVUCONAZOLE IN THE REAL WORLD CLINICAL PRACTICE (submitted in 2019)
	5PSQ-029	SAFE ADMINISTRATION OF SOFOSBUVIR/VELPATASVIR IN A PATIENT WITH PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (submitted in 2019)
	5PSQ-030	ADVERSE DRUG REACTIONS DUE TO INTERACTION WITH COBICISTAT OR RITONAVIR IN HIV POSITIVE PATIENTS: A CASE SERIES (submitted in 2019)
	5PSQ-031	CLINICAL AND ECONOMIC IMPACT AFTER BREAKING THE SINGLE TABLET ABACAVIR/LAMIVUDINE/DOLUTEGRAVIR COMBO TREATMENT INTO TWO DRUG REGIMENES (submitted in 2019)
	5PSQ-032	SUCCESSFUL TREATMENT OF CHRONIC HEPATITIS C INFECTION WITH CRUSHED SOFOSBUVIR/VELPATASVIR (submitted in 2019)
	5PSQ-033	GLECAPREVIR/PIBRENTASVIR USE IN CHRONIC HEPATITIS C: EFFECTIVENESS AND SAFETY (submitted in 2019)
	5PSQ-034	EVALUATION OF OSELTAMIVIR USE IN CLINICAL PRACTICE IN A SECOND LEVEL HOSPITAL. (submitted in 2019)
	5PSQ-035	DUAL THERAPY WITH DOLUTEGRAVIR AND LAMIVUDINE: EFFICACY AND SAFETY. (submitted in 2019)
	5PSQ-036	STOPP/START CRITERIA IN PATIENTS WITH HIV (submitted in 2019)
	5PSQ-037	DOCETAXEL INDUCED NEUTROPENIC ENTEROCOLITIS: A CASE REPORT (submitted in 2019)
	5PSQ-038	SAFETY OF CYCLIN DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF BREAST CANCER WITH POSITIVE HORMONAL RECEPTORS AND NEGATIVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2. (submitted in 2019)
	5PSQ-039	PANCREATITIS INDUCED BY IMMUNOTHERAPY? TWO CASE REPORTS (submitted in 2019)
	5PSQ-040	SECURITY PROFILE OF IBRUTINIB AS MONOTHERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA: EXPERIENCE IN A TERTIARY HOSPITAL (submitted in 2019)
	5PSQ-041	CONSUMPTION OF HERBAL MEDICINE IN PATIENTS ON ORAL ANTICANCER DRUGS: STILL A LONG WAY TO GO! (submitted in 2019)
	5PSQ-042	EVALUATION OF AN INFORMATION CHECKLIST FOR VALIDATION OF ANTINEOPLASTIC PRESCRIPTIONS (submitted in 2019)
	5PSQ-043	IMPLEMENTATION OF A PREPARATION PROTOCOL FOR CHEMOTHERAPY ADMIXTURES OF HIGH ECONOMIC IMPACT (submitted in 2019)
	5PSQ-044	IMPACT OF DRUG INTERACTIONS IN HIGH DOSE METHOTREXATE ELIMINATION (submitted in 2019)
	5PSQ-045	OLARATUMAB: WHAT IS THE ECONOMIC IMPACT ON THE NATIONAL HEALTH SYSTEM? (submitted in 2019)
	5PSQ-046	PREVALENCE OF NIVOLUMAB ADVERSE EVENTS IN ROUTINE CLINICAL PRACTICE (submitted in 2019)
	5PSQ-047	RIBOCICLIB SAFETY IN METASTATIC BREAST CANCER (submitted in 2019)
	5PSQ-048	ANALYSIS OF DRUG INTERACTIONS BETWEEN ORAL ANTINEOPLASTIC AGENTS AND CONCURRENT MEDICATIONS (submitted in 2019)
	5PSQ-049	PALBOCICLIB IN METASTATIC BREAST CANCER TREATMENT: REAL LIFE TOXICITY AND FREQUENCY OF DOSE REDUCTION OR PERMANENT DISCONTINUATION. (submitted in 2019)
	5PSQ-050	SUCCESSFUL DESENSITISATION IN A PATIENT WITH DASATINIB HYPERSENSITIVITY (submitted in 2019)
	5PSQ-051	IMMUNE RELATED ADVERSE EVENTS IN CANCER PATIENTS TREATED WITH CONTROL POINT INHIBITORS (submitted in 2019)
	5PSQ-052	EARLY RESULTS FROM THE EFFECTIVENESS AND SAFETY EVALUATION OF BIOSIMILAR RITUXIMAB AND BRAND-RITUXIMAB IN GLOMERULAR INFLAMMATORY DISEASE (submitted in 2019)
	5PSQ-053	OFF-LABEL USE OF RITUXIMAB IN SYSTEMIC AUTOIMMUNE DISEASES (submitted in 2019)
	5PSQ-054	EXAMINATION OF A NEW METHOD FOR ANALYSING IDENTITY AND CONCENTRATION OF DRUGS IN READY TO USE PREPARATIONS: PROOF OF CONCEPTS OF THE DRUGLOG SYSTEM (submitted in 2019)
	5PSQ-055	FILGRASTIM IN EARLY STAGE BREAST CANCER: DIFFERENCES BETWEEN TWO SMALL HOSPITALS (submitted in 2019)
	5PSQ-056	EXPERIENCE WITH TOFACINITIB AND BARICITINIB IN RHEUMATOID ARTHRITIS (submitted in 2019)
	5PSQ-057	ANALYSIS OF INCIDENCE OF HEPATOTOXICITY ASSOCIATED WITH THE USE OF TOCILIZUMAB (submitted in 2019)
	5PSQ-058	THE IMPORTANCE OF MONITORING ADVERSE DRUG REACTIONS: DATA FROM THE TREATMENT OF A RARE DISEASE (submitted in 2019)
	5PSQ-059	PHARMACIST-LED OBSERVATIONAL STUDY ON QUALITY OF LIFE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: EVIDENCES FROM THE QOSMOS STUDY (submitted in 2019)
	5PSQ-060	EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN CLINICAL PRACTICE FOR CROHN'S DISEASE (submitted in 2019)
	5PSQ-061	ALEMTUZUMAB FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS: EFFECTIVENESS AND SAFETY (submitted in 2019)
	5PSQ-062	EFFECTIVENESS OF ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE AND INFLUENCE OF RESPONSE TO FIRSTLINE TREATMENT (submitted in 2019)
	5PSQ-063	SERIOUS CELLULITIS IN A PATIENT WITH ATOPIC DERMATITIS TREATED WITH BARICITINIB: A CASE REPORT (submitted in 2019)
	5PSQ-064	RELATED RISK OF BIOLOGIC DRUGS FOR CROHN’S DISEASE IN PREGNANCY: A CASE REPORT AND REVISION OF THE LITERATURE (submitted in 2019)
	5PSQ-065	PREDICTION OF TOXICITY OF METHOTREXATE BY MEANS OF GENETIC TESTS IN PATIENTS DIAGNOSED WITH MODERATE-SEVERE PSORIASIS (submitted in 2019)
	5PSQ-066	ANALYSIS OF POTENTIALLY INAPPROPRIATE MEDICATIONS IN ELDERLY ONCOLOGIC PATIENTS BY THE CHECK THE MEDS APP (submitted in 2019)
	5PSQ-067	SAFETY PROFILE OF PIRFENIDONE AND NINTEDANIB IN A REAL LIFE SETTING: ASSESSMENT OF SUSPECTED ADVERSE DRUG REACTIONS IN THE EMILIA ROMAGNA REGION, ITALY (submitted in 2019)
	5PSQ-068	INCIDENCE OF FUNGAL INFECTIONS IN PATIENTS TREATED WITH IXEKIZUMAB (submitted in 2019)
	5PSQ-069	CONCOMITANT PRESCRIPTION OF DRUGS FOR OSTEOPOROSIS AND MEDICATION THAT INCREASE THE OF RISK FALLS (submitted in 2019)
	5PSQ-070	SAFETY STRATEGIES TO IMPROVE DRUG LABELLING IN OPERATING ROOMS (submitted in 2019)
	5PSQ-071	AN ADVERSE DRUG REACTION IN A PAEDIATRIC PATIENT WITH DRAVET SYNDROME: CANNABIDIOL AND VALPROATE DRUG-DRUG INTERACTION (submitted in 2019)
	5PSQ-072	ADEQUACY OF ANTIDEPRESSANT MEDICATION IN ELDERLY PATIENTS (submitted in 2019)
	5PSQ-073	USEFULNESS OF SALIVA IN THERAPEUTIC DRUG MONITORING OF CAFFEINE IN PRETERM INFANTS (submitted in 2019)
	5PSQ-074	FAMPRIDINE RELATED ATRIAL FIBRILLATION: TWO CASE REPORTS (submitted in 2019)
	5PSQ-075	SAFETY PROFILE OF FINGOLIMOD IN REAL WORLD CLINICAL PRACTICE: A PRELIMINARY STUDY (submitted in 2019)
	5PSQ-076	PRESCRIPTION MEDICATION SHARING AMONG ADULTS IN SAUDI ARABIA: A CROSS-SECTIONAL SURVEY STUDY. (submitted in 2019)
	5PSQ-077	PERCEPTIONS ABOUT PRESCRIPTION MEDICATION SHARING AMONG ADULTS IN SAUDI ARABIA: A QUALITATIVE STUDY.
	5PSQ-078	HEALTHCARE PROVIDERS' PERCEPTIONS OF PRESCRIPTION MEDICATION SHARING AMONG ADULTS IN SAUDI ARABIA: A QUALITATIVE STUDY. (submitted in 2019)
	5PSQ-079	IMMUNOTHERAPY IN METASTATIC MELANOMA: A MIRACLE OR POISON (submitted in 2019)
	5PSQ-080	ASSESSMENT OF DOSE PREPARATION PRACTICES FROM LIQUID ORAL FORMS BY MOTHERS OF CHILDREN HOSPITALISED IN OUR PAEDIATRIC DEPARTMENT (submitted in 2019)
	5PSQ-081	THE BENEFITS-RISKS BALANCE OF LEECH THERAPY IN ONE HOSPITAL : A RETROSPECTIVE STUDY (submitted in 2019)
	5PSQ-082	EVALUATING AN ELECTRONIC CLINICAL DECISION SUPPORT SYSTEM FOR DRUG-DRUG INTERACTIONS IN A LARGE ACUTE TEACHING HOSPITAL (submitted in 2019)
	5PSQ-083	A SYSTEMATIC RISK ANALYSIS METHOD APPLIED TO STEAM STERILISATION PROCESS IN A TEACHING HOSPITAL (submitted in 2019)
	5PSQ-084	POTENTIALLY INAPPROPRIATE PRESCRIPTIONS IN GERIATRIC HIV PATIENTS (submitted in 2019)
	5PSQ-085	MEDICATION ERRORS AND PHARMACEUTICAL INTERVENTIONS FOR DRUGS ADMINISTERED BY FEEDING TUBE (submitted in 2019)
	5PSQ-086	MANAGEMENT OF A CONTAMINATION EPISODE IN A PARENTERAL NUTRIENT MIXTURE PREPARATION UNIT (submitted in 2019)
	5PSQ-087	SEVERE MALARIA: 3 YEAR REVIEW OF INTRAVENOUS ARTESUNATE USE IN A UNIVERSITY HOSPITAL (submitted in 2019)
	5PSQ-088	MONITORING OF THE INTRODUCTION OF CHLORHEXIDINE RELEASING POLYURETHANE MEDICATION IN PILOT WARDS OF A LARGE CITY HOSPITAL (submitted in 2019)
	5PSQ-089	CYTOKINE RELEASE SYNDROME REACTION: THE CLINICAL PHARMACIST IN THE CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY TEAM (submitted in 2019)
	5PSQ-090	PHARMACIST'S CONTRIBUTION TO IMPROVING CUSTOMERS SATISFACTION AT HOSPITALS CARE UNITS (submitted in 2019)
	5PSQ-091	ANALYSIS OF POTENTIALLY INAPPROPRIATE MEDICATIONS IN CHRONIC COMPLEX PATIENTS AND IN PATIENTS WITH ADVANCED CHRONIC DISEASE IN THE EMERGENCY DEPARTMENT (submitted in 2019)
	5PSQ-092	HOW DOES THE ON-SCREEN DESIGN OF ELECTRONIC PRESCRIBING SYSTEMS AFFECT SAFE PRESCRIBING? A QUALITATIVE STUDY USING A THINK ALOUD APPROACH. (submitted in 2019)
	5PSQ-093	EXPLORING EYE TRACKING AS A METHOD TO STUDY USERS’ INTERACTIONS WITH A HOSPITAL ELECTRONIC PRESCRIBING SYSTEM: A DESCRIPTIVE STUDY (submitted in 2019)
	5PSQ-094	HOW CAN PATIENT HELD INFORMATION ABOUT MEDICATION IMPROVE PATIENT SAFETY? (submitted in 2019)
	5PSQ-095	ANALYSIS OF THE TOXICITIES ASSOCIATED WITH TYROSINE KINASE INHINITORS IN PATIENTS WITH CHRINIC MYELOID LEUKAEMIA (submitted in 2019)
	5PSQ-096	HAZARD VULNERABILITY ANALYSIS TO EVALUATE RISK OF DRUG SHORTAGES ACCORDING TO THE THERAPEUTIC CLASS (submitted in 2019)
	5PSQ-097	POTENTIALLY HARMFUL EXCIPIENTS IN NEONATAL AND PAEDIATRIC PATIENTS (submitted in 2019)
	5PSQ-098	ALLERGIES AND INTOLERANCES: AN OPPORTUNITY FOR IMPROVEMENT (submitted in 2019)
	5PSQ-099	POTENTIALLY INADEQUATE MEDICATION– DETECTED DIFFERENTLY BY PRISCUS, FORTA OR EU(7)-PIM – IS ASSOCIATED WITH REDUCED COGNITIVE FUNCTION IN MULTIMORBID ELDERLY PATIENTS (submitted in 2019)
	5PSQ-100	COMPARATIVE ANALYSIS OF THE SAFETY AND TOLERABILITY PROFILE OF PIRFENIDONE AND NINTEDANIB IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (submitted in 2019)
	5PSQ-101	DRUG-DRUG INTERACTIONS AND POTENTIALLY RELATED ADVERSE CLINICAL EVENTS IN PATIENTS WITH CARDIOVASCULAR DISEASES (submitted in 2019)
	5PSQ-102	AMBULATORY SUBCUTANEOUS BIOLOGIC THERAPY OPTIMISATION IN RHEUMATOLOGY: IMPLEMENTATION OVER TIME (submitted in 2019)
	5PSQ-103	EXPERIENCE OF ANTIFIBROTIC AGENTS IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (submitted in 2019)
	5PSQ-104	DESCRIPTION OF A PHARMACOVIGILANCE PROGRAMME IN A TERTIARY HOSPITAL (submitted in 2019)
	5PSQ-105	PREVENTING FALLS IN ORTHOGERIATRIC PATIENTS BY MANAGING THEIR THERAPEUTIC PROFILES (submitted in 2019)
	5PSQ-106	ANALYSIS OF HANDLING OF HAZARDOUS DRUGS IN A NURSING HOME (submitted in 2019)
	5PSQ-107	ACTIVE PHARMACOVIGILANCE AND DEDICATED PHARMACIST: THE EXPERIENCE OF A TERRITORIAL HEALTHCARE HOSPITAL (submitted in 2019)
	5PSQ-108	INFECTION WITH CLOSTRIDIUM DIFFICILE: RISK FACTORS AND PHARMACOTHERAPEUTIC MANAGEMENT (submitted in 2019)
	5PSQ-109	READMISSIONS OF OLDER PATIENTS PRESENTING TO HOSPITAL WITH A FALL (RELIEF): A SYSTEMATIC REVIEW (submitted in 2019)
	5PSQ-110	NUTRITIONAL ASSESSMENT IN A LONG TERM CARE FACILITY (submitted in 2019)
	5PSQ-111	ADVERSE DRUG REACTIONS DUE TO MEDICINES UNDER ADDITIONAL MONITORING (submitted in 2019)
	5PSQ-112	IMPACT OF HIGH TEMPERATURE AND SHAKING ON CHARGE VARIANTS OF ADALIMUMAB (HUMIRA) ASSESSED BY LIQUID CHROMATOGRAPHY COUPLED MASS SPECTROMETRY (submitted in 2019)
	5PSQ-113	COMPATIBILITY AND STABILITY OF ONDANSETRON AND MIDAZOLAM MIXTURES USED IN PALLIATIVE CARE (submitted in 2019)
	5PSQ-114	IMPROVING MEDICATION ADMINISTRATION FOR PATIENTS WITH DYSPHAGIA (submitted in 2019)
	5PSQ-115	NEAR MISS DISPENSING ERRORS DURING WORKING HOURS IN INPATIENT DISPENSARIES AT A LARGE UK TEACHING HOSPITAL (submitted in 2019)
	5PSQ-116	SAFER HANDLING OF ORAL HAZARDOUS DRUGS IN HOSPITAL UNITS (submitted in 2019)
	5PSQ-117	ANALYSIS OF MEDICATION ERRORS AN ONCOLOGY SETTING USING AN INTERNAL REPORTING SYSTEMS (submitted in 2019)
	5PSQ-118	DESCRIPTIVE COMPARATIVE SAFETY ANALYSIS OF PALBOCICLIB AND RIBOCICLIB IN METASTATIC BREAST CANCER HER2 NEGATIVE WITH POSITIVE HORMONAL RECEPTORS (submitted in 2019)
	5PSQ-119	PROTON PUMP INHIBITOR PRESCRIPTION PATTERNS AND ASSOCIATED COMPLICATIONS IN THE PAEDIATRIC INTENSIVE CARE UNIT
	5PSQ-120	USE OF PROTON PUMP INHIBITORS IN A GERIATRIC HEALTHCARE CENTRE
	5PSQ-121	FIDAXOMICIN RELATED METABOLIC ACIDOSIS: A CASE REPORT
	5PSQ-122	HEALTH RESULTS AFTER INFLIXIMAB PHARMACOKINETIC MONITORING IN INFLAMMATORY BOWEL DISEASE
	5PSQ-123	SGLT2 INHIBITORS IN TYPE 2 DIABETES PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASES: AN UMBRELLA REVIEW OF SYSTEMATIC REVIEWS
	5PSQ-124	ANTICOAGULATION MANAGEMENT WITHIN A HOSPITAL SETTING: IDENTIFYING RISK FACTORS AFFECTING PATIENT SAFETY
	5PSQ-125	EFFECT OF A MULTIFACETED CLINICAL DECISION SUPPORT INTERVENTION ON ADHERENCE TO THROMBOPROPHYLAXIS GUIDELINES IN NON-SURGICAL PATIENTS
	5PSQ-126	AVICENNE AS A CLINICAL DECISION SUPPORT IN THROMBOPROPHYLAXIS: JUST BECAUSE THE PATIENT’S SITUATION IS IMPROVING DOESN'T MEAN THERE'S NO DRUG RELATED PROBLEM!
	5PSQ-127	ASSESSING APPROPRIATE DOSING OF NEW ORAL ANTICOAGULANTS: APIXABAN, DABIGATRAN AND RIVAROXABAN IN A TERTIARY HOSPITAL
	5PSQ-128	WHICH ENOXAPARIN PREVENTIVE DOSAGE TO CHOOSE FOR OBESE PATIENTS IN ORTHOPAEDIC SURGERY ?
	5PSQ-129	MANAGEMENT OF MULTIFACTORIAL ANAEMIA WITH SUBCUTANEOUS DARBEPOETIN WITH INITIAL MONTHLY DOSAGE, OMITTING INDUCTION ACCORDING TO THE TECHNICAL DATA SHEET, IN ELDERLY PATIENTS
	5PSQ-130	INTRAVENOUS POTASSIUM CHLORIDE: IS THE MEDICATION USE PROCESS SECURE?
	5PSQ-131	ADHERENCE OF THE HOSPITAL CLINICAL MANAGEMENT UNITS TO THE CENTRE'S PROTOCOL FOR THE SAFE USE OF INTRAVENOUS POTASSIUM
	5PSQ-132	FAILURE MODE AND EFFECT ANALYSIS APPLIED TO THE PARENTERAL NUTRITION PREPARATION PROCESS IN A MATERNITY AND NEONATAL HOSPITAL
	5PSQ-133	EVALUATION OF A QUALITY MONITORING PROGRAMME FOR INTRAVENOUS FLUID MANAGEMENT
	5PSQ-134	ANALYSIS OF FACTORS RELATED TO THE CLINICAL COURSE OF COVID-19 INFECTION IN PATIENTS WITH HYPERTENSION
	5PSQ-135	ADEQUACY OF HYPOLIPEMIANT TREATMENT IN PRIMARY HEALTHCARE
	5PSQ-136	DISPROPORTIONALITY ANALYSIS OF THE SKIN TOXICITY OF INGENOL MEBUTATE USING THE FDA ADVERSE EVENT REPORTING SYSTEM DATABASE
	5PSQ-137	ADEQUACY OF DIAGNOSIS AND TREATMENT OF PHARYNGOTONSILLITIS
	5PSQ-138	INFLUENCE OF ANTIBIOTIC STEWARDSHIP PROGRAMME INTERVENTIONS IN A HOSPITAL AT HOME UNIT
	5PSQ-139	PRESCRIPTIVE APPROPRIATENESS OF ANTIBIOTIC THERAPIES: CRUCIAL ROLE OF THE HOSPITAL PHARMACIST
	5PSQ-140	UNIT DOSE SYSTEM: MODEL OF IMPLEMENTATION OF THE ANTIMICROBIAL STEWARDSHIP
	5PSQ-141	ANALYSIS OF THE CEFTAROLINE ASSOCIATED NEUTROPENIA
	5PSQ-142	SAFETY OF AZOLE ANTIFUNGALS IN TRANSPLANTED PATIENTS RECEIVING TACROLIMUS
	5PSQ-143	DRUG RESISTANT TUBERCULOSIS IN A HIGH COMPLEXITY SPECIALISED UNIT: EPIDEMIOLOGY, TREATMENT AND MAIN ADVERSE REACTIONS
	5PSQ-144	PHARMACOTHERAPY OPTISMISATION IN PATIENTS OVER 50 YEARS OF AGE WITH HIV INFECTION: FIRST STEPS
	5PSQ-145	ANALYSIS OF THERAPEUTIC REGIMENS CONTAINING TENOFOVIR DISOPROXIL AND TENOFOVIR ALAFENAMIDE IN THE 4 YEAR PERIOD 2016-2019 IN A RESEARCH, HOSPITALISATION AND HEALTHCARE INSTITUTE
	5PSQ-146	“REAL LIFE” EFFECTIVENESS AND SAFETY ASSESSMENT OF FOSCARNET
	5PSQ-147	IMMUNOGLOBULIN SHORTAGE : PRACTICE MODIFICATIONS AND CLINICAL OUTCOMES IN A REFERENCE CENTRE
	5PSQ-148	IMPROVING SAFETY IN THE VACCINE CIRCUIT
	5PSQ-149	DRUGE INTERACTION IN BREAST CANCER TRIPLE NEGATIVE THERAPY: DOCETAXEL AND FLUVOXAMINE. A CASE REPORT
	5PSQ-150	DISSEMINATED INTRAVASCULAR COAGULATION AFTER PD-1 BLOCKADE WITH NIVOLUMAB IN ADVANCED MELANOMA: A CASE REPORT
	5PSQ-151	SEVERE TOXICITY IN A PATIENT WITH ACUTE LYMPHOBLASTIC LEUKAEMIA RESULTING FROM SUBSTITUTION OF DAUNORUBICIN WITH DOXORUBICIN DUE TO MEDICINE SHORTAGE: A CASE REPORT
	5PSQ-152	REAL-WORLD EFFICACY AND COST DATA ON PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER TREATED WITH CHECKPOINT INHIBITORS IN AN ITALIAN UNIVERSITY HOSPITAL IN SEPTEMBER 2016-2020
	5PSQ-153	CARBOPLATIN AUC DOSING IN PAEDIATRIC PATIENTS: INFLUENCE OF GLOMERULAR FILTRATION RATE MEASUREMENT
	5PSQ-154	DETERMINATION OF GENETIC POLYMORPHISMS OF THE DIHYDROPYRIMIDINE DEHYDROGENASE GENE IN REAL CLINICAL PRACTICE AS PREDICTORS OF SEVERE FLUOROPYRIMIDINE ASSOCIATED TOXICITY
	5PSQ-155	ASSISTANCE PRESSURE IN ONCOHAEMATOLOGICAL DISPENSATION AREA DURING THE COVID PANDEMIC
	5PSQ-156	COMPLIANCE OF RECOMMENDATIONS FOR THE PREVENTION OF HEPATITIS B VIRUS REACTIVATION DURING DARATUMUMAB TREATMENT
	5PSQ-157	EXPENDITURE AND CONSUMPTION DESCRIPTIVE ANALYSIS: RITUXIMAB ORIGINATOR VERSUS BIOSIMILAR IN AN ITALIAN DISTRICT
	5PSQ-158	OFF-LABEL USE OF PEMBROLIZUMAB IN PD-L1 POSITIVE METASTATIC ANAPLASTIC THYROID CARCINOMA: A CASE REPORT
	5PSQ-159	PALBOCICLIB SAFETY IN METASTATIC BREAST CANCER
	5PSQ-160	MOGAMULIZUMAB EXPERIENCE IN ADVANCED SEZARY SYNDROME: A CASE REPORT
	5PSQ-161	EFFECTIVENESS AND SAFETY OF PALBOCICLIB AND RIBOCICLIB
	5PSQ-162	METHOTREXATE-INDUCED MYELITIS IN A CAUCASIAN GIRL WITH LYMPHOBLASTIC LYMPHOMA AND PHARMACOGENETIC STUDY: CASE REPORT
	5PSQ-163	INCIDENCE OF NEUTROPENIA AND EFFECTIVENESS OF PALBOCICLIB IN CLINICAL PRACTICE IN METASTATIC BREAST CANCER AFTER 4 YEARS OF USE
	5PSQ-164	REAL SAFETY OF DARATUMUMAB IN MYELOMA MULTIPLE
	5PSQ-165	INCIDENCE AND MANAGEMENT OF ETOPOSIDE HYPERSENSITIVITY IN PAEDIATRIC PATIENTS
	5PSQ-166	MANAGEMENT OF TOXICITIES RELATED TO CYCLIN DEPENDENT KINASE 4/6 INHIBITORS IN METASTATIC BREAST CANCER
	5PSQ-167	ANALYSIS OF FIRSTLINE TREATMENT IN THE ELDERLY WITH METASTATIC COLORECTAL CANCER
	5PSQ-168	INTEREST AND IMPLEMENTATION OF RAPID DARATUMUMAB INFUSION DURING THE HEALTH CRISIS
	5PSQ-169	SAFETY AND SEVERE NEUTROPENIA IN PATIENTS TREATED WITH PALBOCICLIB AND RIBOCICLIB IN REAL WORLD CLINICAL PRACTICE
	5PSQ-170	PEMBROLIZUMAB IN NON-SMALL CELL LUNG CANCER: ANALYSIS IN REAL LIFE OF TOXICITY AND EFFECTIVENESS
	5PSQ-171	TOCILIZUMAB IN PATIENTS WITH COVID19: RESULTS IN CLINICAL PRACTICE
	5PSQ-172	EXPERIENCE WITH TOCILIZUMAB IN SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) INFECTION
	5PSQ-173	PERSISTENCE OF ABATACEPT TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS
	5PSQ-174	EFFECTIVENESS AND SAFETY OF ABATACEPT THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER PREVIOUS FAILURE WITH TNFi TREATMENT
	5PSQ-175	CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 MUTATIONS ON T REG AND ABATACEPT: A PAEDIATRIC CASE REPORT
	5PSQ-176	DISCONTINUATION OF ETANERCEPT DUE TO ADVERSE EVENTS IN PATIENTS WITH RHEUMATIC DISEASES
	5PSQ-177	CARDIOVASCULAR RISK AND ALTERED LIPID PROFILE ASSOCIATED WITH TREATMENT WITH THE KINASE-JAK INHIBITORS, TOFACITINIB AND BARICITINIB
	5PSQ-178	HEPATOTOXICITY ASSOCIATED WITH ACUTE TOCILIZUMAB TREATMENT IN PATIENTS WITH SARS-CoV-2 INFECTION
	5PSQ-179	REASON FOR DISCONTINUATION OF BIOLOGICAL DRUG TREATMENT IN RHEUMATOID ARTHRITIS
	5PSQ-180	IMPACT OF SEDATIVE DRUGS ON VITAL SIGNS DURING PROCEDURAL SEDATION AND ANAESTHESIA: A RETROSPECTIVE COHORT ANALYSIS
	5PSQ-181	IS INSTANT ALWAYS BETTER? PHARMACOKINETICS OF TABLET VERSUS GRANULATE FORMULATION OF PARACETAMOL IN FRAIL OLDER ADULTS
	5PSQ-182	ANTICHOLINERGIC BURDEN IN PATIENTS ADMITTED TO A PSYCHIATRIC HOSPITAL
	5PSQ-183	CONCOMITANT USE OF ACETYLCHOLINESTERASE INHIBITORS AND DRUGS WITH ANTICHOLINERGIC PROPERTIES AT ADMISSION BY EMERGENCY DEPARTMENT
	5PSQ-184	KNOWLEDGE AND ATTITUDE ASSESSMENT OF PHARMACISTS TOWARD TELEPHARMACY IN RIYADH CITY, SAUDI ARABIA
	5PSQ-185	ARE ADHERENCE TESTS IN ASTHMA STILL RELIABLE WHEN THE PATIENTS KNOWS WHAT WE WANT TO HEAR?
	5PSQ-186	MAIN POTENTIAL INTERACTIONS DETECTED IN THE OUTPATIENT CONSULTATION
	5PSQ-187	ALTERNATIVE TREATMENT TO ORAL IVERMECTIN IN STRONGYLOIDES STERCORALIS HYPERINFECTION IN THE SETTING OF SMALL BOWEL OBSTRUCTION AND PARALYTIC ILEUS
	5PSQ-188	AN AUDIT OF PRESCRIBING, ADMINISTRATION AND STORAGE OF CONCENTRATED ELECTROLYTES
	5PSQ-189	NEAR MISS LOOKALIKE AND SOUNDALIKE INTRAVENOUS MEDICATION ERROR: A 12 MONTH RETROSPECTIVE STUDY
	5PSQ-190	EXPERIENCE AND SATISFACTION OF OUTPATIENTS IN THE DEVELOPMENT OF A PROGRAMME FOR HOME MEDICATION DELIVERY
	5PSQ-191	NEW GENERAL DRUG CHART, POST-IMPLEMENTATION CLINICAL AUDIT
	5PSQ-192	MEDICATION REVIEW OF POLYMEDICATED PATIENTS IN A HEALTH MANAGEMENT AREA
	5PSQ-193	PATIENT SAFETY IN MEDICATION DISPENSING PERFORMED BY PHARMACONOMISTS: A BEFORE AND AFTER STUDY
	5PSQ-194	MANAGEMENT OF EXPERIMENTAL HEALTH PRODUCTS IN HOSPITAL PHARMACIES: A NATIONAL SURVEY
	5PSQ-195	IMPACT OF INTENSIFIED CLINICAL DECISION SUPPORT SYSTEMS ON PRESCRIBING ERRORS: AN INTERRUPTED TIME SERIES ANALYSIS IN TAIWAN
	5PSQ-196	ASSOCIATION BETWEEN PHOSPHODIESTERASE 5 INHIBITOR USE AND INCIDENT DEMENTIA IN PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY
	5PSQ-197	CONTRAINDICATED DRUG-DRUG INTERACTIONS WITH PAN-GENOTYPIC DIRECT ACTING ANTIVIRAL AGENTS IN CHRONIC HEPATITIS C PATIENTS IN TAIWAN
	5PSQ-198	VARIATIONS IN EFFECTIVENESS AND SAFETY OF GLECAPREVIR/PIBRENTASVIR AMONG HEPATITIS C PATIENTS WITH DIFFERENT GENOTYPES: A MULTI-INSTITUTIONAL COHORT STUDY IN TAIWAN
	5PSQ-199	USE OF SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS AND RISK OF FRACTURE IN TYPE 2 DIABETES PATIENTS: A MULTI-INSTITUTIONAL COHORT STUDY IN TAIWAN.
	5PSQ-200	COMPARATIVE CARDIOVASCULAR EVENTS ASSOCIATED WITH DENOSUMAB VERSUS ZOLEDRONATE IN THE ELDERLY: A MULTI-INSTITUTIONAL COHORT STUDY IN TAIWAN
	5PSQ-201	EFFECT OF SACUBITRIL/VALSARTAN ON GLYCAEMIC CONTROL AND RENAL FUNCTION IN PATIENTS WITH DIABETES AND HEART FAILURE: A MULTI-INSTITUTIONAL COHORT STUDY IN TAIWAN
	5PSQ-202	BIOSIMILARS IN THE REAL WORLD: RESULTS FROM AN ACTIVE PHARMACOVIGILANCE PROGRAMME IN A PORTUGUESE ONCOLOGY HOSPITAL
	5PSQ-203	POLYPHARMACY AND POTENTIALLY INAPPROPRIATE MEDICATIONS IN ELDERLY ONCOHAEMATOLOGICAL PATIENTS REFERRED TO PALLIATIVE CARE: APPLICATION OF THE STOPPFrail CRITERIA
	5PSQ-204	DIFFERENCE IN ADHERENCE ASSOCIATED WITH THE ROUTE OF ADMINISTRATION
	5PSQ-205	MANIPULATING TABLETS CONTAINING POORLY SOLUBLE PREDNISOLONE TO OBTAIN PAEDIATRIC DOSES
	5PSQ-206	SATISFACTION OF PATIENTS WITH PHARMACEUTICAL TELECARE
	5PSQ-207	ANALYSIS OF THE MEDICINES UNDER ADDITIONAL MONITORING AUTHORISED IN THE EUROPEAN UNION FROM 2017 TO 2019
	5PSQ-208	PHARMACEUTICAL ALGORITHMS TARGETING ANTICOAGULANT THERAPY: IMPACT OF AVICENNE CLINICAL DECISION SUPPORT IN PATIENT SAFETY
	5PSQ-209	ANTICHOLINERGIC BURDEN AND RISK OF ADVERSE EVENTS IN PATIENTS FROM A SPANISH NURSING HOME
	5PSQ-210	RETROSPECTIVE EVALUATION OF THE DOCUMENTATION OF ALLERGIC AND IDIOSYNCRATIC ADVERSE DRUG REACTIONS IN THE CONTEXT OF THE REQUIREMENTS CONCERNING A CLINICAL DECISION SUPPORT SYSTEM
	5PSQ-211	MEDICATION ERRORS RELATING TO SIMILAR OR MISLEADING MANUFACTURER SPECIFIC DRUG PACKAGING AND LABELLING
	5PSQ-212	NUTRITIONAL SUPPORT AND INTERACTION WITH ONCOLOGICAL TREATMENT IN BREAST CANCER
	5PSQ-213	HOSPITAL ADMISSIONS AFTER DISCHARGED FROM THE EMERGENCY DEPARTMENT TO HOME WITH COVID-19 TREATMENT
	5PSQ-214	"UNIT DOSE": CLINICAL RISK MANAGEMENT OF COVID-19 PATIENTS TREATED WITH HYDROXYCHLOROQUINE
	5PSQ-215	CLINICAL RISK MANAGEMENT THROUGH THE “UNIT DOSE” SYSTEM
	5PSQ-216	IMPLEMENTATION OF A MEDICATION RECONCILIATION PROGRAMME AS A PATIENT SAFETY STRATEGY
	5PSQ-217	MEDICATION RECONCILIATION PROGRAMME OF THE COMPLEX CHRONIC PATIENT IN A TRAUMATOLOGY AND ORTHOPAEDIC SURGERY SERVICE AT HOSPITAL ADMISSION
	5PSQ-218	HAEMORRHAGIC TRANSFORMATION AFTER MECHANICAL THROMBECTOMY ISCHAEMIC STROKE MANAGEMENT: OVERVIEW OF MEDICAL DEVICE VIGILANCE DECLARATIONS
	5PSQ-219	THE ROLE OF THE HOSPITAL PHARMACIST IN MONITORING DRUGS AND MEDICATIONS PRESCRIPTION IN THE HOME CARE SERVICE: A GUARANTEE OF APPROPRIATENESS
	5PSQ-220	DISCREPANCIES BETWEEN PRESCRIPTION AND DISPENSING OF MEDICATION IN AUTOMATIC DISPENSING CABINET
	5PSQ-221	SAFETY PROFILE OF EXPERIMENTAL THERAPIES USED IN THE COVID-19 PANDEMIC BASED ON DATA FROM THE NATIONAL MINIMUM DATA SET
	5PSQ-222	ANTICHOLINERGIC RISK IN THE ELDERLY
	5PSQ-223	DRUGS TO AVOID. AN OPPORTUNITY IN HEALTHCARE PATIENTS: CHECKING PRESCRIRE'S RECOMMENDATIONS
	5PSQ-224	CLINICAL EXPERIENCE OF PEMBROLIZUMAB WITH AXITINIB IN RENAL CELL CARCINOMA
	5PSQ-225	ELDER FALLERS: A GROUP AT RISK OF READMISSION?
	5PSQ-226	ANALYSIS OF HIGH ALERT MEDICATION PRESCRIPTIONS IN A NURSING HOME
	5PSQ-227	CLINICAL TRIALS: A STANDARDISED SELF-ASSESSMENT TOOL TO REDUCE THE MULTIPLE RISKS OF THE PHARMACEUTICAL CIRCUIT
	5PSQ-228	PHARMACIST MEDICINES OPTIMISATION AND ERROR MITIGATION AT PAEDIATRIC CRITICAL CARE DISCHARGE: A HUMAN SOLUTION TO AN ELECTRONIC RISK

Section 6: Education and Research
PDF document	Poster number	Poster Title
	6ER-001	PCSK9 INHIBITORS: VARIATION IN THE LIPID PROFILE IN A REAL WORLD SETTING (submitted in 2019)
	6ER-002	A COMPARATIVE REVIEW OF THE IMPACT OF THE INTRODUCTION OF ON-SITE MOLECULAR TESTING ON THE MANAGEMENT OF ADULT PATIENTS HOSPITALISED WITH SUSPECTED INFLUENZA VIRUS INFECTION (submitted in 2019)
	6ER-003	EFFECTIVENESS OF NEOADJUVANT TREATMENT IN LOCALLY ADVANCED BREAST CANCER (submitted in 2019)
	6ER-004	PRELIMINARY CLINICAL RESPONSE OF RIBOCICLIB AS A SINGLE AGENT IN ADVANCED BREAST CANCER: IN SEARCH OF NEW THERAPEUTIC INDICATIONS (submitted in 2019)
	6ER-005	EFFECTIVENESS OF OMALIZUMAB AND BEE VENOM IMMUNOTHERAPY COMBINATION: CASE REPORT (submitted in 2019)
	6ER-006	DIGITAL LITERACY IN MULTIPLE SCLEROSIS (submitted in 2019)
	6ER-007	PERSISTENCE AND SAFETY OF ADALIMUMAB IN PSORIASIS (submitted in 2019)
	6ER-008	STUDY OF THE USE OF DIMETHYL FUMARATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN A THIRD LEVEL HOSPITAL (submitted in 2019)
	6ER-009	TREATMENT PATTERNS IN MULTIPLE SCLEROSIS WITH DISEASE MODIFYING DRUGS (submitted in 2019)
	6ER-010	THERAPEUTIC DRUG MONITORING OF TUMOUR NECROSIS FACTOR a INHIBITORS IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM A REAL WORLD SETTING (submitted in 2019)
	6ER-011	REAL WORLD ADHERENCE TO MULTIPLE SCLEROSIS THERAPY (submitted in 2019)
	6ER-012	PERSISTENCE FOR DISEASE MODIFYING DRUGS FOR MULTIPLE SCLEROSIS (submitted in 2019)
	6ER-013	ENRICHED DEVELOPMENTAL BIOLOGY MOLECULAR PATHWAYS: IMPACT ON ANTIPSYCHOTIC INDUCED WEIGHT GAIN (submitted in 2019)
	6ER-014	EDUCATION OF PATIENTS RECEIVING OXYGEN THERAPY (submitted in 2019)
	6ER-015	RISKS OF PHARMACIST RECOMMENDED ANTIBIOTIC USE: GENERAL PUBLIC PERCEPTION (submitted in 2019)
	6ER-016	ECONOMIC VALUE OF UNUSED HIGH COST EXPERIMENTAL INFUSION DRUGS: A POTENTIAL SAVING FOR THE NATIONAL HEALTH SYSTEM (submitted in 2019)
	6ER-017	DIGITAL LITERACY OF PATIENTS IN A DAY HOSPITAL ONCOLOGY UNIT (submitted in 2019)
	6ER-018	THE IMPACT OF HOSPITAL PHARMACY SPECIALISATION ON THE PATIENTS’ OUTCOME: A LITERATURE REVIEW (submitted in 2019)
	6ER-019	TEACHING AND LEARNING EFFECT ANALYSIS OF AN INTERPROFESSIONAL TRAINING PROGRAMME FOR UNDERGRADUATE PHARMACY INTERNS (submitted in 2019)
	6ER-020	STANDARDISATION OF PROCESSES BY ELECTRONIC ASSISTED PRESCRIPTION PROGRAMME IN A UNIVERSITY PAEDIATRIC HOSPITAL (submitted in 2019)
	6ER-021	DEGREE OF BURNOUT AMONG PHARMACISTS IN ISRAEL (submitted in 2019)
	6ER-022	PERCEPTION OF RARE DISEASES AND ORPHAN MEDICINES (submitted in 2019)
	6ER-023	THE ROLE OF INSTITUTIONAL REVIEW BOARDS, AND HOSPITAL PHARMACISTS AS MEMBERS, IN THE INFORMED CONSENT PROCESS IN CLINICAL RESEARCH: A RETROSPECTIVE OBSERVATIONAL STUDY (submitted in 2019)
	6ER-024	WHAT OUR PATIENTS KNOW ABOUT ANTIBIOTICS AND ANTIMICROBIAL RESISTANCE. ARE THEY AWARE OF HOW TO MAKE GOOD USE OF THEM?
	6ER-025	IMPORTANCE OF APPROPRIATE BEFORE-AND-AFTER QUASI-EXPERIMENTAL DESIGN TO EVALUATE THE IMPACT OF ANTIMICROBIAL STEWARDSHIP PROGRAMMES: COMPARATIVE RESULTS USING STATISTICAL HYPOTHESIS TESTING OR INTERRUPTED TIME SERIES ANALYSIS
	6ER-026	CREDIBILITY OF SUBGROUP CLAIMS IN HAEMATOLOGY CLINICAL TRIALS
	6ER-027	IMPROVEMENT IN SELF-MANAGEMENT OF BIOLOGICAL DMARDS FOR PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS WHEN A PHARMACIST PARTICIPATES IN A MULTIDISCIPLINARY CONSULTATION
	6ER-028	BARICITINIB AGAINST SEVERE COVID-19: EFFECTIVENESS AND SAFETY IN HOSPITAL CARE
	6ER-029	IMPACT OF MEDICINES INFORMATION APP ON MEDICATION KNOWLEDGE AND WORRY IN POST-MYOCARDIAL INFARCTION PATIENTS
	6ER-030	AN ANNUAL REVIEW OF DRUG SHORTAGES MANAGED BY THE MMUH PHARMACY DEPARTMENT
	6ER-031	DEVELOPMENT OF PATIENT CENTRED VIDEO ON MEDICATION MANAGEMENT AND A QUALITATIVE EXPLORATION OF PATIENTS' OPINIONS TOWARDS THE VIDEO
	6ER-032	PUBLIC OPINION AND PERSONAL SITUATION IN TIMES OF THE COVID-19 PANDEMIC
	6ER-033	PHARMACIST LED DEPRESCRIBING AND FOLLOW-UP IN A SUBACUTE MULTIDISCIPLINARY OUTPATIENT CLINIC: A PILOT RANDOMISED CONTROLLED TRIAL
	6ER-034	MEDICATION DEPRESCRIBING AND FOLLOW-UP: A SURVEY AMONG SUBACUTE MULTIMORBID PATIENTS IN A MULTIDISCIPLINARY OUTPATIENT CLINIC
	6ER-035	AN EVALUATION OF HEALTH PROMOTION AND DISEASE PREVENTION KNOWLEDGE IN PATIENTS ATTENDING A HOSPITAL OUTPATIENT PHARMACY
	6ER-036	DEPRESCRIBING TOOLS FOR THE ELDERLY: A SYSTEMATIC REVIEW
	6ER-037	DRUG - DRUG INTERACTIONS WITH QT PROLONGING DRUGS IN PATIENTS ADMITTED TO A CARDIOVASCULAR DEPARTMENT: A RETROSPECTIVE ANALYSIS

24th Congress of the EAHP

National Poster Prize Winners
PDF document	Poster number	Poster Title
	NP-001	PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH HIGH DOSES OF BIOTIN: PREVENTION OF SIGNIFICANT BIOLOGICAL EXAMINATION DISTURBANCES BY HOSPITAL PHARMACISTS
	NP-002	MEDICATION RECONCILIATION AND MEDICATION REVIEW IN THE UROLOGICAL-ONCOLOGICAL OUTPATIENT CLINIC
	NP-003	ANTIBIOTIC RESISTANCE IN COMMUNITY-ACQUIRED PNEUMONIA: A ROMANIAN EXPERIENCE
	NP-004	IMPLEMENTATION OF CLINICAL PHARMACY SERVICES IN LONG-TERM CARE WARDS
	NP-005	ESTIMATING RENAL FUNCTION FOR DRUG DOSING: EQUATIONS MATTER
	NP-006	EARLY DETECTION OF RETINOPATHY IN PREMATURE INFANTS USING MIXTURE OF EYE DROPS WITH 2.5% PHENYLEPHRINE HYDROCHLORIDE AND 0.5% TROPICAMIDE
	NP-007	MEDICATION ANALYSIS FOR HOSPITAL PATIENTS WITH RENAL INSUFFICIENCY: FROM DEVELOPMENT PHASE TO STANDARD PRACTICE
	NP-008	STABILITY OF CEFTOLOZANE/TAZOBACTAM IN SOLUTION AS INFUSION FOR PROLONGED OR CONTINUOUS APPLICATION
	NP-009	PATIENTS’ PERSONAL TREATMENT MANAGEMENT IN A UNIVERSITY HOSPITAL
	NP-010	WHAT IS THE EFFECT OF INTERPROFESSIONAL STUDENT PLACEMENTS IN PRIMARY CARE? A RETROSPECTIVE PRE-POST STUDY
	NP-011	MEDISCREEN: IMPLEMENTATION OF A TOOL FOR DETECTING PATIENTS AT RISK OF ADVERSE DRUG EVENTS VIA THE ELECTRONIC MEDICAL RECORD
	NP-012	STANDARDISATION OF ANALGESIA AND SEDATION INFUSION SOLUTIONS IN PAEDIATRIC PALLIATIVE PATIENTS RECEIVING END-OF-LIFE CARE AT HOME
	NP-013	IMPLEMENTING THE EUROPEAN STATEMENTS OF HOSPITAL PHARMACY IN ITALY: RESULTS OF A WORKING GROUP
	NP-014	DEVELOPMENT OF NEW PRODUCTION WHEN NEITHER PACKAGING NOR SOME OF THE RAW MATERIALS CONFORM TO EUROPEAN STANDARDS

Section 1: Introductory Statements and Governance
PDF document	Poster number	Poster Title
	1ISG-001	HEALTH UTILITIES IN CHRONIC HEPATITIS C PATIENTS ONE YEAR AFTER SUCCESSFUL TREATMENT WITH DIRECT-ACTING ANTIVIRALS
	1ISG-002	BUDGETARY IMPACT OF ALIROCUMAB REPACKAGING IN A THIRD-LEVEL HOSPITAL
	1ISG-003	BIOSIMILAR GROWTH HORMONE: DEFINED DAILY DOSE IN AN ITALIAN DISTRICT AFTER THE REGIONAL TENDER
	1ISG-004	ABSTRACT WITHDRAWN
	1ISG-005	A COST EFFECTIVE STRATEGY: SWITCHING FROM ONE TO TWO TABLETS, IN A ONCE-DAILY REGIMEN IN HIV PATIENTS
	1ISG-006	HEPATITIS C TREATMENT: COST AND EFFECTIVENESS
	1ISG-007	PEMETREXED´S LESSON
	1ISG-008	FLAT DOSES OF ANTI-PD1: WHAT IS THE ECONOMIC IMPACT?
	1ISG-009	AVOIDED COST STUDY OF DRUGS IN CLINICAL TRIALS AT A TERTIARY HOSPITAL
	1ISG-010	REAL-WORLD EVIDENCE OF HIGH-COST DRUGS FOR METASTATIC MELANOMA: EFFECTIVENESS, COMPLIANCE TO CLINICAL PRACTICE GUIDELINES AND ECONOMIC EVALUATION
	1ISG-011	REDUCTION OF THE PATIENT WAITING TIME: WHAT COST FOR THE CHEMOTHERAPIES PREPARATION UNIT?
	1ISG-012	COST-EFFECTIVENESS OF AZACITIDINE IN THE REAL-WORLD: ANALYSIS IN HIGH-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM THE PERSPECTIVE OF A EUROPEAN PUBLIC HOSPITAL
	1ISG-013	BUDGET IMPACT ANALYSIS OF LUNG CANCER IMMUNOTHERAPY: A HOSPITAL PERSPECTIVE
	1ISG-014	RHEUMATOID ARTHRITIS: BIOLOGICAL DRUGS PHARMACEUTILISATION ANALISYS IN AN ITALIAN DISTRICT
	1ISG-015	OPTIMISATION OF BIOLOGICAL THERAPIES IN THE TREATMENT OF PSORIASIS
	1ISG-016	COST-EFFECTIVENESS OF MORPHINE VERSUS FENTANYL IN MANAGING VENTILATED NEONATES WITH RESPIRATORY DISTRESS SYNDROME IN THE INTENSIVE CARE SETTING
	1ISG-017	CLINICAL AND ECONOMIC EVALUATIONS OF MORPHINE AND FENTANYL WITH MECHANICAL VENTILATION IN INTENSIVE CARE SETTINGS: A SYSTEMATIC REVIEW OF METHODOLOGICAL TRENDS, AND REPORTING QUALITY
	1ISG-018	ORGANISATIONAL COMMITMENT OF HOSPITAL PHARMACISTS, RELATING TO THE SUPPORTIVE ORGANISATIONAL ENVIRONMENT
	1ISG-019	INSIGHT INTO PHARMACY AND THERAPEUTICS COMMITTEES' STRUCTURE AND ACTIVITIES AMONG HOSPITALS IN X: MIXED-METHODS APPROACH
	1ISG-020	CHEMICAL RISK ASSESSEMENT IN A QUALITY CONTROL LABORATORY BY A TOOL USING ACTIVITY ANALYSIS
	1ISG-021	A COMPREHENSIVE REGIONAL STRATEGY ADDRESSING GUIDANCE ON SAFE HANDLING OF HAZARDOUS DRUGS
	1ISG-022	FINANCIAL IMPACT OF THIRD-GENERATION CEPHALOSPORINES RESISTANCE IN HOSPITAL SETTINGS – AN EXAMPLE WITH CEFTRIAXONE
	1ISG-023	CYSTIC FIBROSIS OUTPATIENT TREATMENT COSTS: A RETROSPECTIVE ANALYSIS
	1ISG-024	BIOSIMILARS SWITCH: DO DOCTORS AND PATIENTS REVERT BACK AFTER SWITCHING?
	1ISG-025	A CONNECTED APPLICATION FOR BETTER FORMATION
	1ISG-026	ABSTRACT WITHDRAWN
	1ISG-027	INTRODUCTION OF SELF-MANAGEMENT IN A HOSPITAL PHARMACY
	1ISG-028	AN ASSESSMENT OF HOSPITAL PHARMACISTS' JOB SATISFACTION: APPLICATION OF THE JOB SATISFACTION SURVEY
	1ISG-029	IMPACT OF THE IMPLEMENTATION OF THE ENFIT SYSTEM ON THE ADMINISTRATION OF ENTERAL MEDICATION
	1ISG-030	BIOLOGICS UTILISATION AND ITS EFFICIENCY THROUGH A HOSPITAL PHARMACY CENTRALISED MANAGEMENT SYSTEM
	1ISG-031	ABSTRACT WITHDRAWN
	1ISG-032	SURGICAL SUTURE TO REDUCE NEEDLE-HOLE LEAKAGE: COMPARISON OF TWO SUTURES
	1ISG-033	INFLAMMATORY BOWEL DISEASE: BIOLOGICAL PRESCRIBING TRENDS IN AN ITALIAN HOSPITAL
	1ISG-034	A CRITICAL LOOK AT ERRONEOUS INCENTIVES AND LACKING LEGAL FRAMEWORK AS DRIVERS OF MEDICINES SHORTAGES AND OBJECTORS TO PROBLEM-SOLVING APPROACHES
	1ISG-035	URETERAL MAGNETIC CATHETER: AN EASY AND ECONOMICAL WAY TO REMOVE THE DEVICE
	1ISG-036	THE IMPACT OF HOSPITAL PHARMACY INFRASTRUCTURE AND HUMAN RESOURCES ON MEDICINES OPTIMISATION AND INTEGRATED CARE
	1ISG-037	HEALTH-RELATED QUALITY OF LIFE IN HEPATITIS C PATIENTS WHO ACHIEVE SUSTAINED VIROLOGICAL RESPONSE TO DIRECT-ACTING ANTIVIRALS: A COMPARISON WITH THE GENERAL POPULATION
	1ISG-038	CRITICAL ANALYSIS OF THE INFORMATION AND COMMUNICATION TECHNOLOGIES’ TOOLS MOST USED IN CLINICAL PRACTICE BY THE PHARMACIST
	1ISG-039	THE COST-SAVINGS POTENTIAL OF BIOSIMILAR DRUGS: A BUDGET IMPACT ANALYSIS
	1ISG-040	EMERGENCY AND DISASTER SITUATIONS : HOW ARE HOSPITAL PHARMACIES PREPARED IN EUROPE?

Section 2: Selection, Procurement and Distribution
PDF document	Poster number	Poster Title
	2SPD-001	DESCRIBING A THICKENER HOME DELIVERY PROTOCOL AND THE BENEFITS OF ITS IMPLEMENTATION
	2SPD-002	COMPARATIVE EFFICACY OF DIMETHYLFUMARATE AND OTHER TREATMENTS FOR MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
	2SPD-003	MONITORING THE USE OF LINEZOLID IN A THIRD-LEVEL HOSPITAL
	2SPD-004	DRUG CONSUMPTION DATA FOR GUIDING ANTIBIOTIC USE RATIONALISATION IN A SURGICAL DEPARTMENT
	2SPD-005	ECONOMICAL ANALYSIS OF TENOFOVIR ALAFENAMIDE VERSUS TENOFOVIR-DISOPROXIL FURAMATE
	2SPD-006	ECONOMIC IMPACT OF INLFLIXIMAB BIOSIMILAR REFERENCING IN THE HOSPITAL
	2SPD-007	COST-MINIMISATION ANALYSIS OF LUNG CANCER PD-L1 POSITIVE TREATMENT
	2SPD-008	RISK ANALYSIS ON CYTOTOXIC CIRCUIT IN A CENTRAL PHARMACY
	2SPD-009	ANALYSIS OF OLAPARIB AND TALAZOPARIB AS POSSIBLE THERAPEUTIC ALTERNATIVES IN ADVANCED BREAST CANCER AND A GERMLINE BRCA MUTATION
	2SPD-010	INDIRECT COMPARISON OF PEMBROLIZUMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN LUNG CANCER
	2SPD-011	NETWORK META-ANALYSIS OF FIRST-LINE ANTIANGIOGENIC DRUGS IN ADVANCED RENAL CELL CARCINOMA
	2SPD-012	RELATIVE VALUE UNITS AS A PRODUCTIVITY SCORE OF MANAGEMENT OF ONCOLOGY MEDICATION IN SPECIAL SITUATIONS
	2SPD-013	ECONOMIC IMPACT OF THE USE OF FLAT DOSE VS PERSONALISED DOSE OF PEMBROLIZUMAB
	2SPD-014	MULTIDISCIPLINARY STOCK MANAGEMENT AND REDUCED DISTRIBUTION OF MEDICINE UP TO A DRUG PATENT EXPIRY REDUCED EXPENSES WITHOUT COMPROMISING MEDICINE SUPPLY IN A HOSPITAL SETTING
	2SPD-015	RISK-ADAPTED MANAGEMENT OF DRUG SHORTAGES TO ENSURE PROPER CARE FOR PATIENTS IN MEDICAL NEED
	2SPD-016	BIOSIMILARS OF INFLIXIMAB AND RITUXIMAB: DOES THE INITIAL STRATEGY OF SELECTION HELP THEIR PRESCRIPTIONS?
	2SPD-017	ECHO-ENDOSCOPY : FOR A SOURCING AS SHARP AS A NEEDLE
	2SPD-018	AUDIT ON THE MANAGEMENT OF PERSONAL TREATMENT OF PATIENTS AT THE HOSPITAL
	2SPD-019	EVALUATION OF THE INTRODUCTION OF A MEDICAL DEVICE FOR MECHANICAL INDUCTION OF LABOUR IN WOMEN WITH UNFAVOURABLE CERVIX
	2SPD-020	EXPIRED MEDICINES AND MEDICAL DEVICES, AN ACROBATIC MANAGEMENT
	2SPD-021	NONCOMPLIANCE OF DATAMATRIX CODES, AN OBSTACLE TO IMPLEMENTATION OF THE FALSIFIED MEDICINES DIRECTIVE
	2SPD-022	ON THE ROAD TO SERIALISATION: A PRATICAL APPLICATION
	2SPD-023	INTEREST IN CONSIGNMENT INVENTORY MANAGEMENT OF ARTICULAR PROSTHESES AT A UNIVERSITY HOSPITAL
	2SPD-024	IMPLEMENTED STRATEGIES TO SOLVE MEDICINES SHORTAGES
	2SPD-025	OPTIMISING OF PLANNED DRUGS ORDERS AND RECEPTION PLATFORM ACTIVITY
	2SPD-026	AUTOMATED UNIT DOSE-DISPENSING DEVICE: ASSESSMENT OF THE CONTROL METHOD
	2SPD-027	MULTI-CRITERIA DECISION ANALYSIS FOR EVALUATING NEW MEDICINES IN HEALTH TECHNOLOGY ASSESSMENT FRAMEWORK ANALYSIS
	2SPD-028	OPTIMISATION OF SURGICAL PROCEDURAL-KIT SETTING
	2SPD-029	MEDICAL DEVICES MANAGEMENT: CONSUMPTION IN SURGICAL PRACTICE WITH RADIO FREQUENCY IDENTIFICATION SYSTEM
	2SPD-030	OPTIMISING INVENTORY MANAGEMENT IN A HOSPITAL PHARMACY
	2SPD-031	MANAGEMENT OF DRUG SHORTAGES IN A TERTIARY HOSPITAL
	2SPD-032	PHARMACY, CLINICAL SERVICES: COMMUNICATE WELL TO SERVE BETTER! EXAMPLE OF THE CARDIOLOGY CENTRE OF A UNIVERSITY HOSPITAL
	2SPD-033	IMPACT OF SUPPLY PROBLEMS IN A HOSPITAL PHARMACY SERVICE
	2SPD-034	DRUG SHORTAGES. ANALYSIS OF THE ECONOMIC IMPACT
	2SPD-035	MEDICINE SHORTAGES: IMPACT ON A THIRD-LEVEL HOSPITAL PHARMACY DEPARTMENT ACTIVITY
	2SPD-036	STORAGE AND DISPENSING OF SOLID ORAL DOSAGE FORMS FROM MULTIPLE UNIT CONTAINERS
	2SPD-037	OVER 5 YEARS OF MEDICINES SHORTAGES IN A UNIVERSITY HOSPITAL
	2SPD-038	HOW LONG DO HOSPITAL PHARMACISTS SPEND IN MANAGING MEDICINES SHORTAGES?
	2SPD-039	MEDICINE SHORTAGES IN A GENERAL COUNTY HOSPITAL: EVALUATION AND ESSENTIAL QUALITY
	2SPD-040	IS PNEUMATIC TUBE DELIVERY SAFE FOR MEDICINES?
	2SPD-041	DRUG SHORTAGES ANALYSIS FROM AN ITALIAN HOSPITAL PHARMACY PERSPECTIVE

Section 3: Production and Compounding
PDF document	Poster number	Poster Title
	3PC-001	MAGISTRAL FORMULATION OF 10% SUCRALFATE ENEMAS IN PROCTITIS
	3PC-002	PRELIMINARY RESULTS ON THE USE OF ORAL REHYDRATION SOLUTION IN THE FORM OF GELATO FOR REHYDRATION OF CHILDREN WITH ACUTE GASTROENTERITIS
	3PC-003	WEIGHT-LOWERING PSEUDOEPHEDRINE-BASED PRESCRIPTIONS: MONITORING PATIENT FEEDBACK AFTER UPDATE OF NATIONAL PRICE LIST OF MEDICINES AND MAGISTRAL PREPARATION
	3PC-004	WHAT HAPPENS WHEN INSULIN ASPART IS DILUTED IN DEXTROSE?
	3PC-005	STABILITY STUDY OF A 10% SODIUM BENZOATE ORAL SOLUTION
	3PC-006	ANALYSIS OF THE REGIMENS ESTABLISHED AT THE PHARMACY SERVICE FOR TOTAL PARENTERAL NUTRITION AND THE USE OF GLUTAMINE AS SOURCE OF NITROGEN
	3PC-007	IMPLEMENTATION AND QUALITY CONTROL OF A 5% FRUCTOSE AND 10% GLYCEROL STERILE SOLUTION FOR DIGESTIVE ENDOSCOPY
	3PC-008	PHYSICOCHEMICAL STABILITY OF NOREPINEPHRINE BITARTRATE IN POLYPROPYLENE SYRINGES AT HIGH CONCENTRATIONS FOR INTENSIVE CARE UNITS
	3PC-009	SUCCESSFUL TREATMENT OF HAMARTOMA IN CHILD SYNDROME AFTER 30 MONTHS WITH TOPICAL ADMINISTRATION OF SIMVASTATIN/CHOLESTEROL CREAM: A CASE REPORT
	3PC-010	STABILITY OF CHLORHEXIDINE 0.05% EYE DROPS COMPOUNDING DRUG
	3PC-011	EFFECTIVENESS OF 3% TOPICAL IMIQUIMOD IN OFF-LABEL USE FOR ORAL FLORIDA PAPILLOMATOSIS: A CASE REPORT
	3PC-012	TOPICAL CIDOFOVIR COMPOUNDING CREAM FOR THE TREATMENT OF DISSEMINATED INFECTION BY MOLLUSCUM CONTAGIOSUM
	3PC-013	FEEDBACK FROM A FEASIBILITY STUDY OF ALLERGY TEST PREPARATIONS IN DAY HOSPITALISATION
	3PC-014	STABILITY OF 1 MG/ML AND 4 MG/ML HYDROCORTISONE SOLIUM SUCCINATE SOLUTIONS IN 0.9% SODIUM CHLORIDE AND 5% GLUCOSE
	3PC-015	PHYSICOCHEMICAL STABILITY OF CEFOTAXIME IN POLYPROPYLENE SYRINGES AT HIGH CONCENTRATIONS FOR INTENSIVE CARE UNITS
	3PC-016	PHYSICOCHEMICAL STABILITY OF VANCOMYCIN HYDROCHLORIDE IN POLYPROPYLENE SYRINGES AT HIGH CONCENTRATIONS FOR INTENSIVE CARE UNITS
	3PC-017	PHYSICAL COMPATIBILITY OF INTRAVENOUS ANTI-INFECTIVE DRUGS WITH MEDICATIONS COMMONLY USED IN INTENSIVE CARE UNITS
	3PC-018	IMPLEMENTATION OF QUALITY CONTROL OF PAEDIATRIC CYTOTOXIC DRUG PREPARATIONS: PILOT TRIAL WITH ETOPOSIDE.
	3PC-019	RISK MANAGEMENT OF CROSS-CONTAMINATION OF PAEDIATRIC ANTI-CANCER PREPARATIONS USING FAILURE MODE AND EFFECTS CRITICALITY ANALYSIS
	3PC-020	NIVOLUMAB WEIGHT-BASED DOSING VS FLAT DOSE ECONOMIC ANALYSIS
	3PC-021	IMPACT OF A CENTRALISED INTRAVENOUS ADDITIVE SERVICE IN PATIENTS AND HEALTHCARE WORKERS RISK REDUCTION
	3PC-022	PRELIMINARY MICROBIOLOGICAL STUDY OF INJECTABLE CHEMOTHERAPY DOSE-BANDING
	3PC-023	A RISK ANALYSIS METHOD TO EVALUATE THE IMPACT OF A CHEMOTHERAPY COMPOUNDING WORKFLOW MANAGEMENT SYSTEM ON CANCER PATIENTS' SAFETY
	3PC-024	THE VALIDATION OF CONTROL METHOD : THE GRAVIMETRIC ANALYSIS IN CYTOTOXIC DRUG PREPARATION
	3PC-025	OPTIMISATION OF COMPOUNDING ORGANISATION AFTER IMPLEMENTING A ROBOTIC SYSTEM FOR AUTOMATED PREPARATION OF ONCOLOGIC DRUGS
	3PC-026	WHAT IS THE BEST CHEMICAL DECONTAMINATION SOLUTION FOR CONVENTIONAL ANTI-NEOPLASTIC DRUGS IN A HOSPITAL COMPOUNDING UNIT?
	3PC-027	PRODUCTIVITY ANALYSIS OF AN AUTOMATED COMPOUNDING SYSTEM FOR INTRAVENOUS CHEMOTHERAPY
	3PC-028	DOSE-BANDING GEMCITABINE AND STANDARDISATION OF CHEMOTHERAPY PROTOCOLS PRODUCTION
	3PC-029	QUALITY OF GEMCITABINE READY TO ADMINISTER PREPARATIONS
	3PC-030	PHYSICAL, CHEMICAL AND MICROBIOLOGICAL STABILITY OF SIROLIMUS 0.4% IN TOPICAL FORMULATIONS
	3PC-031	THE TRANSITION FROM THE USE OF BUPIVACAINE TO ROPIVACAINE IN THE DELIVERY ROOM, IN ORDER TO ACHIEVE A BETTER ANALGESIC EFFECT
	3PC-032	LOW-DOSE MORPHINE SOLUTION FOR SPINAL ANAESTHESIA - READY TO USE TO IMPROVE PATIENT SAFETY IN DRUG THERAPY
	3PC-033	LABELLING WITHOUT STRENGTH FOR A PHARMACEUTICAL PREPARATION USED IN A BLINDED DOSAGE ADJUSTMENT OF CLOZAPINE
	3PC-034	IMIPENEM-FORTIFIED EYE DROPS FOR THE TREATMENT OF BACTERIAL KERATITIS: DEVELOPMENT AND CHARACTERISATION
	3PC-035	GALENIC FORMULATIONS FOR OPHTALMOLOGISTS: NEW FORMULATIONS, PRESCRIBING PATHWAYS AND PATIENT INFORMATION
	3PC-036	COMPARISON OF METABOLITE LEVELS IN SERUM AND TEARS: IMPLICATIONS FOR THE DILUTION OF AUTOLOGOUS-SERUM-EYE-DROPS
	3PC-037	DEVELOPMENT OF VIRTUAL DRUG INFORMATION CENTRE FOR PHARMACY COMPOUNDING AREA
	3PC-038	ABSTRACT WITHDRAWN
	3PC-039	STABILITY STUDY OF (99MTC)DOTATOC AND (68GA)DOTATOC IN SYRINGES
	3PC-040	HEALTH HAZARDS OF RAW MATERIALS USED IN THE COMPOUNDING OF PHARMACEUTICALS FORMULATIONS
	3PC-041	AUTOMATION OF PARENTERAL NUTRITION COMPOUNDING: RESULTS OF GRAVIMETRIC QUALITY CONTROL BEFORE AND AFTER ITS IMPLEMENTATION
	3PC-042	A SCIENCE- AND RISK-BASED STRATEGY TO QUALIFY STERILISED PREFILLED SYRINGES AS PRIMARY PACKAGING MATERIAL IN A HOSPITAL PHARMACY
	3PC-043	NEW FORMULATION OF NOREPINEPHRINE SOLUTION IN PREFILLED CYCLIC OLEFIN STERILISED SYRINGES
	3PC-044	PARAFFIN OIL-BASED EMULSION: INFLUENCE OF GUM ARABIC AND THE MIXING RATE ON EMULSION STABILITY
	3PC-045	FORMULATION AND STABILITY STUDY OF EXTEMPORANEOUS ORAL LIQUID DOSAGE FORMS CONTAINING FLECAINIDE ACETATE 2MG/ML FOR PAEDIATRIC USE
	3PC-046	STUDY OF STABILITY OF TWO LIQUID FORMULATIONS OF OMEPRAZOLE ELABORATED IN THE PHARMACEUTICAL SERVICE
	3PC-047	EVALUATION OF THE EFFECTIVENESS AND SATISFACTION OF THE MASTER SUSPENSION FORMULA FOR MUCOSITIS ELABORATED IN A TERTIARY HOSPITAL
	3PC-048	ORAL MUCOADHESIVE DEXAMETHASONE 0.1% (M / M) GEL: A STRATEGY FOR MOTOR INHIBITORS MUCOSITIS
	3PC-049	MOBILE APPLICATIONS RELATED TO PARENTERAL NUTRITION: QUALITATIVE AND QUANTITATIVE ANALYSIS
	3PC-050	APPLICATION OF HAZARD VULNERABILITY ANALYSIS TO EVALUATE POTENTIAL RISKS OF PHARMACY COMPOUNDING
	3PC-051	IMPACT OF OPHTHALMOLOGICAL PREPARATIONS IN THE PHARMACY SERVICE OF A REFERENCE HOSPITAL
	3PC-052	CHEMICAL DISINFECTANTS VS STERILE WATER AND COMPOSITE FIBRE: THE EFFECT OF CLEANING METHODS ON MICROBIAL CONTAMINATION IN A CLASS A PHARMACEUTICAL COMPOUNDING ENVIRONMENT
	3PC-053	NEW FORMULATIONS FOR THE TREATMENT OF ANTINEOPLASTIC AND RADIOTHERAPY-INDUCED MUCOSITES
	3PC-054	ADDED VALUE FROM AN INFORMATION AND COMMUNICATION TECHNOLOGY-ASSISTED INTERVENTION IN A TOTAL PARENTERAL UNIT OF A PAEDIATRIC HOSPITAL PHARMACY
	3PC-055	CYTOTOXIC AGENTS: SKIN TESTS FOR THE DIAGNOSIS OF DRUG HYPERSENSITIVITY
	3PC-056	PERFORMANCE ANALYSIS OF A FULLY AUTOMATED ONCOLOGY PHARMACY PRODUCTION: A 2018 UPDATE
	3PC-057	ECONOMIC IMPACT AFTER THE IMPLEMENTATION OF A RISK MATRIX IN THE PREPARATION OF CHEMOTHERAPY
	3PC-058	ROBOTIC COMPOUNDING: SAFETY AND PRODUCTIVITY ACHIEVEMENTS IN THE PREPARATION OF HAZARDOUS DRUGS
	3PC-059	USE OF EXTEMPORANEOUS ORAL SUSPENSIONS OF OXYBUTININ AND PRAZOSINE IN NEONATES
	3PC-060	HOT-MELT RAM EXTRUSION 3D PRINTING: A SMART METHOD FOR COMPOUNDING ORODISPERSIBLE FILMS IN HOSPITAL PHARMACIES
	3PC-061	OPTIMISATION OF INTRACAMERAL CEFUROXIME CONSUMPTION IN THE PREVENTION OF POSTOPERATIVE ENDOPHTALMITIS
	3PC-062	ABSTRACT WITHDRAWN
	3PC-063	GALENIC PREPARATION OF 40% DEXTROSE GEL: NEW APPROACH TO MANAGEMENT OF NEONATAL HYPOGLYCAEMIA
	3PC-064	FEEDBACK FROM LEAN MANAGEMENT IN A STERILISATION UNIT
	3PC-065	ORODISPERSIBLE FILMS – AN INTERESTING DOSAGE FORM!
	3PC-066	PT-SMELL TEST: A NOVEL HOSPITAL COMPOUNDING AND ITS CLINICAL VALIDATION TO DIAGNOSE OLFACTORY DYSFUNCTION
	3PC-067	ABSTRACT WITHDRAWN
	3PC-068	ABSTRACT WITHDRAWN

Section 4: Clinical Pharmacy Services
PDF document	Poster number	Poster Title
	4CPS-001	A REVISION OF PRESCRIBING PUMP INHIBITOR PRESCRIPTIONS IN INTERNAL MEDICINE AND ADDICTOLOGY DEPARTMENT
	4CPS-002	ANALYSIS AND IMPROVEMENT OF PROFESSIONNAL PRACTICES: PRESCRIPTION’S EVALUATION OF PROTON PUMP INHIBITORS IN ORAL ROUTES
	4CPS-003	AN EVALUATION OF GASTROINTESTINAL PROPHYLAXIS IN ELDERLY PATIENTS ON ASPIRIN THERAPY
	4CPS-004	PERTINENCE OF THE PRESCRIPTION OF STRESS ULCER PROPHYLAXIS IN INTENSIVE CARE MEDICINE
	4CPS-005	GLP-1 AGONIST LIRAGLUTIDE AS ADD-ON THERAPY IN TYPE 2 DIABETES
	4CPS-006	PHARMACIST-LED MEDICINE RECONCILIATION AT DIABETES OUTPATIENT CLINIC
	4CPS-007	COST MINIMISATION STUDY: SWITCH VIAL TO PEN IN GERIATRICS
	4CPS-008	IMPACT OF PHARMACEUTICAL INTERVIEW IN PATIENT ACCEPTANCE OF INSULIN GLARGINE’S BIOSIMILAR 100UI/ML
	4CPS-009	EVALUATION OF THE SAFETY OF INHIBITORS OF THE CO-TRANSPORTER 2 IN A UNIVERSITY CARE HOSPITAL
	4CPS-010	INSULIN PRESCRIPTION ANALYSIS IN A THIRD-LEVEL HOSPITAL
	4CPS-011	PREVALENCE AND RELATIONSHIP BETWEEN HYPOVITAMINOSIS D AND INSULIN RESISTANCE IN OBESE PATIENT CANDIDATES FOR BARIATRIC SURGERY
	4CPS-012	PREVALENCE OF NUTRITIONAL COMPLICATIONS ACCORDING TO THE REQUESTED HOSPITALISATION SERVICE OF TOTAL PARENTERAL NUTRITION
	4CPS-013	ORAL ANTICOAGULANT PRESCRIPTION PRACTICE AFTER AN ISCHAEMIC STROKE
	4CPS-014	ABSTRACT WITHDRAWN
	4CPS-015	EVALUATION OF ANTICOAGULANTS MISUSE IN PATIENTS ADMITTED FOR ISCHAEMIC STROKE IN A NEUROLOGY UNIT
	4CPS-016	ABSTRACT WITHDRAWN
	4CPS-017	EVALUATION OF PHARMACISTS' INPUT IN ANTICOAGULATION CLINIC REVIEWING DIRECT ORAL ANTICOAGULANTS INITIATED IN A SECONDARY CARE HOSPITAL IN LONDON
	4CPS-018	EVALUATION OF ANTIPLATELET AGENT PRESCRIBING IN PATIENTS ON DIRECT ORAL ANTICOAGULANT
	4CPS-019	MEDICATION USE EVALUATION OF EDOXABAN IN A TERTIARY HOSPITAL
	4CPS-020	ANTICOAGULATION THERAPY IN HAEMODIALYSIS - A CLINICAL PHARMACIST EXPERIENCE IN A PRIMARY CARE TEAM
	4CPS-021	ABSTRACT WITHDRAWN
	4CPS-022	HIGH INPUT IN PATIENT SAFETY - DOCUMENTATION OF CARDIOVASCULAR SYSTEM DRUGS
	4CPS-023	SACUBITRIL/VALSARTAN (ENTRESTO) IN REAL LIFE: AN OBSERVATIONAL STUDY IN A HOSPITAL CENTRE
	4CPS-024	EFFICACY, SAFETY AND ACCEPTANCE OF TREATMENT WITH ALIROCUMAB OR EVOLOCUMAB IN PATIENTS WITH DYSLIPIDAEMIA
	4CPS-025	LIPID MODIFICATION THERAPY FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE
	4CPS-026	ADHERENCE AND EFFECTIVENESS OF PCSK9 INHIBITORS IN ROUTINE CLINICAL PRACTICE
	4CPS-027	REAL-WORLD EFFECTIVENESS OF EVOLOCUMAB AND ALIROCUMAB AT 12 MONTHS OF TREATMENT
	4CPS-028	STATIN OVERUSE? EVALUATION OF STATIN INITIATION FOR PRIMARY PREVENTION DURING HOSPITALISATION BETWEEN TWO NEIGHBOURING COUNTRIES IN EUROPE IN HIGH-RISK PATIENTS
	4CPS-029	CLINICAL EXPERIENCE OF NEW LIPID-LOWERING THERAPIES: EVOLOCUMAB AND ALIROCUMAB
	4CPS-030	ANALYSIS OF ADAPTATION TO A PROTOCOL OF USE OF THE PCSK9 INHIBITORS
	4CPS-031	THE PRIMARY EFFICACY ENDPOINT FOR ALIROCUMAB, REDUCTIONS IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL
	4CPS-032	SKIN PROTECTION AND PREVENTION OF CUTANEOUS MYCOSIS
	4CPS-033	THE USE OF ORAL APREMILAST FOR THE TREATMENT OF PLAQUE PSORIASIS
	4CPS-034	USE OF USTEKINUMAB IN REFRACTORY PATIENTS OF PSORIASIS
	4CPS-035	PERSISTENCE AND SAFETY OF APREMILAST IN PSORIASIS
	4CPS-036	APREMILAST ADHERENCE IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS
	4CPS-037	THE IMPACT OF MULTIDISCIPLINARY COLLABORATION IN OPTIMISING THE PRESCRIPTION OF ANTIBIOTICS IN A PAEDIATRIC HOSPITAL
	4CPS-038	QUALITY OF LIFE OF PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS UNDERGOING OUT-PATIENT TREATMENT WITH DUPILUMAB
	4CPS-039	DUPILUMAB TREATMENT DISCONTINUATION DUE TO LIMITING ADVERSE EFFECTS: A CASE REPORT
	4CPS-040	OPTIMISING OF ANTIBIOTIC PROPHYLAXIS AT CARDIAC SURGERY CLINIC
	4CPS-041	IMPLEMENTATION OF AN EMPIRICAL ANTIBIOTIC TREATMENT GUIDE: IMPACT ON ANTIOBITIC PRESCRIPTION IN AN EMERGENCY DEPARTMENT
	4CPS-042	SWITCH FROM CLARITHROMYCIN TO AZITHROMYCIN - ONE OPTION TO OPTIMISE MACROLIDE USE THROUGH CLINICAL PHARMACISTS
	4CPS-043	EXTENSIVELY PANDRUG-RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS: ANALYSIS AND OUTCOMES
	4CPS-044	IMPACT OF CLINICAL PHARMACIST-VANCOMYCIN MONITORING ON PATIENT SAFETY OUTCOME
	4CPS-045	VALUE OF THE CLINICAL PHARMACIST IN THE PHARMACOKINETIC MONITORING OF ANTIMICROBIALS: HEALTH OUTCOMES
	4CPS-046	PHARMACEUTICAL INTERVENTIONS IN ANTIMICROBIAL TREATMENT IN A 150-BED HOSPITAL
	4CPS-047	FEASIBILITY OF PHARMACY FOLLOW-UP OF ANTIBIOTIC RE-EVALUATION IN A UNIVERSITY HOSPITAL: DAY-2 OR/AND DAY-7?
	4CPS-048	QUALITY OF THE EMPIRIC ANTIBIOTIC TREATMENT IN COMMUNITY-ACQUIRED PNEUMONIA
	4CPS-049	CEFTOBIPROLE IN EMPIRICAL TREATMENT OF BONE AND JOINT INFECTIONS: SURVEY OF THE PRESCRIPTIONS, RESPECT OF THE PROTOCOL AND ECONOMIC EVALUATION OVER 6 MONTHS
	4CPS-050	ANALYSIS OF ANTIBIOTIC ADMINISTRATION IN SURGICAL PROPHYLAXIS
	4CPS-051	ABSTRACT WITHDRAWN
	4CPS-052	FROM THE SURVEILLANCE OF ANTIBIOTICS PRESCRIPTIONS TO LIMITATION OF MULTIDRUG RESISTANT BACTERIA STRAINS: THE ROLE OF THE HOSPITAL PHARMACY IN DEFINING A CARBAPENEM-SPARING-STRATEGY
	4CPS-053	STUDY ON DAPTOMYCIN USE AS A FIRST STEP TOWARDS AN ANTIMICROBIAL STEWARDSHIP PROGRAMME
	4CPS-054	USE OF ANTIMICROBIAL AGENTS IN THE EMERGENCY DEPARTMENT IN A THIRD-LEVEL HOSPITAL
	4CPS-055	EFFICACY AND SAFETY OF ARTEMISININE DERIVATIVES IN THE TREATMENT OF MALARIA
	4CPS-056	MAPPING ANTIBIOTIC USE PATTERNS IN A SEPTIC ORTHOPAEDIC WARD
	4CPS-057	HOW WELL IS THE TARGET CONCENTRATION OF VANCOMYCIN ACHIEVED IN INTENSIVE CARE UNIT PATIENTS?
	4CPS-058	AVOID SIMULTANEUS PRESCRIPTION BETWEEN LINEZOLID AND VORICONAZOLE: PHARMACOKINETIC STUDY
	4CPS-059	EFFECTIVENESS OF MEROPENEM TREATMENT IN CRITICAL PATIENTS: PHARMACOKINETIC STUDY
	4CPS-060	PREVALENCE OF VANCOMYCIN-RELATED NEUTROPAENIA, THROMBOCYTOPAENIA AND ACUTE KIDNEY INJURY
	4CPS-061	EXTENDED INFUSION OF MEROPENEM IN A NEONATE WITH COMPLICATED KLEBSIELLA PNEUMONIAE MENINGITIS
	4CPS-062	IMPACT OF ANTIMICROBIAL STEWARDSHIP PROGRAMME ON CARBAPENEMS RESISTANCE AND CONSUMPTION IN A TERTIARY HOSPITAL: A BEFORE-AND-AFTER INTERVENTIONAL STUDY
	4CPS-063	IMPACT OF PHARMACEUTICAL CARE IN THE RATIONAL USE OF DAPTOMYCIN
	4CPS-064	EVALUATION OF BROAD-SPECTRUM BETA-LACTAM PRESCRIPTIONS (EXCEPTCARBAPENEMS) IN THE MILITARY HOSPITAL OF INSTRUCTION MOHAMMED V RABAT
	4CPS-065	CLINICAL IMPACT EVALUATION OF IMPLEMENTING ANTIBIOTHERAPY CONTROL OF MORE THAN 7 DAYS
	4CPS-066	ADHERENCE OF PATIENTS RECEIVING ANTIBIOTIC THERAPY AFTER HOSPITALISATION
	4CPS-067	EFFECTIVENESS AND SAFETY OF THE EARLY SWITCH FROM INTRAVENOUS TO ORAL ANTIBIOTICS TREATMENT IN THE PNEUMOLOGY WARD
	4CPS-068	IMPACT OF THE PHARMACEUTICAL RECOMMENDATIONS FOR THE IMPROVEMENT IN ANTIBIOTICS PRESCRIPTION
	4CPS-069	IMPACT OF IMPLEMENTING A GLOBAL COLLABORATIVE PHYSICIAN-PHARMACIST STRATEGY ON PROPHYLACTIC ANTIBIOTIC PRACTICES IN A UNIVERSITY HOSPITAL CENTRE
	4CPS-070	DOES ANTIBIOTIC CONSUMPTION PREDICT THE INCIDENCE DENSITY OF HEALTHCARE-ASSOCIATED INFECTIONS?
	4CPS-071	SHORTAGE OF DRUGS ERA: IMPACT OF PIPERACILIN/TAZOBACTAM SHORTAGE
	4CPS-072	ABSTRACT WITHDRAWN
	4CPS-073	FOLLOW-UP OF RECOMMENDATIONS ON DOSE ADJUSTMENT OF CEFTOLOZANE/TAZOBACTAM IN RENAL FAILURE
	4CPS-074	ROLE OF THE PHARMACIST IN THE EVALUATION OF THE PRESCRIPTIVE APPROPRIATENESS IN ANTIBIOTIC THERAPY AS A “SINGLE DOSE”
	4CPS-075	CREATION OF AN INNOVATIVE AND ATTRACTIVE TRAINING PROGRAMME FOR PRESCRIBERS TO PROMOTE THE CORRECT USE OF FLUOROQUINOLONES
	4CPS-076	ENCOURAGING THE RESPONSIBLE USE OF ANTIBIOTICS: AWARENESS AND UNDERSTANDING AMONG A UNIVERSITY STUDENT POPULATION OF A COMMUNITY PHARMACY PUBLIC HEALTH CAMPAIGN IN SCOTLAND
	4CPS-077	INHALED COLISTIN AS CHRONIC SUPPRESSOR THERAPY IN PATIENTS WITH BRONCHIECTASIAS WITH NON-CYSTIC FIBROSIS
	4CPS-078	ADEQUACY OF SYSTEMATIC ANTIFUNGAL AGENT PRESCRIPTIONS IN A TEACHING HOSPITAL
	4CPS-079	PATIENT WITH COMPLICATED FUNGAL ENDOCARDITIS : A CASE REPORT
	4CPS-080	APPROPRIATE USE OF ANTIFUNGALS: IMPACT OF AN ANTIFUNGAL STEWARDSHIP PROGRAMME ON THE CLINICAL OUTCOME OF CANDIDAEMIA IN A UNIVERSITY HOSPITAL
	4CPS-081	EVALUATION OF THE STANDARD DOSAGE REGIMEN OF VORICONAZOLE IN A PAEDIATRIC AND ADULT POPULATION THROUGH THERAPEUTIC DRUG MONITORING
	4CPS-082	NEPHROGENIC DIABETES INSIPIDUS INDUCED BY LIPOSOMAL AMPHOTERICIN B: A CASE REPORT
	4CPS-083	AGING WITH HIV: OPTIMISING PHARMACOTHERAPY BEYOND INTERACTIONS
	4CPS-084	EVOLUTION OF NONOCCUPATIONAL POSTEXPOSURE PROPHYLAXIS USE SINCE 2010 IN A THIRD-LEVEL HOSPITAL
	4CPS-085	STEWARDSHIPS OF HEPATITIS C VIRUS PATIENTS IN PRISONS
	4CPS-086	A FULLY INTEGRATED CLINICAL TRIAL-LIKE SYSTEM TO MANAGE AND MONITOR PERSISTENCE IN PLANNED HEPATITIS C TREATMENT
	4CPS-087	EVOLUTION OVER TIME OF ANTIRETROVIRALS
	4CPS-088	EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C
	4CPS-089	RETREATMENT OF PATIENTS WITH HEPATITIS C VIRUS INFECTION AFTER VIROLOGICAL FAILURE TO DIRECT-ACTING ANTIVIRALS
	4CPS-090	HEALTH OUTCOMES USING DIRECT-ACTING ANTIVIRAL DRUGS FOR THE TREATMENT OF PATIENTS WITH HEPATITIS C VIRUS AND F0-F1 LIVER FIBROSIS STAGE
	4CPS-091	CURRENT STATE OF RETREATMENT OF HEPATITIS C INFECTION IN PATIENTS WHOM PRIOR THERAPY FAILED IN A HEPATITIS REFERRAL CENTRE
	4CPS-092	PREVALENCE OF POLYPHARMACY IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION
	4CPS-093	PERSISTENCE OF AN ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS PATIENTS IN A TERTIARY LEVEL HOSPITAL
	4CPS-094	EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR IN REAL-WORLD CLINICAL PRACTICE FOR CHRONIC HEPATITIS C INFECTION
	4CPS-095	RESCUE OF PATIENTS INFECTED WITH HEPATITIS C VIRUS NOT RESPONDING TO INTERFERON-FREE THERAPIES
	4CPS-096	ABSTRACT WITHDRAWN
	4CPS-097	COBICISTAT INTERACTIONS WITH CHRONIC TREATMENTS
	4CPS-098	INFLUENCE OF PHARMACOLOGICAL INTERACTIONS IN HEPATITIS C TREATMENT SELECTION IN OPIATE-DEPENDENT PATIENTS
	4CPS-099	PALIVIZUMAB OFF LABEL USE IN TERTIARY REFERRAL HOSPITAL
	4CPS-100	QUALITY OF INTRATECT: IN VITRO EVALUATION OF BIOLOGICAL ACTIVITIES
	4CPS-101	INTRAVENOUS IMMUNOGLOBULINS USE FOR CHILDREN'S NEUROLOGICAL AND NEURODEVELOPMENTAL DISORDERS
	4CPS-102	MEASUREMENT OF HEALTH OUTCOMES OF POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE COMBINATION IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
	4CPS-103	EVALUATION OF HEALTH OUTCOMES OF DARATUMUMAB IN MONOTHERAPY IN ADULT PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
	4CPS-104	CHEMOTHERAPY TREATMENT IN COLORECTAL CANCER PATIENTS OLDER THAN 70 YEARS AT A TERTIARY HOSPITAL
	4CPS-105	PRESCRIBED ANTINEOPLASTIC AGENTS IN PAEDIATRIC PATIENTS
	4CPS-106	MULTI-STATE MODEL TO ESTIMATE THE OPTIMAL DURATION OF FIRST-LINE CHEMOTHERAPY IN ADVANCED GASTRIC CANCER: DATA FROM THE NATIONAL REGISTRY AGAMENON
	4CPS-107	EFFECTIVENESS AND SAFETY STUDY OF NIVOLUMAB IN THE SECOND LINE OF ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
	4CPS-108	DABRAFENIB AND TRAMETINIB: COMBINATION THERAPY FOR METASTATIC MELANOMA
	4CPS-109	POTENTIAL DRUG-DRUG INTERACTIONS INVOLVING TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA TREATED AT A UNIVERSITY HOSPITAL
	4CPS-110	SAFETY AND EFFECTIVENESS OF OBINUTUZUMAB IN CHRONIC LYMPHOCYTIC LEUKAEMIA: OUR EXPERIENCE
	4CPS-111	TREATMENT OF FOLLICULAR LYMPHOMA IN ROUTINE CLINICAL PRACTICE.
	4CPS-112	ASSESSMENT OF AGGRESSIVE CARE IN ONCOLOGY PATIENTS AT THE END OF LIFE IN CLINICAL PRACTICE
	4CPS-113	DRUG COST SAVING RESULTING FROM METASTATIC MELANOMA CLINICAL TRIALS
	4CPS-114	DOSING OF PLATINUM AND TAXANES IN OBESE PATIENTS: A SYSTEMATIC REVIEW
	4CPS-115	RITUXIMAB IN THE TREATMENT OF PRIMARY GLOMERULONEPHRITIS
	4CPS-116	VEMURAFENIB-INDUCED STEVENS-JOHNSON SYNDROME IN A PATIENT WITH METASTATIC MELANOMA: A CASE REPORT
	4CPS-117	DOSE BANDING - OPTIMISING DOSES IN CETUXIMAB OR BEVACIZUMAB REGIMENS
	4CPS-118	EXPERIENCE OF DUAL TARGETING USE OF NEOADJUVANT HER2-POSITIVE BREAST CANCER
	4CPS-119	EXPERIENCE OF NAB-PACLITAXEL AND GEMCITABINE USE IN METASTATIC PANCREATIC CANCER
	4CPS-120	ERLOTINIB IN NON-SMALL-CELL LUNG CANCER WITHOUT EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATIONS
	4CPS-121	COST-MINIMISATION ANALYSIS OF MAINTENANCE THERAPY OF ANTINEUTROPHIL CYTOPLASM ANTIBODY-ASSOCIATED VASCULITIDES
	4CPS-122	EFFICACY AND SAFETY OF COBIMETINIB USED IN MONOTHERAPY FOR ERDHEIM-CHESTER DISEASE
	4CPS-123	EFFICACY AND SAFETY OF COBIMETINIB USED IN MONOTHERAPY FOR ERDHEIM-CHESTER DISEASE
	4CPS-124	SAFETY AND EFFECTIVENESS OF TRASTUZUMAB EMTANSIN IN LOCALLY ADVANCED OR METASTATIC HER2 POSITIVE BREAST CANCER
	4CPS-125	TOLERANCE TO CHEMORADIOTHERAPY TREATMENT: COMPARING CAPECITABINE WITH 5-FLUOROURACIL IN NEOADJUVANT THERAPY FOR STAGE II-III RECTAL CANCER
	4CPS-126	EFFECTIVENESS AND SAFETY OF NAB-PACLITAXEL IN PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN A REAL-WORLD SETTING
	4CPS-127	DEVELOPMENT OF A STRATIFICATION MODEL FOR AMBULATORY ONCOLOGY PHARMACY PATIENTS
	4CPS-128	ADEQUACY OF NIVOLUMAB AND PEMBROLIZUMAB IN NON-SMALL-CELL LUNG CANCER
	4CPS-129	CHEMOTHERAPY NEAR THE END OF LIFE IN ONCO-HAEMATOLOGICAL ADULT PATIENTS
	4CPS-130	PALBOCICLIB COMBINED WITH HORMONAL THERAPY FOR METASTATIC BREAST CANCER TREATMENT
	4CPS-131	RUXOLITINIB AS SALVAGE THERAPY IN PAEDIATRIAC PATIENTS WITH STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE
	4CPS-132	INTERACTIONS BETWEEN ALTERNATIVE THERAPIES AND PRODUCTS IN CLINICAL TRIAL IN ONCO-HAEMATOLOGY
	4CPS-133	DARATUMUMAB (DARZALEX) FOR THE TREATMENT OF MULTIPLE MYELOMA IN A THIRD-LEVEL HOSPITAL: VARIABILITY OF USE AND EFFECTIVENESS
	4CPS-134	HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS TREATED WITH DISEASE-MODIFYING THERAPIES
	4CPS-135	TERIFLUNOMIDE AND DIMETHYLFUMARATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
	4CPS-136	ANALYSIS OF THE USE OF OMALIZUMAB IN ORAL TOLERANCE INDUCTION FOR HIGH-RISK FOOD ALLERGIES IN CHILDREN
	4CPS-137	NATALIZUMAB: A REVIEW OF ITS USE IN THE MANAGEMENT OF MULTIPLE SCLEROSIS, EXPERIENCE IN A UNIVERSITY HOSPITAL
	4CPS-138	BIOSIMILARS' UTILISATION UNDER HOSPITAL PHARMACY MANAGEMENT POLICY
	4CPS-139	THE PIRAMID STUDY: PATIENTS TREATED BY MYELOMA ORAL MEDICATION HAVE A BAD COMPLIANCE
	4CPS-140	HOW PHARMACISTS CAN IMPROVE PATIENTS' CARE MANAGEMENT IN SUBCUTANEOUS ANTIPSORIATIC BIOLOGIC THERAPY
	4CPS-141	ECONOMIC IMPACT OVER THE PAST 4 YEARS ASSOCIATED WITH BIOLOGICAL THERAPY OPTIMISATION IN RHEUMATIC DISEASES PATIENTS
	4CPS-142	ADJUVANT CHEMOTHERAPY AND RELAPSE-ASSOCIATED PROGNOSTIC FACTORS IN OPERABLE BREAST CANCER
	4CPS-143	EVALUATION OF KNOWLEDGE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED BY THE REFERENCE PRODUCT CONCERNING BIOSIMILARS: ROLE OF CLINICAL PHARMACISTS
	4CPS-144	ESTABLISHMENT OF A PHARMACEUTICAL STANDARDISED INTERVIEW CONCERNING BIOSIMILARS OF INFLIXIMAB IN THE DAYCARE CLINIC OF A GASTROENTEROLOGY DEPARTMENT FOR PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE
	4CPS-145	PHARMACOGENETICS AS A TOOL IN DOSE ADJUSTMENT OF IMMUNOSUPPRESSIVE DRUGS: A CASE REPORT
	4CPS-146	SUBLINGUAL AND ENTERIC TACROLIMUS WHOLE BLOOD LEVELS IN AN INTENSIVE CARE UNIT
	4CPS-147	CLINICAL EXPERIENCE OF OPTIMISING CO-ADMINISTRATION THERAPY OF LOW-DOSE ALLOPURINOL WITH LOW-DOSE THIOPURINES IN INFLAMMATORY BOWEL DISEASE PATIENTS ATTENDING A VIRTUAL PHARMACIST CLINIC
	4CPS-148	ANALYSIS OF INTRA-PATIENT VARIABILITY OF PLASMATIC LEVELS OF TACROLIMUS IN EARLY MAINTENANCE OF RENAL POST-TRANSPLANT
	4CPS-149	EVALUATION OF INTRA-PATIENT VARIABILITY OF THE TACROLIMUS PLASMATIC LEVELS IN THE DIFFERENT PERIODS OF THE KIDNEY POST-TRANSPLANT
	4CPS-150	EVALUATION OF INTRA-PATIENT VARIABILITY OF THE TACROLIMUS PLASMATIC LEVELS IN DIFFERENT PERIODS AFTER LIVER TRANSPLANT
	4CPS-151	INFLUENCE OF THE ROUTE AND PHARMACEUTICAL PREPARATION IN INTRA-PATIENT VARIABILITY OF TACROLIMUS SERUM LEVELS IN THE LIVER TRANSPLANT PATIENT
	4CPS-152	CHEMOTHERAPY PHARMACEUTICAL CONSULTATION: PHARMACEUTICAL INTERVENTIONS AFTER 18 MONTHS OF IMPLEMENTATION
	4CPS-153	COMPARATIVE ANALYSIS BETWEEN ORIGINATOR AND BIOSIMILAR INFLIXIMAB ACCORDING TO TROUGH LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
	4CPS-154	ABSTRACT WITHDRAWN
	4CPS-155	A NEW MULTIDISCIPLINARY MODEL WITH THE CLINICAL PHARMACIST FOR MEDICATION RECONCILIATION IN THE PATIENT WITH ADVANCED RENAL DISEASE
	4CPS-156	SAFETY PROFILE OF APREMILAST IN PSORIASIS AND PSORIATIC ARTHRITIS
	4CPS-157	TUMOUR NECROSIS FACTOR INHIBITORS: UTILITY OF PHARMACOKINETICS MONITORING IN INFLAMMATORY BOWEL DISEASE MANAGEMENT
	4CPS-158	CLINICAL BENEFIT OF INFLIXIMAB MONITORING IN INFLAMMATORY BOWEL DISEASE
	4CPS-159	PERIOPERATIVE MANAGEMENT OF ANTIRHEUMATIC MEDICATION IN REAL PRACTICE: IS MISMANAGEMENT RELATED TO POST-SURGICAL COMPLICATIONS?
	4CPS-160	EFFICACY AND SAFETY OF ANAKINRA AND CANAKINUMAB FOR THE TREATMENT OF IL-36R ANTAGONIST DEFICIENCY
	4CPS-161	SCOPING REVIEW ON THE USE OF CANAKINUMAB AND ANAKINRA IN INTERLEUKIN-1 ANTAGONIST RECEPTOR DEFICIENCY
	4CPS-162	MEDICATION COUNSELLING BY CLINICAL PHARMACISTS IN NEWLY GRAFTED RENAL TRANSPLANT RECIPIENTS